Gap Junction Intercellular Communication in the Immune System: The Role in Lymphocyte Activation and Differentiation. by Issac, Rueban Jacob Anicattu.
UNIVERSITY OF
SURREY
Gap Junction intercellular communication in 
the immune system: The role in lymphocyte 
activation and differentiation
By
Rueban Jacob Anicattu Issac
Thesis submitted for the degree of Doctor of Philosophy
Faculty of Health and Medical Sciences 
University of Surrey, Guildford 
December 2011
ProQ uest N um ber: 27598753
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27598753
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract
Background: Atherosclerosis is a chronic inflammatory disease characterised by 
monocyte/macrophage and T cell infiltration of the vascular wall in response to a variety of 
stimuli including oxidised low density lipoprotein (oxLDL). Studies on human blood vessels 
and on mouse models o f the disease, as well as population studies, have led to the hypothesis 
that connexins (Cx) and gap junction channels play an important role in the pathogenesis of 
atherosclerosis. Three major Cxs (Cx37, Cx40 and Cx43) have been shown to be 
differentially expressed within atherosclerotic plaques at different stages of its development.
Objectives: We sought to characterise the expression o f Cxs in macrophages and T 
lymphocytes induced by oxLDL in the presence or absence of statins, we aimed to assess the 
molecular pathways linking leukocyte stimulation and junctional channel formation and 
function under the above mentioned conditions. Finally, we aimed to correlate these effects 
with T cell functionality in vitro.
Methods: The expression of Cx37, Cx40 and Cx43 in human monocytes derived from 
peripheral blood mononuclear cells was determined after pre-treatment with oxLDL 
(lOOpg/ml), for 48 hours, with/without Simvastatin (lOOpM) and Pravastatin (lOOpM) for 24 
hours using RT-PCR, western blotting and confocal fluorescence microscopy.
T cell proliferation was assessed by the CyQuant assay (that measures the content o f DNA of 
the culture) after co-culturing human naïve CD4+ T lymphocytes (also derived from 
peripheral blood mononuclear cells) with macrophages. Macrophages were first pre-treated 
with Tetanus Toxin (TTox; 4pg/ml) to induce a rapid, adaptive immune response. Then 
CD4+ T lymphocyte were added for 48 hours with or without lOOpg/ml o f oxLDL. The 
influence of the gap junction inhibitors (peptides ^^ ’"^^GAP27 and "^®GAP27, 300pM), 18-a-
glycyrrhetinic acid (lOOpM) and/or statins (Simvastatin, lOOjiM; Pravastatin, lOOpM) on T 
cell proliferation was examined.
Macrophage-T cell junctional coupling was assessed by calcein AM dye transfer with the 
same treatments as for T cell proliferation using flow cytometry.
The effects of oxLDL and statins on T lymphocytes signal transduction pathways was 
assessed by immunoprécipitation and western blots to measure the synthesis and 
phosphorylation of PKC0, IkBa, IKKa, IKKp and NFkBp50 intracellular proteins.
Results: Our results show the expression of Cx37, Cx40 and Cx43 mRNA and protein in 
macrophages. Cx43 was predominantly expressed by macrophages when treated with 
oxLDL. Conversely, Simvastatin had the opposite effect on Cx40 and Cx43 mRNA and 
Cx37, Cx40 and Cx43 protein expression whereas Pravastatin reduced the expression o f both 
mRNA and protein o f the three Cxs. Both statins also significantly inhibited T cell 
proliferation. Simvastatin reduced the expression o f IKKp while Pravastatin had a similar 
effect but on IKKa expression. Both statins were found to specifically halt the expression of 
NFkBpSO and PKC0 in oxLDL activated CD4+ T lymphocytes. A differential effect of 
oxLDL and statins on dye transfer coupling was also observed mirroring the change in Cxs 
mRNA and protein expression levels.
Conclusions: Our results show for the first time that statins regulate the levels of Cxs 
expression in macrophages and CD4+ T lymphocytes and the levels o f junctional 
communication between these two cell types after exposure to atherogenic insult.
The athero-protective role attributed to statins may be mediated by gap junction expression 
and function and is likely linked to key specific protein kinase phosphorylation pathways
associated to lymphocyte immune function. Abrogation o f the oxLDL effect on Cxs 
expression by statins further supports these conclusions.
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CHAPTER 1 
GENERAL INTRODUCTION
23
1.1 Cellular communication
The basic principle o f any biological system is communication with the environment. With 
the increasing complexity o f higher organisms, cells had to evolve leading to a diversification 
in mechanisms involving the exchange of spatial and temporal information crucial for tissue 
organisation and the maintenance of the organism as a whole. Furthermore, tissues are not 
just a loose accumulation o f individual cells, but a highly organised population of interacting 
cells. Thus, in various types o f tissues, cell to cell communication is important for 
maintaining a supracellular organisation.
Cell to cell communication in general is carried out by signalling in the form of soluble 
chemical messengers, the reception of the signal by target cell receptors and the propagation 
of the signal via second messengers amongst receiving cells (Fig 1.1). The immune system 
stands as a classic example of all these mechanisms exhibiting virtually all types o f cell-cell 
interactions such as homotypic and heterotypic communication among lymphoid and stromal 
cells.
24
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Figure 1.1: Overview on cellular communication. Extracellular stimuli carry out their effect by 
acting on specific cell receptors that transduce signals into the cell through a cascade of second 
messengers. Gap junction channels, an example of intercellular communication system, are a major 
group of cell surface specializations that allow the bi-directional exchange of signalling molecules 
between cells.
1.1.1 Direct intercellular communication
In order to establisli intercellular communication, the process of interaction primarily 
involves the participation of a range of adhesion molecules such as cadherins, integrins and 
selectins located on the cell surface that ensures intercellular adhesion and further enable cell­
cell signalling (Mroue et al., 2011). Specialised close contacts such as gap junctions, tight 
junctions, adherens junctions, desmosomes, hemi-desmosomes and focal adhesions are also 
considered complex multi-unit plasma membrane structures that participate in this process 
(Mroue et al., 2011).
Over 50 years have elapsed since the discovery of a low resistance electrical transfer 
(insufficient to elicit an action potential) between adjacent crayfish axons by Furshpan and 
Potter (Furshpan and Potter, 1959). Further work had shown the existence of minute cellular 
junctions between non-neuronal cells that did not act as barriers but instead aided in the
25
diffusion of small molecules (Revel and Karnovsky, 1967). These junctions later came to be 
known as “Gap junctions” and their distinction from tight junctions (Goodenough and Revel, 
1970).
Figure 1.2: Electron Microscopic identification of Gap Junctions. (A) shows liver plasma 
membranes negatively stained after isolation showing the hexagonal pattern of gap junction 
channels (B) and the high magnification view of a thin section. The intercellular space (ics) is 
reduced to a gap of ~2nm (g) in the junctional area (Adapted from Revel and Karnovsky 1967).
1.2 Gap junction intercellular channels
Gap junctions (GJ) can be defined as intercellular membrane bound protein channels 
comprising tightly packed aggregated particles that directly connect the cytoplasms of 
adjacent cells and further allow the bidirectional exchange of small molecules like ions, 
metabolites, second messangers and peptides of up to IkDa between them (Neijssen et al., 
2005, Goodenough et al., 1996). These different molecules that can be transferred via GJ 
allow electric, metabolic and immunological transfer of information and can direct processes 
like development, inflammation and cell death (Montecino-Rodriguez et al., 2000, Matsue et 
al., 2006).
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1.2.1 Structure of gap junction channels
A functional GJ channel constitutes an assembly of six connexin (Cx) subunits arranged 
around a central pore that make up a single multimeric transmembrane structure (hexamer) 
called a connexon. These connexons may dock with other connexons in opposing 
neighbouring cells or remain hemichannels (Unger et al., 1999, Hemler, 2005) (Fig 1.3). The 
composition of a connexon may be either homomeric or heteromeric meaning that a 
connexon can be composed of either six identical subunits of Cxs (homomeric) or may 
consist of more than one species of Cx isoform (heteromeric) (He et al., 1999) (Fig 1.4).
Connexon
Plasma membrane
Intercellular space 
Connexin monomer -4
Hydrophobic channel
Figure 1.3: Structure of Gap Junction intercellular channels. The structure of a gap junction channel 
formed by opposing connexons present in the plasma membrane of two adjoining cells. A connexon is a 
multimeric transmembrane structure composed of six Cx subunits.
Homomeric connexon / 
homotypic gap junction
Homomeric connexon / 
heterotypic gap junction
Heteromeric connexon / 
heterotypic gap junction
Figure 1.4: Putative potential combinations of connexons and Gap Junction channels in 
adjoining cells. Six connexon subunits oligomerise into a connexon or hemichannel that dock into 
different arrangements. They include homotypic channels that are made from two identical homomeric 
connexons, heterotypic/homomeric channels made from two homomeric connexons of different Cx and 
heteromeric/heterotypic channels made from a combination of either heteromeric or homomeric 
connexons with a heteromeric connexon.
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1.2.2 Connexins: The gap junction channel forming proteins
1.2.2.1 Nomenclature of connexin proteins and genes
Early research involving the produetion of antibodies to the main protein in isolated liver gap 
junction preparations and the synthesis of oligonucleotide probes based on the amino terminal 
sequence information led to the isolation o f rat and human cDNA clones encoding a liver gap 
junction protein of 32kDa (Lau et al., 1992, Paul, 1986). The proof that this protein produces 
gap junction channels came from its expression in Xenopus oocytes (Ebihara et al., 1989, 
Swenson et al., 1989, Werner et al., 1989) which later became evident that there was a family 
of subunit gap junction proteins when Beyer et. al. (Beyer et al., 1987) isolated cDNA clones 
encoding a polypeptide o f 43kDa corresponding to a rat heart gap junction protein which they 
named Cx43.
While Cxs were originally denoted according to the tissue of origin or the apparent size of a 
polypeptide as determined by SDS-PAGE, it soon became clear that such designations were 
deemed inappropriate because many o f these proteins are not uniquely expressed in a single 
tissue (Beyer et al., 1987) and that their mobility’s on SDS-PAGE vary with electrophoresis 
conditions (Green et al., 1988). Hence, in order to distinguish members of this family, a 
standard nomenclature was needed. The most widely used system uses Cx followed by a 
suffix indicating the predicted molecular mass of the polypeptide Cx in kilodaltons (kDa) to 
distinguish different protein subunits (Beyer et al., 1987, Beyer et al., 1990).
The finding that two or more Cxs may have similar molecular mass has led to the use o f a 
decimal point to distinguish them. Some confusion has also been created when orthologous 
and functionally homologous Cxs have different molecular masses leading to the proposal of 
an alternative nomenclature in which Cxs are classified in subclasses according to amino acid 
sequence homology (O'Brien et ak, 1998, Risek et al., 1990, Willeeke et al., 2002). This
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system was developed when Cx genes were separated into subgroups which include the a, p, 
y, 6 and s subgroups based on sequence homology (Gimlieh et al., 1990, Kumar and Gilula, 
1992). It is not clear if there are specific protein sequences or domains that reliably define 
either group, nor are there functional correlates to the sequence differences. Analysis of 
several subsequently characterized Cx protein sequences suggests that this categorisation 
scheme needed to be restructured (Sohl and Willeeke, 2003). However, the Greek letter 
classification forms the basis for the current official nomenclature for identification o f Cx 
genes. They are named starting with Gj for mouse or GJ for human genes as an abbreviation 
for gap junction, followed by a letter indicating the Greek letter subgroup, and then a number 
indicating the order o f discovery. In the most studied organisms, human and mouse, 21 and 
20 genes respectively have been identified which encode Cxs (Sohl and Willeeke, 2004, 
Laird, 2006, Harris et ak, 2009, Sohl and Willeeke, 2004) (Table 1.1).
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Table 1.1: Nomenclature o f connexin proteins and genes in human and mouse. The Cx gene 
names have been adopted from those suggested by Sohl and Willeeke (Sohl and Willeeke, 2003) , 
taking into consideration the phylogenetic tree from Cruciani and Mikalsen (Cruciani and Mikalsen, 
2006). For simplicity, pseudogenes have not been included in this table. There is an ongoing discussion 
within the gap junction research community about whether to change the system of naming Cxs in order 
to eliminate discrepancies between the names of orthologous Cxs in humans and other vertebrates.
HUMAN MOUSE
Protein name Gene name Protein name Gene name
Cx43 GJAl Cx43 Gjal
Cx46 GJA3 Cx46
Cx37 GJA4 Cx37 : GJa4
Cx40 GJA5 Cx40 Gja5
Cx50 Cx33 Gja6
Cx59 GJA9 Cx50
Cx62 GJAIO Cx57 GjalO
Cx32 GJBl Cx32 G/67
Cx26 GJB2 Cx26 G/62
Cx31 GJB3 Cx31
Cx30.3 GJB4 Cx30.3
Cx31.1 GJB5 Cx31.1
Cx30 GJB6 Cx30
Cx25 GJB7 Cx45
Cx45 GJCl Cx47
Cx47 Cx29
Cx30.2/Cx31.3 Cx36 G/W2
Cx36 GJD2 Cx30.2
Cx31.9 GJD3 Cx39
Cx40.1 GJD4 Cx23
Cx23 GJEl
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1.2.2.2 Connexin gene structure
Initial identification of Cx genes suggested a relatively simple structure. A typical Cx gene 
consists of a 5’-untranslated region (UTR) designated exon 1 which contains the transcription 
initiation site. This structure is followed by an intron of variable size, a second exon encoding 
the full coding region of the Cx and a 3’ UTR (Sohl and Willeeke, 2004) (Fig 1.5).
Exon 1 Exon 2
(B)
Exon 1A 1B. Exon 2
Exon 1 . .. 2 Exon 3
Exon 1 Exon 2
Figure 1.5: Connexin gene structure. Structure of different Cx gene organisation with the exons 
in purple and the introns in brown. Most Cx genes illustrated contain the complete, uninterrupted 
coding region in a single exon (A, B and C). The variations occur in the 5’-UTR. (A) The initially 
described Cx gene structure contained only one 5’-UTR exon. (B) Some Cx genes contain two or 
more 5’-UTR exons (1A and 1B) that are alternatively utilised due to transcription from tissue 
specific promoters. (C) Other Cx genes contain two or more 5’-UTR exons (1 and 2) that may be 
present with the coding exon 3 in the mature mRNA or that may be alternatively spliced to 
generate multiple mRNA variants. For these Cx genes, multiple mRNA’s can be generated after 
transcription driven from a single promoter. (D) In a few Cx genes, the coding region is interrupted 
by an intron.
Studies by Pfeifer et. al. indicated that the mouse Cx43 gene contains six exons (exons lA  to 
IE), five of which correspond to 5’-UTRs and one containing the coding region (exon 2) 
(Pfeifer et ak, 2004). It also has three alternate promoter regions (PI to P3). Similarly, genes 
for Cx40, Cx45 and other Cxs appear to contain multiple exons allowing the generation of 
alternatively spliced transcripts containing differing 5’-UTRs (Baldridge et ak, 2001, Jacob 
and Beyer, 2001).
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1.2.2.3 Connexin protein structure
Based on cloning studies, hydropathy plots were generated and used to predict the locations 
of transmembrane helices and to produce a topological model for Cxs. The model has been 
tested and verified through the use of immunocytochemistry to determine the cytoplasmic or 
extracellular reactivity of antibodies directed against peptides corresponding to subdomains 
within the Cx polypeptides (Goodenough et al., 1988, Beyer et al., 1989, Yancey et al., 
1989). The strategy has been applied to several Cxs, but the model has been extrapolated to 
all family members. The topological model revealed that Cx are comprised of four membrane 
spanning regions or transmembrane domains (M1-M4), two extracellular loops (El and E2) 
comprise the gap facing extracellular side with characteristically spaced cysteine residues, 
three cytoplasmic portions which include a single intercellular loop (IE), the amino (NT) and 
earboxy terminal (CT) domains (Martin and Evans, 2004, Yeager and Gilula, 1992, Zhang 
and Nicholson, 1994) (Fig 1.6).
H3N " ---------------- ^  I  IL /  f -------- - COO'
Figure 1.6: Connexin protein structure. The general structure of a connexin protein depicting 
its orientation relative to the plasma membrane. The protein contains four transmembrane 
domains (M1 to M4) with the amino terminal and carboxyl terminal domains (NT and CT 
respectively) located on the cytoplasmic side of the membrane. The protein also contains two 
extracellular loops (E1 between M1 and M2, and E2 between M3 and M4) and an intercellular 
loop (IL) between M2 and M3. The IL and CT domains are the most variable regions while E1 and 
E2 are more conserved regions.
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Functionally, when assembled into connexons, the transmembrane domains anehor the 
protein in the plasma membrane; the cytoplasmic domains regulate the physiological 
properties of the channel and the extracellular domains aecount for cell-cell compatibility and 
docking between the channel pairs (White and Bruzzone, 1996, Laird, 2006).
1.2.2.3.1 Transmembrane domains
Topological studies have shown that the four transmembrane domains (M1-M4) are 
composed of about 20 amino acids. Further analysis into the transmembrane sequenees lead 
to a hypothesis which stated that the M3 transmembrane domain contains a series of well 
spaeed polar amino acids forming an amphipathic a-helix. Therefore, it was proposed that the 
M3 transmembrane domains of each Cx subunit form the innermost boundary o f the 
transmembrane pore (Milks, 1988).
1.2.2.3.2 Cytoplasmic domains
Compared to the transmembrane and extraeellular domains, the eytoplasmic domains are the 
domains that diverge on their amino aeid composition. The difference among Cx family 
members is due to structural differences within the cytosolic areas (Vinken et ak, 2006). X- 
ray diffraetion and acidification studies have shown that although the cytoplasmic domains 
are structurally variable throughout the Cx family, they exhibit a high degree o f flexibility 
within the intercellular channel that are functionally involved in the opening and closing of 
the channel pore (Makowski et ak, 1977). It was originally proposed that the carboxyl tail of 
the cytoplasmic domains, in particular for Cx43, acts as an independent binding particle that 
recognises and non eovalently binds to a specific peptide sequenee at or near the pore 
(partiele-receptor hypothesis) that results in the closing and opening o f the channel pore 
(Morley et ak, 1996). The cytoplasmic carboxyl tail of Cx is also considered to be a major 
target of post translational events sueh as phosphorylation that further regulate connexon 
assembly into GJs and channel gating (Wam-Cramer et ak, 1998).
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1.2.2.3.3 Extracellular domains
The extracellular loops (El and E2) display the highest conservation in sequenee. They are 
charaeterised by three cysteine residues in a eharaeteristieally conserved spacing that follows 
the pattern, CXgCXgC in E l and CX4CX5C in E2 respeetively (Hoh et al., 1991, Elfgang et 
al., 1995). The “X” represents the integration of any amino acid and the subscript number 
signifies the number of residues.
The extraeellular loop cysteine residues are also known to engage in intramolecular 
disulphide bridge formation and it has been established that disulphide bonds do not form 
between two opposing connexons in a GJ channel, but rather, they form within the two 
extracellular loops o f a Cx (Dupont et ak, 1989, John and Revel, 1991, Rahman and Evans, 
1991, Foote et ak, 1998). Disruption of these motifs has been shown to abolish GJ funetion 
indicating the importanee o f secondary and tertiary structures imposed on Cx topology by 
disulphide bonds (Dahl et ak, 1991, Dahl et ak, 1992).
1.2.3 Molecular structure of the gap junction membrane channels
Based on atomic force microseopy (Hoh et ak, 1993, Lai et ak, 1995, Lai and Lin, 2001) and 
eleetron crystallography (Perkins et ak, 1998, Unger et ak, 1999) combined with 3-D 
computer modeling, it was shown that the extracellular interface of a homomeric connexon is 
a torus arrangement consisting of alternating “peak and valley” motifs. GJ ehannels are 
formed by the end to end non covalent interaction o f two connexons. The docking o f the two 
apposing connexons is mediated by a 30° rotation in such a manner that the peaks o f one 
hemiehannel fit into the valleys of the other (Perkins et ak, 1998, Unger, 1997) (Fig 1.7). This 
“key and loek” arrangement offers an increased surface area for the formation of hydrogen 
bonds, hydrophobic and/or other attractive interactions that keep the two connexons tightly 
sealed.
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Figure 1.7: Computer modelling of connexons and Gap Junction channels. (A) Computer 
generated model of a connexon illustrating the “p^aks and valleys” topology of the extracellular 
surface. Note the different appearances of the surface structure of the extracellular and 
cytoplasmic surfaces (Reproduced from Perkins et. al 1998). (B) Reconstruction of a C-terminally 
truncated 0x43 channel. The entire channel is shown on the left of the panel and on the right side 
of the panel; the density of the channel has been cropped to show the channel interior. The 
approximate boundaries for the membrane bilayers (M), extracellular gap (E) and the cytoplasmic 
space (C) are indicated. The red asterisk indicates the narrowest part of the channel (Adapted from 
Unger et. al. 1999).
The outer diameter of a connexon is ~7nm at the intracellular region and ~5nm at the 
extracellular region, the pore diameter narrows from ~4 nm in the intracellular to ~1.5nm in 
the extracellular region. Depending on the length of the CT domain of a Cx, the length of 
connexons ranges from 8.5-12.5nm resulting in channels of 17-25nm length. Protrusions at 
the extracellular interface extend to a range of 1.5-2nm contributing half o f the gap in the 
formation of the channel.
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The connexon ring consists o f 24 closely packed a-helices corresponding to the four 
transmembrane regions contributed by each o f the six Cxs (Yeager and Harris, 2007). As 
previously mentioned, the M3 transmembrane segment has been suggested to line the pore. 
However, the M3 transmembrane segment being the only pore-lining helix has not been 
established. Furthermore, structural studies have indicated that segments o f two 
transmembrane regions from each of the six Cxs may line the pore (Fleishman et ak, 2004, 
Unger et ak, 1999). Cysteine mutagenesis scanning of Cx46 and Cx32 suggested that M l and 
possibly M2 may also contribute to the pore formation (Kronengold et ak, 2003, Skerrett et 
ak, 2002, Zhou et ak, 1997). The identification of a second pore lining helix has remained a 
matter of controversy. Additionally, other parameters that have to be considered are whether 
the channel is in an open or closed state (Sosinsky and Nicholson, 2005). It has been 
suggested that hemichannel closure depends on rigid Cx monomers undergoing a torsional 
tilt, sliding against each other and twisting to occlude the lumen o f the pore at the 
cytoplasmic end (Unwin and Zampighi, 1980, Unwin and Ennis, 1984, Muller et ak, 2002).
1.3 Assembly of gap junction intercellular channels
The assembly of GJ intercellular channels can be broken down into two major parts that 
include; the formation and removal of GJ channels. The formation process involves the 
transcription of the Cx gene, the translation to the Cx protein, the non-covalent 
oligomerisation of sets of six Cx monomers into connexons, the trafficking o f connexons to 
the plasma membrane, their docking with neigbouring connexons and aggregation into GJ 
plaques. The removal process involves internalization of either portions o f GJ or entire 
plaques and degradation o f connexons and constituent Cx proteins (Koval, 2006, Evans et ak, 
2006a, Laird, 2006).
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1.3.1 Half life time of plasma membrane gap junction plaques
Pulse-chase analysis o f metabolically labeled Cx in tissue culture cells and whole organs has 
revealed that the pool of newly synthesised, immunoprecipitable Cx protein has a half life 
time of only 1.5 to 3.5 hours (Traub et al., 1989, Musil et al., 2000, Beardslee et al., 1998, 
Darrow et al., 1995, Thomas et al., 2005). Although highly unusual for plasma membrane 
proteins, which typically have turnover rates o f greater than 24 hours, rapid degradation 
kinetics are common characteristics of cytosolic and nuclear proteins involved in signal 
transduction. For several such regulatory molecules, a decrease in their turnover rate is a 
physiologically important mechanism whereby their function is prolonged or enchanced. 
Because GJ assembly appears to be a cooperative self assembly process, reducing the rate of 
Cx degradation would lead to a large increase in GJ formation and intercellular 
communication. It has been found in treatments that decrease Cx turnover rapidly induce the 
assembly o f cell surface Cx43 into long lived, functional GJs (VanSlyke and Musil, 2002, 
Musil et ak, 2000, Laird, 2006).
1.3.2 The biosynthesis and assembly of connexins into gap junction intercellular 
channels
Cxs are synthesised and co-translationally inserted within the endoplasmic reticulum (ER) as 
four transmembrane integral membrane proteins (Ahmad et ak, 1999, Falk et ak, 1994, Falk 
and Gilula, 1998, Zhang et ak, 1996). The precise location of their oligomerisation remains 
the subject of debate; however, some results indicate that Cxs assemble into connexons 
during their presence in the ER-Golgi intermediates and others favour the assembly to 
connexons in the trans-Golgi network. The only identified exception is Cx26, which has been 
demonstrated to bypass the Golgi network and be directly trafficked to the plasma membrane 
(Zhang et ak, 1996, Ahmad and Evans, 2002). Recent studies by VanSlyke et. al. (VanSlyke 
et ak, 2009) had indicated that the expression level o f Cx32 and Cx43 influences assembly
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into connexons during trafficking through the trans-Golgi network. This led to the hypothesis 
that folding, trafficking and oligomerisation occurs gradually.
Transport of connexons to the cell surface generally follows the conventional secretory 
pathway; passage from ER to intermediate compartment and from there to the cis- medial- 
and trans-Golgi cisternae, the trans-Golgi network and to the plasma membrane (Fig 1.8) 
(Musil and Goodenough, 1993, Laird et ak, 1995, Koval et ak, 1997, Lauf et ak, 2002, 
Thomas et ak, 2003, VanSlyke and Musil, 2000).
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Figure 1.8; Life cycle of connexins. The GJ life cycle is a complex multi-step pathway which 
involves Cx biosynthesis and insertion into the ER, connexon assembly and trafficking to the 
plasma membrane, channel docking, GJ internalisation and Cx degradation. Cxs furthermore 
interact with many protein partners, some of which are indicated in this figure. (1) and (2 ) in the 
figure indicate two alternative pathways for vesicle transport to the plasma membrane {Adapted 
from Laird 2009).
Studies from live cells, using fluorescent protein tagged Cxs have shown that Cxs enter a 
variety of transport intermediates of different sizes and shapes en route to the plasma 
membrane (Jordan et ak, 1999, Lauf et ak, 2002, Thomas et ak, 2005). Cx transport may be 
mediated in part by microtubules, which appear to act by improving the effieiency of
38
delivery. This role has been identified using nocodazole i.e, a drug that disrupts microtubules 
(George et al., 1999, Johnson et al., 2002, Martin et al., 2001, Lauf et al., 2002, Thomas et al., 
2005). Brefeldin A (a drug that disrupts the Golgi apparatus) has been used to identify an 
alternative pathway in which Cxs bypass the Golgi apparatus (George et al., 1998a, George et 
al., 1999, Martin et al., 2001). Once within the lipid bilayer of the plasma membrane, 
connexons diffuse laterally and dock with connexons from adjacent cells to form GJs under 
the guidance of specific N- and E- cadherin based events (Musil et ak, 1990, Jongen et ak, 
1991, Meyer et ak, 1992, Wei et ak, 2005). Pulse chain and fluorescent recovery after 
photobleaehing (FRAP) experiments have shown that new GJ channels form at the edge of 
GJ plaques whereas the older ones accumulate in the centre of the plaque (Gaietta et ak, 
2002, Lauf et ak, 2002).
The undocked connexons or hemichannels that are trafficked to the plasma membrane remain 
closed under physiological conditions (Saez et ak, 2005, Evans et ak, 2006b). However, they 
are reported to open in low extracellular Ca^^ or Mg^ "^  solutions (Valiunas and Weingart, 
2000, Valiunas et ak, 2002). Whether a connexon becomes docked into a GJ channel or 
remains a hemichannel likely depends on the physiological condition and the correlating 
phosphorylation status of the Cxs (Saez et ak, 2005).
1.3.3 Gap junction degradation
Because GJ channels have short half lives, an efficient mechanism must exist to internalise 
and degrade them. Unlike for most other types of protein assembly, turnover o f a GJ plaque 
involves two cells. Previous studies have documented the formation of “annular junctions” in 
which an intact GJ plaque is internalised as a double membrane structure into the cytosol of 
one o f the two partner eells (Jordan et ak, 2001). The factors that determine which o f the two 
cells receive the vesicle is still unknown.
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Electron microscopic imaging have suggested that “aged” channels that reside in the centre of 
the plaque are internalised which suggests that not only large membrane areas can be 
endocytosed and Cx degradation can occur without destroying entire GJs (Falk et ak, 2009, 
Gaietta et ak, 2002). It has been suggested that two pathways regulate GJ quantity by 
endocytosis. They are 1) the internalisation of entire GJ plaques in order to be able to regulate 
GJ communication and 2) the internalisation and degradation of small vesicles derived from 
the centre of the GJ for renewal of channels in an individual plaque (Falk et ak, 2009).
Degradation of Cxs either follows the lysosomal or the proteasomal ubiquitin mediated 
pathway. Evidence supporting the lysosomal degradation pathway eomes from electron 
microscopy data and studies performed in cells treated with inhibitors of lysosomal enzymes 
such as leupeptin and ammonium chloride (Leithe and Rivedal, 2004a, Leithe and Rivedal, 
2004b, Qin et ak, 2003, Berthoud et ak, 2004). These studies indicate that internalised Cx- 
enriched fragments localise and fuse with lysosomes. In the case o f proteasomal degradation, 
there is a substantial body of evidence from the use o f proteasomal inhibitors and from the 
finding that Cx43 is a suitable substrate for ubiquitin (Laing and Beyer, 1995, Musil et ak, 
2000, Leithe and Rivedal, 2004b). An emerging view from this work is that proteasomes may 
act primarily in ER-associated degradation as a quality control of protein folding and 
assembly, whereas lysosomes play a major role in degrading Cxs from the plasma membrane 
(Salameh, 2006, Laird, 2006).
1.4 Biochemistry of gap junction channels
1.4.1 Interactions between gap junctions and adhesion molecules in the cell membrane
The relationship among adherens junctions, tight junctions and GJs has been explored in 
many cell types with generally consistent but occasionally conflicting results (Fujimoto et ak, 
1997, Wu et ak, 2003). Adherens junctions are known to provide strong mechanical
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attachments between cells mediated by cadherins. Cadherins contain an extracellular domain 
that can homodimerise, thereby bringing cells into close contact. Through interactions with 
catenins via their intracellular domains, they can remain anchored to the actin cytoskeleton. 
Tight junctions perform a barrier function in epithelial cells, creating a tight seal between 
cells thereby defining and restricting movement o f integral membrane proteins between the 
apical and basolateral surfaces.
In many, although not all cases, formation of adherens junctions has been shown to be 
necessary for and to precede GJ formation. This association is generally thought to reflect the 
physical need for membranes to come into close proximity for hemichannels in apposing 
cells to dock (Xu et al., 2001, Luo and Radice, 2003). In addition, adherens junction proteins 
are likely involved in signaling pathways that promote GJ assembly. This is consistent with 
the fact that the ability of cadherins to enhance GJ formation can be dependent on cell type 
(Meyer et ak, 1992, Paul et ak, 1995, Lee et ak, 1987).
Consistent with much of the data is a model in which adherens junction formation or cross- 
linking o f cadherins activates a signaling pathway that promotes delivery o f Cx containing 
vesicles to the plasma membrane so that GJs form in the vieinity of adherens junctions 
(Fujimoto et ak, 1997). This is supported by time-lapse studies in cardiomyocytes, where a 
Ca^ "^  switch was used to induce junction formation. In this study, accumulation of adherens 
junctional components such as a-catenin, p-catenin and ZO-1 occurred at the plasma 
membrane before Cx43 accumulation at the same sites (Wu et ak, 2003). Another time-lapse 
study utlilising live cell imaging and fluorescenee microseopy on transiently transfected 
HeLa cells showed increased delivery of Cx43 containing vesicles to the plasma membrane 
in cells in which N-cadherin was cross linked (Shaw et ak, 2007). This study also showed 
evidence that both GJs and adherens junctions may provide tethering sites for plus end
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microtubules carrying Cx43 cargo, allowing for directed delivery o f Cx43 to the sites of cell­
cell contact (Shaw et al., 2007).
Other studies using biochemical techniques and immunofluorescence microscopy show that 
the interaction between adherens junction components and Cx43 occurs intracellularly and 
that catenins, cadherins Cxs and ZO-1 form complexes in the secretory pathway that are 
delivered to the plasma membrane together (Wei et al., 2005, Wu et al., 2003). This study had 
also shown that N-cadherin was quickly internalised after plasma membrane arrival, leading 
to a decrease in adherens junctions, whereas GJs were not affected arguing that the important 
interactions are oceurring before Cxs reach the plasma membrane (Wei et ak, 2005).
GJs, especially those containing Cx32 have also been convincingly shown to be associated 
and intermingled in tight junction strands by freeze fracture electron microscopy (Kojima et 
ak, 2001, Fujimoto et ak, 1997) and that they can be co-immunoprecipitated along with 
several tight junction proteins such as occluding and claudins (Kojima et ak, 2001, Nagasawa 
et ak, 2006). Thus, there are substantial and convincing data showing that adherens and tight 
junction components interact with and affect the Cx life cycle both at the plasma membrane 
and secretory compartments. Additionally, there are common proteins found in cell-cell 
junctions also known as scaffolding proteins such as ZO-1 and ZO-2. ZO-1, which is binding 
partner of Cx43 based on a number of studies, interacts with all Cxs that contain a Post 
synaptic density protein. Drosophila disc large tumor suppressor and ZO-1 (PDZ) binding 
motif in their CT (Giepmans, 2004).
As a scaffolding protein, ZO-1 provides a linkage between the different cell-cell junctions, 
junctional components and the cytoskeleton. In studies involving Cx43, ZO-1 interaction has 
been shown to be cell cycle regulated. In rat kidney cells, Go-phase cells show increased 
colocalisation and interaction of ZO-1 and Cx43 by immunofluorescence and western blot
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analysis (Singh et al., 2005). This correlates with the report that Go is the phase in which rat 
kidney cells are most efficient at GJ assembly (Solan et ak, 2003). However, in spite of being 
a well described Cx interacting protein, the functional significance of the interactions o f Cxs 
with ZO-1 has remained elusive.
1.4.2 Regulation of gap junction channels 
1.4.2.1 Intracellular Ca^^
The closure of GJ by intracellular Ca^^ plays a vital role in protecting intact cells from
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membrane depolarisation and leakage of metabolites through GJs by uncoupling them from 
damaged cells. The GJ sensitivity to Ca^^ ranges from nanomolar (nM) to micromolar (pM) 
concentrations and depends on Cx and cell types (Rose and Loewenstein, 1976, Dahl and 
Isenberg, 1980, Noma and Tsuboi, 1987, Neyton and Trautmann, 1985, Peracchia, 1990, 
Lazrak and Peracchia, 1993). However, it is not completely understood whether Ca^^ acts on 
GJ channel gating directly or through some intracellular intermediates. High Ca^ "^  medium 
does not alter the permeability o f Cx32 hemichannels incorporated into liposomes (Bevans 
and Harris, 1999). Furthermore, many experimental studies suggest that Ca^^ dependent GJ 
gating may be mediated by calmodulin (Peracchia, 2004). It contains specialised domains in 
the N- and C-lobes that follow NH2-terminus. Ca^^ binding to these domains induce 
conformational changes enabling calmodulin to interact with receptors. Such interaction was 
demonstrated with Cx38, Cx32, Cx37, Cx43, Cx44 and Cx50 (Peracchia et ak, 2000, Sotkis 
et ak, 2000, Zhou et ak, 2009, Zhang et ak, 2006).
1.4.2.2 Intracellular pH
Sensitivity to intracellular pH depends on Cx type. Delmar et. ak tested gj (macroscopic 
junctional conductance)-pH dependence in oocyte pairs expressing different Cxs and have 
shown the following order of decreasing sensitivity to pH:
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Cx50>Cx46>Cx45>Cx26>Cx37>Cx43>Cx40>Cx32 (Stergiopoulos et al., 1999). 
Protonation o f histidine residues in CT and IL o f Cxs modulates GJ channel permeability. 
The latest study provided evidences that pH- dependent increase in gj o f Cx57 GJ channels 
was caused by an increase o f channel open probability and number of functional channels 
(Palacios-Prado et al., 2009). Furthermore, Cx36 GJ channels demonstrate opposite gj 
dependence on pH (Gonzalez-Nieto et al., 2008). However, these data contradict earlier 
reports demonstrating uncoupling of Cx36 GJs under acidifieation with CO2 (Teubner et al., 
2000). By now, it is not completely clear whether pH acts directly on GJ channels. 
Heteromeric Cx26/Cx32 hemichannels incorporated into liposomes were insensitive to low 
pH when buffered with maleate, bicarbonate or Tris, but showed some pH sensitivity in the 
presence of aminosulfonate buffers (Bevans and Harris, 1999). Henee, it was concluded that 
pH affected GJ gating indirectly via protonation of endogenous aminosulfonate taurine (L. 
Harris, 2001). However, sensitivity of Cx46 hemichannels to cytoplasmic pH suggests that 
gating is affected by direct protonation (Brady Trexler et al., 1999).
1.4.2.3 Connexin phosphorylation
Cytoplasmic CT of Cxs contains multiple serine, threonine and tyrosine residues that may be 
phosphorylated by various protein kinases. Activation of protein kinases (Cottrell et ak, 2003, 
Duncan and Fletcher, 2002, Simes et ak, 2009) or phosphotases (John et ak, 2003) may eause 
changes in cell-cell communication and rapid turnover o f channels (Laird, 2005, Lampe and 
Lau, 2004a). Phosphorylation modifies electrical and metabolic communication between cells 
by changing channel molecular structure that affects channel unitary conductance, mean open 
time or open probability (van Veen et ak, 2000). Furthermore, phosphorylation alters the net 
charge o f CT that in turn may modulate voltage or pH sensitivity of Cxs.
Cx43 has been the most intensively studied Cx as it is present in atleast 34 tissues and 46 cell 
types (Solan and Lampe, 2009). Cx43 does not contain serine residues in IL and there are no
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reports on phosphorylation of Cx43 N-terminus. However, kinase activation can cause 
phosphorylation o f S368 by PKC, S255, S279 and S282 by mitogen-activated protein kinase 
(MAPK), S325, S328 and S330 by casein kinase CKl, S247 and S265 by Src tyrosine kinase 
and S364, S365, S3 69 and S373 by PKA in the C-terminus. Elucidation o f the role of single 
kinase in regulation of Cx properties and expression is quite sophisticated because it often 
exerts not only direct effects but causes the activation of other kinases with successive 
phosphorylation o f multiple residues and overlapping consequences (Solan and Lampe, 
2009).
1.5 Gap junction modulators
Despite the universality in multicellular organisms of GJIC, relatively few reagents are 
known that block GJIC in an acceptably specific manner. The GJ channel is well insulated 
from the extracellular space, and access to allow direct channel modulation appears to be 
restricted.
PKC has received considerable attention beeause PKC activators which promote 
tumorigenesis, both increase Cx43 phosphorylation and decrease GJ communication in a 
number o f different cell types (Brissette et ak, 1991, Reynhout et ak, 1992, Lampe, 1994). 
Several PKC isofroms are implicated in Cx43 regulation (Lampe and Lau, 2004b, Bowling et 
ak, 2001, Cruciani et ak, 2001). The introduction o f several inhibitors and activators o f PKC 
specific for different isotypes has helped identify PKC isomers responsible for Cx43 
regulation (Bowling et ak, 2001, Lampe and Lau, 2004b, Cruciani et ak, 2001). For example, 
PKCy can associate with Cx43 and reduce Cx43 GJ formation in lens epithelial cells. 
Experiments with specific inhibitors also indicate that PKCa, -p and -6  can disrupt coupling 
between fibroblasts (Lampe and Lau, 2004b). Furthermore, PKCa and -8  can associate with 
Cx43 in cardiomyocytes (Bowling et ak, 2001).
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1.5.1 Chemical inhibitors
Classical inhibitors of GJs -  octanol, heptanol, carbenoxolone and the anaesthetic halothane 
have been suggested to limit GJIC by dissolving in the membrane lipids, inducing localised 
changes in membrane fluidity that lead to contraction or squeezing of intercellular channels. 
However, it is likely that other ion channels are also modified by these lipophilic compounds, 
thus comprising their specificity. Sharing the same drawback of a general action on other 
membrane channels besides GJs is the fatty acid amide; oleamide, which affects many 
physiological functions, including sleep, thermoregulation, sensitivity to pain and 
angiogenesis (Boger et ak, 2000). Furthermore, the actions o f oleamide, as well as the 
increasingly popular 18-a-glycyrrhetinic acid, a lipophilic aglycone with a steroidal structure 
isolated from liquorice root, and the structurally related cardiotonic digitalin ouabin 
(strophanthin G) are metabolically complex for they act indirectly on GJs, for example 
through activation o f protein kinases, G-proteins or transport ATPases. The general metabolic 
sequel of effects of such broad inhibitors are often reflected by changes occurring in the 
multiple phosphorylation sites located in the CT of specific Cxs (Goodenough et ak, 1996).
Fatty acid GJIC inhibitors, especially oleic and arachidonic acids, act on GJs in the heart and 
have been examined in detail by electrophysiological approaches (Hirschi et ak, 1993, 
Lavado et ak, 1997, Schmilinsky-Fluri et ak, 1997). These studies suggest that their effect in 
modifying the conductance of GJs may involve changes in lipid biosynthetic and signalling 
pathways that underpin normal operation of GJs. Anandamide, an endogenous cannabinoid 
mimetic metabolically related to arachidonic acid, appears to influence GJIC indirectly by 
depleting internal calcium stores, implicating modification of phospholipase C activities 
(Venance et ak, 1997). Tamoxifen, a synthetic non-steroidal triphenylethylene derivative and 
anti-tumour reagent, blocks the intercellular transfer of fluorescent dyes in a protein kinase- 
independent manner i.e, without modifying the phosphorylation of Cx43. Paradoxically, this
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anti-tumour drug also increases the extent of propagation o f intercellular calcium waves 
(Zhang et ah, 2000). A variety of tumour promoters influence GJIC; for example, phorbol 
esters act on the assembly of GJs and other adhesive junctions such as cadherins (Jansen et 
al., 1996). In summary, the above mentioned inhibitors certainly block intercellular 
communication, but their mechanisms o f action frequently lead to other complex and non­
specific effects.
1.5.2 Connexin mimetic peptides
Cx mimetic peptides are short synthetic peptides corresponding to chosen sequences in the 
extracellular loops of Cxs. They were developed by screening the efficacy of a range o f short 
peptides covering most of EL 1 (50 amino acids) and EL 2 (60 amino acids) o f Cx32 in 
delaying synchronised contraction by aggregating myocytes dissociated from chick hearts 
(Warner et ak, 1995). These cells express mainly an unknown Cx homogous to Cx32 
characterised in mammals (Barker and Gourdie, 2002). Similar short synthetic Cx peptides 
were used to dissect the docking process of connexons expressed in paired Xenopus embryos 
(Bao et ak, 2004b). Once formed, GJs, especially when large numbers o f units accrete 
laterally in the plasma membrane, are extremely difficult to tear apart into the constituent 
hemichannels.
Experimentally useful inhibitory peptides emerging from subsequent work correspond to 
mainly extracellular sequences in Cx43 positioned next to the second and fourth 
transmembrane domains and have been labelled GAP26 (EL 1; VCYDKSFPISHVR) and 
GAP27 (EL 2; SRPTEKTIFII and SRPTEKNVFIV) (Fig 1.9) (Chaytor et ak, 1997, Dahl et 
ak, 1994, Oviedo-Orta et ak, 2000, Oviedo-Orta et ak, 2001). GAP27 incorporates the 
sequenee SRPTEK present in most Cxs and the utility of this potential universal GJ- 
inhibitory peptide was found to be enhanced significantly by including amino acids that are 
located in the fourth transmembrane region (Chaytor et ak, 1999).
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The utility of these benign and reversible inhibitors of GJIC aeting from the outer aspeet of 
eells has been documented in a number of systems. They bloek the intercellular transfer of 
fluoreseent dyes in various cultured cells (Oviedo-Orta et al., 2001, Oviedo-Orta et al., 2000), 
the propogation of calcium waves across groups of confluent cells and electrical 
communication (Isakson et al., 2001, Boitano and Evans, 2000). The effects of the Cx 
mimentie peptides on communication efficiency in tissues has, so far, proved difficult to 
demonstrate for technical reasons. However, the inherent specifieity of the inhibition of GJIC 
by Cx mimetic peptides makes them ideal candidates for the eventual modulation of tissue 
and organ function.
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Figure 1.9: GAP26 AND GAP27 connexin mimetic peptides position in the intercellular gap 
region of the junction. Topographical representation of connexin mimetic petides positions, GAP26 
binds to extracellular loop 1 and GAP27 binds to extracellular loop in turn distrupting the formation of 
functional gap junction channels. (Adapted from Evans et. al. 2001).
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1.6 Intercellular communication across gap junctions in the immune system
1.6.1 Connexin expression in cells of the immune system
Multiple cell types of the immune system have been shown to express Cxs (Table 1.2; Fig 
1.10). These cells usually have different functions and control immune responses or execute 
these in a series of different manners (Oviedo-Orta et al., 2001). For example, phagocytic 
cells of the innate immune system are dendritic cells (DCs) and monocytes/macrophages. 
These cells express Cxs and can form functional GJs between identical (Matsue et al., 2006, 
Eugenan et al., 2003) as well as different cells (Krenacs et al., 1997, Martin et al., 1998b). 
Cxs are expressed by almost all immune cells and can be upregulated when the immune cells 
become exposed to inflammatory factors (Eugenan et al., 2003).
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Table 1.2: Connexin expression in Immune cells. Cx43 is expressed in almost all immune cells. In 
most cases, expression of Cx can facilitate the formation of both homo- and heterotypic gap junctions. 
Transfer of information in the form of small molecules play an important role in many processes critical 
for the proper functioning of the immune system (Adapted from Oviedo-Orta at. at. 2004).
Connexin Isotype Cell Type Function
Cx43 Bone marrow derived DC Cross presentation 
DC activation
Bone marrow stromal eells Haematopoiesis
Haematopoietic stem eells Germinal centre development
Follicular DC Cross-presentation
Monocytes 
Tonsil DC
Appendix DC 
Langerhans cells
Inflammation
Macrophages 
Thymus epithelial eells
T cell development
T cell progenitors Maturation
T eells Antibody secretion
B cells Activation
NK cells Unknown
Mast cells Extravasation
Neutrophils Maturation
Cx40 T eells Immunoglobulin secretion
B eells Atherogenesis
Cx37 Macrophages Prevention o f atherosclerosis
Monocytes Unknown
Cx32 Mast eells Unknown
Cx30.3 Thymocytes
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Figure 1.10: The distribution of connexins in the primary and secondary lymphoid organs.
The connexin mediated interactions may operate between monocytes (M), lymphocytes (L), 
macrophages (MOs) and endothelial cells of the vascular wall. The lymphocytes and monocytes 
cross the endothelium by communicating with each other via gap junctions or by ATP/NAD^ 
released by the undocked connexin hemichannels. (Adapted from Oviedo-Orta et. al. 2004).
Immune cells originate in the bone marrow. Immune stem cells located in the bone marrow 
may communicate with their surrounding stromal cells since both express Cx43 (Cancelas et 
al., 2000). These stem cells can differentiate into the nine defined circulating blood cells, 
including all members of the cellular immune system. In this early phase of haematopoiesis, 
Cx43-containing GJs appear to be critical for terminal differentiation of primary T and B 
cells as tested in Cx43 deficient mice (Montecino-Rodriguez et al., 2000).
T and B cells further develop or are activated in the lymphoid organs like the thymus and the 
lymph nodes. In the thymus, progenitor T cells have extensive contact with the surrounding 
thymic epithelial cells and thymic DCs. These cell types express Cx43, possibly allowing 
homo- and heterotypic interactions (Montecino-Rodriguez et al., 2000). In secondary
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lymphoid organs, the T cells encounter antigen presented by DCs. T cells that are not deleted 
during negative selection in the thymus migrate into peripheral tissues to search for antigenic 
information in the form of peptides. The expression o f Cx43 by these T cells might allow 
communication with surrounding tissues, possibly allowing proper activation and 
differentiation.
B cells also express Cx43 and they may interact via GJs with follicular DCs in the secondary 
lymphoid organs. The coupling o f these cells and might help synchronising genrminal centre 
events or facilitate transfer of antiapoptotic molecules to rescue B cells from apoptosis 
(Krenacs et al., 1997). T, B and NK cells isolated from tonsils express low levels o f Cx40, 
but the function of GJs in these cells and their connected tissue is unknown. It has been 
proposed that these cells form hemichannels composed o f Cx40 and that these channels 
facilitate ATP-mediated propagation o f Ca^^ waves (Oviedo-Orta et al., 2001, Oviedo-Orta, 
2002). B cells ultimately produce antibodies and T helper cells control this process. Oviedo- 
Orta et. al. studied the role of GJs in a mixed lymphocyte culture and showed that GJ 
communication is required for efficient antibody secretion by B cells (Oviedo-Orta, 2002). 
Although the exact intracellular signals being exchanged are unclear, the result show that GJ 
mediated intercellular signaling to B cells is required for optimal antibody production.
DCs also express GJs to communicate with their environment. In addition, human monocytes 
as well as DCs upregulate Cx43 and form GJs when detecting inflammation suggesting that 
they contact the environment to sample metabolic information from neighboring cells in 
response to infection (Eugenan et al., 2003, Neijssen et al., 2005). It has been shown that GJ 
communication between DCs is required for their activation, but the specific signals 
involved/transferred between the cells are unclear (Matsue et al., 2006).
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1.6.2 Pathogenesis of inflammation
The inflammatory response is an important homeostatic mechanism to counter tissue 
dyregulation and malfunction, and is classically viewed as a reaction to infection or tissue 
injury (Medzhitov, 2008). In this context, inflammation is an important physiological process 
resulting from a complex network o f cellular and molecular processes. The inflammatory 
response is inititated by the recognition of a proinflammatory stimulus by immune sensors 
which is followed by the release of proinflammatory mediators and leads to the activation of 
effector cells and tissues. However, several different factors may promote inflammation and 
contribute to vastly different outcomes ranging from tissue repair to detrimental chronic 
inflammation that underpins diseases with an auto-immune component such as type II 
diabetes and atherosclerosis (Barton, 2008, Pickup, 2004).
Leukocyte infiltration to the site of infection or injury is one of the key steps in the initiation 
of an inflammatory response. It has been shown that the pro-inflammatory cytokine IL-6 
plays an important role in modulating this process through the upregulation o f adhesion 
molecules and chemokine secretion by endothelial cells (Hurst et al., 2001). In addition, the 
secretion of chemokines, vasoactive amines and eicosanoides by tissue resident macrophages 
and mast cells mediates the extravasation of leukocytes and plasma proteins to the site of 
inflammation (Medzhitov, 2008, Cailhier et al., 2006). Neutrophils are the first and most 
abundant cell type at the site o f inflammation and these cells are activated by 
proinflammatory cytokines secreted by the tissue resident cells or through direct contact with 
pathogens which leads to degranulation and the release of anti-microbial compounds such as 
reactive oxygen species, as well as enzymes such as proteinase 3, cathepsin G and elastase 
(Hurst et al., 2001, Segal, 2005). These are non-specific effector proteins and cause damage 
to host tissues while destroying pathogens. However, removal of the initial instigator of 
inflammation leads to the initiation of the resolution and repair phase. This proeess is largely
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mediated by macrophages that remove apoptotic cells and debris by phagocytosis (Khanna et 
ah, 2010). This results in macrophage polarisation toward an anti-inflammatory profile (Chan 
et ah, 2011). These cells secrete several other anti-inflammatory molecules including IL-10, 
resolvins, protectins and growth factors. In this way, lasting damage as a result of 
inflammation is avoided. Lipoxins are also important anti-inflammatory lipid mediators that 
promote monocyte recruitment while inhibiting neutrophil recruitment (Segal, 2005, Serhan 
et ah, 2008).
1.6.3 Gap junction communication andinflammation
Cell-cell interactions are of major importance for expanding the competency o f cells in the 
immune system to control infections and maintain tolerance. Activation of adaptive immune 
response involves the interaction between T cell antigen receptors (TCR) and major 
histocompatibility complex (MHC) molecule-peptide complexes. The nanometer scale gap 
between the T lymphocyte and the antigen-presenting cell (APC) is referred to as the 
immunological synapse (Bromley et ah, 2001). Specificity o f these recognitions is critical 
since reactions to microbial peptides are required for clearance of many infections and 
responses to self-derived peptides on APCs can give rise to autoimmunity. Despite, the early 
observation of GJs in lymphocytes and the extensive characterisation of Cx in primary and 
secondary lymphoid organs, knowledge on the potential role of GJs in the immune system are 
limited.
GJs, composed of at least Cx43, between antigen-presenting Langerhans cells and T 
lymphocytes were observed both in vitro and in vivo (Concha et ah, 1988, Concha et ah, 
1993, Saez et ah, 1999, Brand et ah, 1995). Furthermore, it was demonstrated that disruption 
of GJIC influeneed fundamental aspects lymphocyte function, including immunoglobulim 
(Ig) secretion and cytokine production (Oviedo-Orta et ah, 2001). Inhibiton of GJIC by 
synthetic peptides homologous to the first and second EL of Cx43 markedly reduced
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secretion of IgM, IgG and IgA in mixed cultures of activated purified human B and T 
lymphocytes. Additionally, complex temporal inhibitory effects on cytokine synthesis, in 
particular; interleukin-10 (IL-10) was observed in human B an T lymphocytes. These results 
lead suggest that Cxs and GJIC may be an important component of the molecular mechanism 
underlying lymphocyte activation and function in the immune response (Oviedo-Orta and 
Evans, 2002).
1.6.3.1 Gap junction communication in leukocyte recruitment
Cx37, Cx40 and Cx43 are the three Cxs that have been detected in the vascular endothelium 
and the precise distribution of these Cxs within the vessel wall is known to be species and 
vessel specific (van Kempen and Jongsma, 1999). Studies on human umbilical vein 
endothelial cells (HUVEC) have shown the expression o f the three vascular Cxs and their 
location is confined at cell-cell contacts (van Rijen et al., 1998). Furthermore, TNF-a altered 
the Cx expression pattern and reduced GJIC between these endothelial cells (EC) (van Rijen 
et al., 1998). This reduction in GJIC within the endothelium might be a protection of the 
endothelium by restricting the spread o f injurious signals via EC GJs, thus limiting the area of 
inflammation. Additionally, as more Cxs from the ECs become available for docking, they 
might form heterocellular GJs with leukocytes to control leukocyte migration across the 
endothelium. There have been recent indications o f GJs between ECs and leukocytes and that 
GJIC might play a role in leukocyte extravasation.
Oviedo-Orta et. al first described cell communication via GJs during transmigration. They 
demonstrated by using dye transfer experiments that lymphocytes and ECs generate 
functional heterocellular GJ channels during extravasation in vitro (Oviedo-Orta et al., 2002). 
Additonally, blocking GJIC with pharamacological agents or Cx mimetic peptides caused 
only a modest reduction in transmigration of lymphocytes across an EC monolayer (Oviedo- 
Orta and Evans, 2002). Neutrophils and HUVECs also form functional GJ channels in vitro.
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This bidirectional coupling was reduced when HUVECs were stimulated with TNF-a but not 
when stimulated with IFN-y. This indicates that coupling between neutrophils and HUVECs 
is selectively modulated during an inflammatory reaction. Additionally, neutrophil 
transmigration was enhanced when GJIC was inhibited thereby suggesting a negative 
regulatory role for this coupling during transmigration process. It was also shown that 
strongly adherent neutrophils were more coupled than weakly adherent ones and that the 
adhesive properties between connexons played no role in this strengthened cell adhesion 
process (Zahler et al., 2003). This lead to a hypothesis that the tight adhesion mediated by 
integrins and their ligands between leukocytes and ECs might be modulated by signaling 
through GJs.
Human monoeytes were shown to form GJs with ECs in a blood brain barrier model during 
the process of transmigration (Eugenan et al., 2003). The blockade of GJIC using GAP27 Cx 
mimetic peptide reduced the number o f monocytes that transmigrated suggesting that cell-cell 
signaling through GJ channels might even affect the efficiency o f the transmigration process 
across a tight endothelium. Transendothelial migration (TEM) o f the different leukocytes 
appears to be differentially regulated by GJIC such that inhibition of GJIC increased TEM of 
neutrophils but decreased TEM of monocytes and had modest effects on lymphocyte TEM. 
However, more work is required before definitive proof demonstrates that GJs do play a role 
in leukocyte TEM.
1.6.4 Connexins and atherosclerosis
1.6.4.1 Pathogenesis of atherosclerosis
A healthy artery consists of three layers; the tunica intima, tunica media, and tunica 
adventitia. The tunica intima is the layer closest to the arterial lumen and consists of 
connective tissue covered by a layer o f endothelial cells. Atherosclerotic lesions can be
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initiated by injury to endothelial cells through mechanisms such as increased shear stress 
through disruption of laminar flow and hypertension, infection or increased oxidative stress. 
This leads to activation of the endothelial cells and increased permeability resulting in 
increased accumulation of LDL particles within the intima. LDL accumulation in the intima 
leads to aggregation and retention through ionic interactions between proteoglycans produced 
by smooth muscle cells (SMC) and apoB-100 in LDL (Daugherty et al., 2008, Haka et al., 
2009, Hermansson et al.). Oxidation of LDL in the vascular intima is a critical step in the 
initiation of atherosclerotic lesions and occurs through the presence of transition metal ions, 
hemin and other cell-derived free radicals. In addition, several enzymes including 
lipooxygenase and myeloperoxidase as well as reactive oxygen species produced by activated 
macrophages catalyse LDL oxidation (Yoshida and Kisugi, 2010). LDL oxidation occurs in 
stages and minimally modified LDL results from partial oxidation of lipis moieties while 
apoB-100 remains intact. The term oxidised LDL (oxLDL) includes all LDL particles that 
have undergone oxidative modification, and many differ in terms o f size, charge and lipid 
content (Daugherty et al., 2008, Bobryshev et al., 2007).
Activated endothelial cells also show increased expression of vascular adhesion molecules 
such as VCAM-1, ICAM-1 and P-selectin as well as the secretion of chemokines such as 
monocyte recruitment protein 1 and IL-8 which facilitates the adhesion and migration to the 
subendothelial layer of the intima (Yuri V, 2006, Bobryshev, 2005). Once inside the intima, 
the majority o f monocyte differentiate into macrophages but some develop into DC. In the 
lipoprotein rich environment, most macrophages take up large amounts o f oxLDL mainly 
through scavenger receptors (Bobryshev et al., 2007, Libby et a l, 2011). It was also found 
that macrophages take up aggregated LDL complexes through the formation of an acidic 
extracellular hydrolytic compartment, and minimally modified LDL through the LDL 
receptor (Haka et a l, 2009). OxLDL is broken down in the lysosome to cholesteryl-fatty acid
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esters and stored in cytoplasmic droplets associated with the cell membrane. However, at 
advanced stages of foam cell formation, not all the oxLDL is broken down and be found in 
cytoplasmic microvesicles (Bobryshev et al., 2007, Yuri V, 2006). In addition, oxLDL uptake 
activates macrophages, and foam cells are known to produce reactive oxygen species, thus 
promoting LDL oxidation and forming a self propagating loop between lipid accumulation, 
oxidation and immune activation (Libby, 2002).
Foam cell deposition leads to fatty streak formation, the earliest form of an atherosclerotic 
lesion. Fatty streaks are asymptomatic and are present at all ages. They can disappear with 
time or progress to structurally complex atheromas (Yoshida and Kisugi, 2010). Early in 
atherosclerosis, foam cell formation may have a protective effect through the removal of 
oxLDL which is a potent proinflammatory stimulus. However, beyond fatty streak formation, 
foam cell formation contributes to lipid accumulation and plaque growth (Yuri V, 2006, 
Bobryshev, 2005). SMCs normally reside in the arterial media, although increased numbers 
of SMCs are found in the intima in areas of intimai thickening, which are also predisposed to 
atherosclerotic lesion development. Intial SMCs play an important role in the initiation of 
atherosclerosis and, like macrophages, can take up oxLDL to form foam-like cells. In 
addition, these cells promote the accumulation o f monocytic cells in the vascular intima 
through the expression o f adhesion molecules such as VCAM-1 and ICAM-1 and by 
inhibiting apoptosis in these cells (Libby et al., 2011).
Lesion progression is further mediated by migration o f SMCs from the media to the intima 
and differentiation of SMCs into fibroblasts that secrete matrix proteins such as collagen 
proteoglycans that lead to the formation of a fibrous cap (Doran et al., 2008, Sherer and 
Shoenfeld, 2002). At this stage, SMCs play a protective role by containing the lesion through 
secreting extracellular matrix proteins that form the fibrous cap (Doran et al., 2008). The 
lesion underneath the fibrous cap contains immune cells including foam cells, macrophages,
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T cells, DCs, B cells, NK cells, mast cells and neutrophils (Libby et ah, 2011). Excessive 
lipid uptake by macrophage foam cells lead to cell detah due to extensive DNA damage 
caused by oxLDL, and accumulation of extracellular lipid and cellular debris, which 
contributes to the formation o f a necrotic core. Further lipid accumulation contributes to 
plaque growth and with time the plaque becomes inclreasingly acellular due to necrosis of 
foam cells and SMCs at the core (Ira, 1997).
Most stable plaques with an intact fibrous cap remain asymptomatic and more than 75% 
clinieal events associated with atherosclerosis result from plaque destabilisation and rupture 
due to degradation of the fibrous cap. The two main contributory factors to a thin fibrous cap 
is reduced collagen and proteoglycan synthesis due to decreasing SMC numbers and 
increased degradation by matric metalloproteases secreted by macrophages and other cell 
types (Galis et ah, 1994, Andrew C, 2007). When the fibrous cap ruptures, it exposed the 
necrotic core to the blood and this may lead to thrombosis through the release of tissue factor 
expressing microparticles derived from apoptotic cells in the core (Zoll et ah, 2008). The 
formation of an occluding thrombus results in ischaemic damage to downstream organs, 
causing myocardial infarction or stroke. However, the formation of thrombi depends on the 
size and location of the plaque rupture and also on the systemic balance between coagulation 
and fibrinolysis. Therefore, plaque ruptures are often clinically silent and heal through the 
accumulation of SMC that secrete collagen and glycosaminoglycans (Bentzon et ah, 2007). 
This process of plaque rupture and healing may be repeated several times in the same plaque 
and ultimately contributes to arterial stenosis (Hunninghake et ah, 2001). Figure 1.11 is a 
graphical representation of the progression of atherosclerosis from fatty streak formation to 
plaque rupture.
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Figure 1.11: Stages In the development of atherosclerotic lesions. The initial steps of 
atherosclerosis include adhesion of blood leukocytes to the activated endothelial monolayer, directed 
migration of the bound leukocytes into the intima, maturation of monocytes into macrophages, and their 
uptake of lipid yielding foam cells (Panel (a) and (b)). Lesion progression involves the migration of 
SMCs from the media to the intima, the proliferation of resident intimai SMCs and media-derived 
SMCs, and the heightened synthesis of extracellular matrix molecules such as collagen, elastin and 
proteoglycans. Plaque macrophages and SMCs can die in advancing lesions, some by apoptosis. 
Extracellular lipid derived from dead and dying cells can accumulate in the central region of a plaque, 
often denoted the lipid or necrotic core (Panel (c)). Thrombosis, the ultimate complication of 
atherosclerosis, often complicates a physical disruption of the atherosclerotic plaque. Fracture of the 
plaques fibrous cap enables blood coagulation components to come into contact with tissue factors in 
the plaques interior, triggering the thrombus to extend into the vessel lumen, where it can impede blood 
flow (Panel (d)). (Adapted from Libby et. al. 2011).
It is well recognised that inflammation is central in all stages of atherosclerosis. Paracrine 
intercellular communication involving cytokines, chemokines and growth factors is known to 
play an important role in the development of atherosclerotic lesions (Natalia et al., 2008). 
However, another form of intercellular communication involving Cxs have also been 
implicated in the development of the disease.
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1.6.4.2 Connexin expression during atherogenesis
Cx expression is modulated during atherosclerosis. Cx37, Cx40 and Cx43 expression patterns 
change during plaque formation in murine and human atherosclerotic plaques (Kwak et al.,
2002) (Fig 1.12).
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Figure 1.12: Connexin expression during atherogenesis. A schematic drawing of an 
atherosclerotic lesion in the artery wall indicating the expression patterns of the three vascular 
connexins at the non diseased part of the artery, the shoulder, and the centre of the advanced 
atheroma. The endothelial cells (EC), the smooth muscle cells (SMC), and the extracellular matrix 
(ECM) are indicated. (Adapted from Pfennigeret. al. 2009).
1.6.4.2.1 Connexin37
Cx37 is expressed in healthy ECs, but disappears from these cells in advanced atherosclerotic 
plaques (Kwak et al., 2002). Cx37 expression is also found in macrophages in early and late 
atheroma (Yeh et al., 2003). Taking into account that ECs and monocytes/macrophages have 
central roles in atherogenesis, Cx37 is expected to play a role during atherosclerotic lesion 
development (Wong et al., 2004, Kwak et al., 2002).
61
Cx37 appeared to have a protective effect against atherosclerosis in ApoE '^ ' mice subjected to 
a high cholesterol diet for 10 weeks. It was shown that the Cx37 deletion accelerated 
atherosclerotic lesion development in thoracic abodiminal aorta, in aortic sinus, increased the 
number o f leukocytes in atherosclerotic plaques in comparison with Cx37^'^^ApoE‘^‘ mice 
(Wong et al., 2006). Thus, the recruitment of leukocytes appeared dependent on the presence 
of Cx37 in monocytes/macrophages but not between ECs, or on intercellular communication 
within the endothelium.
Inflammation is mediated in part by extracellular purines (ATP, ADP and adenosine) and 
ATP is known to pass through various types o f GJs and hemichannels (Evans and Leybaert, 
2007). The absence of Cx37 or the inhibition o f Cx37 by blocking peptides reduced the 
release of ATP by monocytes/macrophages and increased their adhesion indicating that Cx37 
protects against atherosclerosis by regulating ATP-dependent monocyte adhesion (Wong et 
al., 2006).
Cx37 is also expressed in medial SMCs beneath advanced atherosclerotic lesions in mice 
(Kwak et al., 2002). A similar expression was observed in advanced atherosclerotic plaques 
in human carotid artery. However, the role o f Cx37 in SMCs is yet to be fully established.
1.6.4.2.2 Connexin40
Cx40 is present in ECs of healthy vessels and this Cx disappears from the endothelium 
covering advanced atherosclerotic plaques (Kwak et al., 2002). It has been demonstrated that 
abrupt reoxygenation following hypoxia reduces GJ coupling between microvascular ECs of 
wild type but not o f Cx40 deficient mice. The reduction in GJIC involves a protein kinase A 
(PKA) - dependent pathway and reactive oxygen species (Bolon et al., 2005).
Cx40 deficient mice are hypertensive, a major independent risk factor for atherosclerosis. To 
overcome this limitation, ApoE'^' mice with specific Cx40 deletion in ECs were designed (de
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Wit et al., 2000). These mice were not hypertensive and had a normal heart rate. Studies 
using this system had indicated that the EC-specific deletion of Cx40 induced increased 
atherosclerotic plaque compared to control mice (Chadjichristos et al., 2010). These results 
suggested an atheroprotective role of Cx40; however, the mechanisms implicated remain to 
be investigated.
1.6.4.2.3 Connexin43
Cx43 is mostly expressed in SMCs of healthy vessels. Coronary arteries o f heart removed 
from patients undergoing cardiac transplantation show markedly increased Cx43 expression 
in GJs between intimai SMCs compared with undiseased vessels (Blackburn et al., 1995). In 
advanced atherosclerotic plaques, the intimai expression for Cx43 decline. Cx43 increase in 
intimai SMCs was found in early atherosclerotic lesion in LDLR'^' mice fed with cholesterol 
rich diet. Cx43 expression was also shown in macrophage foam cells of mouse aorta and of 
human carotid artery, in ECs covering the shoulder region of atherosclerotic lesions, and in 
ECs at the branch points of large arteries (Gabriels and Paul, 1998).
Atherosclerotic plaques are generally formed at branch points or at curved areas o f large 
arteries that regions associated with turbulent blood flow (Davies, 2009). Oseillatory shear 
stress induces a high and rapid increase of endothelial Cx43 expression (Kwak et al., 2005, 
Cowan et al., 1998). The effects of unidirectional shear stress on endothelial Cx43 expression 
are less clear. This shear stress is associated with an increase or with no change in Cx43 
expression dependent on the experimental conditions used. Increased hydrostatic pressure 
does not modify the Cx43 levels in ECs (Kwak et al., 2005).
Cx43 knockout mice die at birth because of severe cardiac malformations (Reaume et al., 
1995). As a result, studies implicating Cx43 in the development of atherosclerotic plaques 
were carried out by interbreeding atherosclerotic susceptible LDLR' ' mice with heterozygous
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Cx43"^ "^ mice. The expression of Cx43 was found to be reduced by half in Cx43’^ '^ mice 
(Guerrero et al., 1997). Ten week old Cx43^^" LDLR'' that were fed a cholesterol rich diet for 
14 weeks had shown reduced atherosclerotic plaque development in the thoracic-abdominal 
aorta and in the aortic sinus by 50% in comparison to Cx43^ ^^  ^ LDLR" ' mice (Kwak et al.,
2003). Furthermore, it was also shown that atherosclerotic lesions in Cx43'^ '^ " LDLR" ' mice 
had smaller lipid cores and fewer macrophages whereas leukocyte counts in peripheral blood 
were found to be similar between both groups o f mice. Additionally, the fibrous cap of 
atherosclerotic plaques in Cx43'^ "^ LDLR- ' mice were shown to contain more SMCs and 
interstitial collagen. However, synthetic SMCs have been described to express higher levels 
of Cx43 than the contractile phenotype (Chadjichristos et al., 2008, Rennick et al., 1993). The 
vulnerability o f atherosclerotic lesions to rupture is dependent of the content of SMCs and 
macrophages, the extent of collagen within the lesion and the size of the lipid core. As plaque 
rupture might lead to acute myocardial infarction, it has been hypothesised that targeting 
Cx43 may be promising for stabilisation of the plaque. However, the mechanism by which 
Cx43 influences atherosclerotic lesion formation and plaque stability are yet to be clearly 
identified (Wong et al., 2003).
1.6.4.3 Connexins as therapeutic targets in the treatment of atherosclerosis
1.6.4.3.1 Percutaneous coronary interventions
Coronary atherosclerosis might lead to the occlusion of the artery and to myocardial 
infarction. This vascular problem is often treated by percutaneous coronary intervention 
(PCI) consisiting of balloon dilatation with or without stent implantation (Serruys et al., 
1994). However, clinical studies have shown that the long-term efficacy of PCI is limited by 
restenosis or renarrowing o f the arteries at the site of intervention. The diseased artery can 
induce an exaggerated response to injury that involves the recruitment and infiltration of 
leukocytes into the damaged site and a surge in cytokines and growth factors. Furthermore,
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medial SMCs undergo a phenotypic modulation from a contractile to a synthetic phenotype, 
proliferate and migrate to toward the intima. These events induce the formation o f the 
neointima.
Drug eluting stents (DES) prevent restenosis by inhibiting neointimal hyperplasia. However, 
they also delay rendothelialisation which increases the period of time during which the stent 
remains thrombogenic leading to late in-stent thrombosis (Newsome et al., 2008). Yeh et. al. 
had described an upregulation of Cx43 between medial and intimai SMCs after balloon 
catheter injury in the rat carotid artery (Yeh et al., 1997). Chadjichristos et. al. had 
investigated the role of Cx43 in neointima formation by performing carotid balloon 
distension injury in hypercholesterolemic Cx43^ 'LDLR' " mice. It was shown that neointima 
formation, macrophage infiltration, SMCs migration and proliferation were reduced and 
endothelial repair was accelerated (Chadjichristos et al., 2006). Furthermore, recent in vitro 
studies showed that Cx43 antisense prevented platelet-derived growth factor-BB-induced 
deletrious phenotypic changes of porcine SMCs (Hao et al., 2002). These results suggest that 
targeting Cx43 may be a promising strategy for reducing restenosis after PCI.
1.6.4.3.2 Statin treatment
In 1971, Endo and co-workers identified a fungal metabolite (compactin) with properties of 
bloeking cholesterol synthesis (Endo, 1971). In 1976, the “Compactin development project” 
composed of several experts lead to the discovery and development of the first statin called 
“lovastatin” and it was not until 1980 that this statin was shown to lower LDL cholesterol 
levels in patients with hypercholesterolemia (Tobert et al., 1982a, Tobert et al., 1982b, Hoeg 
and Brewer, 1987, Illingworth and Bacon, 1987, Mabuchi et al., 1981). These results induced 
the US Food and Drug Administration to approve the commercial use of statins in 1986 
(Steinberg, 2006). After lovastatin, three generations of statins have been commercially 
introduced; they include, pravastatin and fluvastatin (first generation), atorvastatin and
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simvastatin (second generation) and rosuvastatin and pitavastatin (third generation). 
Lovastatin, pavastatin and simvastatin are obtained after fungal fermentation whereas 
fluvastatin, atorvastatin and cerivastatin are artificially synthesis. It must be stressed that on 
August 8 , 2001, Bayer AG voluntarily withdrew cerivastatin from the world pharmaceutical 
market after 31 patients died by acute renal failure caused by rhabdomyolysis. As a result, 
only five statins are, at this moment, in clinical use: lovastain, simvastatin, pravastatin, 
atorvastain and fluvastatin (Fig 1.13).
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Figure 1.13: Chemical structure of statins. The chemical structure of the five statins; Simvastatin, 
Pravastatin, Lovastatin, Fluvastatin and Atorvastatin currently in clinical use. (Adapted from Mach at. 
al. 2010).
Statins target hepatocytes and inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
reductase, the enzyme that converts HMG-CoA into mevalonic acid, a cholesterol precursor. 
The statins do more than just compete with the normal substrate in the enzymes active site. 
They alter the conformation of the enzyme when they bind to its active site (Corsini et al., 
1999). This prevents HMG-CoA reductase from attaining a functional structure. The change
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in conformation at the active sites makes these drugs very effective and specific. Binding of 
statins to HMG-CoA reductase is reversible and their affinity for the enzyme is in the 
nanomolar range, as compared to the natural substrate, which has micromolar affinity 
(Corsini et al., 1999). The inhibition of HMG-CoA reductase determines the reduction of 
intracellular cholesterol, inducing the activation of a protease which slices the sterol 
regulatory element binding proteins from the ER. Sterol regulatory element binding proteins 
are translocated at the level o f the nucleus, where they increase the gene expression for LDL 
receptor (Wilson et al., 2003). The reduction of cholesterol in hepatocytes leads to the 
increase of hepatic LDL receptors; that determines the reduction o f circulating LDL and o f its 
precursors. All statins reduce LDL cholesterol non-liniarly, dose dependently, and after 
administration of a single daily dose. Efficacy on triglyceride reduction parallels LDL 
cholesterol reduction (Lefer et al., 2001).
Although statins have been introduced as HMG-CoA reductase inhibitors to lower LDL- 
cholesterol synthesis and serum levels, there has been emerging evidence indicating that 
statins have multiple pleiotropic effects that modulate atherogenesis independently on their 
mechanisms on lipids (Vaughan et al., 2000, Arnaud et al., 2005) (Fig 1.14).
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Figure 1.14: Classical and Not-Classical HMG-CoA mevalonate pathways. Anti-inflammatory 
activities of statins depend on both “classical” and “not classical” HMG CoA mevalonate pathways. 
Statin anti-inflammatory activities depend on the inhibition of both “classical” (HMG CoA-Mevalonate- 
FPP-cholesterol) and “not classical” (HMG CoA-Mevalonate-FPP-kinase) pathways. Other studies 
have shown that GGPP may be also involved in the intracellular signalling proteins regulating kinase 
activation. (Adapted from Mach et. al. 2010).
Various types o f statins have been identified to dose dependently inhibit Cx43 expression in 
human vascular cells (Kwak et al., 2003). The presence of L-mevalonate abolished the effect 
o f statins on Cx43 expression thereby confirming that HMG-CoA reductase was responsible 
for this reduction. The reduction in Cx43 expression was associated with reduction in GJIC.
In mice, statin treatment does not reduce plasma lipid levels due to a compensatory 
upregulation of HMG-CoA reductase. The maintenance of high plasma lipids allows the 
study of the pleiotropic effects of statins independent o f its effects on plasma cholesterol. 
Statins were shown to reduce Cx43 expression in atherosclerotic plaque o f LDL' " mice 
thereby displaying beneficial changes in plaque morphology (Kwak et al., 2003). Long-term 
hyperlipidemia in mice decreases Cx37 and Cx40 expression in aorta. However, treatment 
with simvastatin was found to reverse this hyperlipidemia induced decrease in Cx37 and 
Cx40 (Yeh et al., 2003).
68
In rabbit atherosclerotic lesions, lovastatin and fluvastatin reduced the mRNA and protein 
expression of Cx40. These statins were also found to reduce Cx40 and Cx43 expression at the 
same time which indicated the effect o f statins on GJ communication leading to altered 
proliferation of SMCs and atherogenesis (Wang et al., 2005). Thus, the statin-induced 
regulation of Cx expression might be classified as one more pleiotropic beneficial effect of 
these compounds.
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1.7 Hypothesis and Aims
We hypothesise that GJIC plays a crucial role on the steps leading to leukocyte activation and 
differentiation, and that these effects are modulated by atherosclerosis related antigens (such 
as oxLDL) which can induce a differential structural and functional effect on GJIC during T 
cell activation in vitro.
The aims and objectives o f this project are listed as follows:
AIM 1: Characterisation of the expression of connexins in macrophages induced by 
oxidised LDL.
Objectives:
i. Peripheral blood monocyte-derived macrophages will be obtained and 
stimulated with oxLDL in vitro.
ii. OxLDL stimulated macrophages will be utilised to assess its effect on Cx37, 
Cx40 and Cx43 mRNA and protein expression using RT-PCR, Western 
Blotting and Confocal Fluorescence Microscopy.
iii. In oxLDL stimulated macrophages, the anti-inflammatory effects of 
Simvastatin and Pravastatin on Cx37, Cx40 and Cx43 mRNA and protein 
expression will be assessed using RT-PCR, Western Blotting and Confocal 
Fluorescence Microscopy.
AIM 2: Characterisation of the effect of oxidised LDL on the expression and 
function of connexins and gap junctions during T cell antigen-induced proliferation. 
Objectives:
i. CD4^ T cells and macrophages will be isolated from human peripheral blood
and CD4^ T cell-macrophage co-cultures will be setup and stimulated using 
oxLDL in vitro.
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ii. OxLDL induced CD4^ T cell-macrophage co-cultures will be further treated 
with Simvastatin, Pravastatin, GJ blockers i.e, 18-a-glycyrrhetinic acid and 
GAP27 peptides.
iii. GJ mediated intercellular communication leading to T lymphocyte 
proliferation will be assessed by calcein AM dye transfer and CyQUANT® 
assay.
AIM 3: Assessment of the effect of oxidised LDL on connexin mediated T cell 
intracellular signalling.
Objectives:
i. CD4^ T cells will be isolated from human peripheral blood and CD4^ T cell- 
macrophage co-cultures will be setup in vitro. These co-cultures will be 
stimulated using oxLDL and further treated with statins.
ii. The effects of oxLDL and statins on Cx43 linked to the synthesis and 
phosphorylation of intracellular proteins associated with the NFkB pathway in 
activated CD4^ T cells will be assessed by Immunoprécipitation and Western 
Blotting.
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CHAPTER 2  
GENERAL MATERIALS AND METHODS
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2.1 General Materials
2.1.1 Laboratory reagents
2.1.1.1 Reagents
Ail reagents and chemicals were purchased from Sigma-Aldrich (UK) or Fisher Scientific 
(UK) unless otherwise stated.
2.1.2 Cell culture reagents
All cell culture reagents were obtained from Gibco (UK) and Sigma-Aldrich (UK) unless 
stated. Media used was RPMl 1640 culture medium supplemented with 10% of fetal bovine 
serum (FBS) and 5% of penicillin-streptomycin antibiotics. Tissue culture hoods were always 
treated with a solution of 70% (v/v) ethanol before use.
2.1.3 Oligonucleotides
2.1.3.1 Design and synthesis
Oligonucleotide primers were designed from published human connexin cDNA sequences 
and synthesised at Invitrogen (UK). The primers and their respective sequences are listed in 
Table 2.1.
73
Table 2.1: Details of the primers used in this study
Prim er Name Oligonucleotide Sequence
Expected size of 
PGR product in 
base pairs
Cx37 Forward 
Cx37 Reverse
5’ -GGT GGG TAA GAT CTG GCT GA- 3’ 
3’ -GGG GGT GTT AG A GTG GAA AT- 5’ 1 0 0
Cx40 Forward 
Cx40 Reverse
5’ -TAG GGA AGG TGT GGG TGA GT- 3’ 
3’ -TGA TGT GGA GGA GGG AGT AG- 5’ 186
Cx43 Forward 
Cx43 Reverse
5’ -ATG AGG AGT GTG GGT TTG GT- 3’ 
3’ -TGT GGT TGA AGT GGA TGT GG- 5’ 249
GAPDH Forward 
GAPDH Reverse
5’ -GAG TGA AGG GAT TTG GTG GT- 3’ 
3’ -GAG AAG GTT GGG GTT GTG AG- 5’ 185
2.1.4 Peptides
The peptides were synthesised by Activotec (UK). They were provided at >80% purity as a 
dry powder. The peptides and their respective sequences are listed in Table 2.2.
Table 2.2: Details of the peptides used in this study
Peptide Name Target Sequence
3/,4^GAP27
^®GAP27
EL 2 (Gx37 and Gx43) 
EL 2 (Gx40)
NH2-SRPTEKTIFII-0H
NH2-SRPTEKNVFIV-0H
A scrambled peptide was not utilised as a control since a number of studies have been carried 
out demonstrating the specificity of the GAP27 peptides in distrupting GJIC between cells 
(Chaytor et al., 1997, Leybaert et al., 2003, Evans and Leybaert, 2007).
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2.1.5 Primary and secondary antibodies
All primary and secondary antibodies used in the study are listed in Table 2.3 and Table 2.4 
respectively.
Table 2.3: Details of the primary antibodies used in this study
Antibody Host Type Dilution Final
Concentraction
Source
Cx37 Rabbit Polyclonal 1 : 1 0 0 2pg/mL Chemicon, UK
Cx40 Rabbit Polyclonal 1:50 2pg/mL Chemicon, UK
Cx43 Rabbit Polyclonal 1:50 0.5pg/mL Sigma, UK
CD14 Mouse Monoclonal 1 : 2 0 0 1 pg/mL Abeam, UK
PKC0 Rabbit Monoclonal 1 : 1 0 0 0.5pg/mL Epitomics, USA
IkB o Mouse Monoclonal 1 : 1 0 0 2pg/mL Santa Cruz, USA
IKKa/p Rabbit Polyclonal 1 : 1 0 0 2pg/mL Santa Cruz, USA
NFkBp 50 Rabbit Polyclonal 1 : 1 0 0 2pg/mL Santa Cruz, USA
Phosphoseri
ne/threonine
/tyrosine
Mouse Monoclonal 1 : 2 0 0 Ipg/mL Abeam, UK
Beta actin Rabbit Polyclonal 1 : 2 0 0 1 pg/mL Abeam, UK
Table 2.4: Details of the secondary antibodies used in this study
Antibody Host Dilution Final
Concentration
Source
Anti-rabbit IgG-HRP Goat 1:6000 25pg/mL Bio-Rad, UK
Anti-mouse IgG-HRP Goat 1:6000 25pg/mL Bio-Rad, UK
Alexa Fluor® 488 
Anti-rabbit IgG
Goat 1:500 lOpg/mL Invitrogen, UK
Alexa Fluor® 568 
Anti-mouse IgG
Rabbit 1:500 lOpg/mL Invitrogen, UK
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2.1.5 Mitogens and cytokines
Polyclonal stimulators with mitogen activity used were: LPS (Sigma-Aldrich, UK) purified 
from E. coli 055:B5, provided as sterile lyophilised powder, prepared by phenol extraction 
was reconstituted in RPMl cell culture medium to prepare a stock concentration of Img/mL. 
Tetanus toxin (Sigma, UK) from Clostridium tetani, provided as sterile lyophilised powder 
was reconstituted in RPMl cell culture medium to prepare a stock concentration of 50pg/mL.
Human recombinant Interferon (IFN)-y was obtained from R&D systems (UK) as sterile 
lyophilised powder. The cytokine was reconstituted in sterile phosphate buffered saline (PBS) 
with 1% bovine serum albumin (BSA) to prepare a stock solution of 50pg/ml and stored at - 
20°C until use.
2.1.6 Composition of general buffers and solutions
Table 2.5: Composition of general buffers and solutions used in this study
Name of general buffers 
and solutions
Composition Source
Cell lysis 
Radioimmunoprecipitation 
assay (RIPA) buffer
25mM Tris-HCl pH 7.6, 150mM NaCl, 
1 % nonyl phenoxypolyethoxylethanol 
(NP)-40, 1% sodium deoxycholate, 0.1% 
sodium dodecyl sulphate (SDS)
Pierce, UK
Erythocyte lysing buffer 1.5M NH4CI and O.IM Tris-HCl, pH 7.5 R&D System, UK
DNA loading dye (6 X) 2.5% Ficoll 400, 1 ImM EDTA, 3.3mM 
Tris-HCl, 0.017% SDS, 0.015% 
Bromophenol blue pH 8.0
New England 
Biolabs, UK
Optiprep solution lodixanol (60% w/v) Fresinius Kabe 
Norge, Norway
PBS 137mM NaCl, 2.7mM KCl, 4.3mM 
Na2HP0 4  and 1.47mM KH2PO4 , pH 7.4
Gibco, UK
Ponceau S solution Ponceau S (0.1% w/v) in acetic acid (5% 
v/v)
Fluka, UK
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Protease inhibitor cocktail 
(lOOX)
4-(20aminoethyl)benzenesulfonyl 
fluoride, transepoxysuccinyl-L-leucyl- 
amido(4-guanidino)butane, bestatin, 
leupeptin, aprotinin and sodium EDTA
Roche, UK
SDS-PAGE sample buffer Tris-HCl (250mM) pH 6 .8 , SDS (2% 
w/v). Glycerol (10% v/v), DTT (20mM), 
bromophenol blue (0 .0 1 % w/v)
SDS-PAGE (lOX) running 
buffer
Glycine (1.92M), Tris-base (0.25M), SDS 
(1% w/v) pH 8.4
Bio-Rad, UK
SDS-PAGE separating gel 
buffer
Tris-base (1.5M), SDS (0.4% w/v) pH 8 . 8 -
SDS-PAGE stacking gel 
buffer
Tris-base (0.5M), SDS (0.4% w/v) pH 6 . 8
Transfer buffer Glycine (192mM), Tris-base (25mM), 
methanol (20% w/v) pH 8.3
Tris-acetate EDTA (TAE) 
buffer (lOX)
Tris-base (0.5M), Glacial acetic acid 
(17.4M), EDTA (0.5M) pH 8.0
2.1.7 Health and safety
Use and handling of all reagents was carried out according to the safety regulations provided 
by the suppliers of each product, COSHH regulations and local university regulations. 
Biological waste was disposed according to university regulations.
2.1.8 Ethical approval for collection of human blood samples
Peripheral blood mononuclear cells (PBMC) were isolated either from whole blood collected 
in EDTA vacuette tubes (Griener Bio-One, UK) from healthy consenting volunteers or from 
leukocyte cones purchased from the National Blood Service in accordane with the Faculty of 
Health and Medical Sciences Ethics Committee guidelines (reference number EC2008/45).
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2.2 General Methods
2.2.1 Cell culture
2.2.1.1 Isolation of peripheral blood mononuclear cells using Histopaque-1077®
2.2.1.1.1 Principle
Mononuclear cells from anticoagulant-treated venous blood are isolated by layering onto 
Histopaque®-1077; a solution containing polysucrose and sodium diatrizoate, adjusted to a 
density of 1.077g/mL. During centrifugation, erythrocytes and granulocytes rapidly settle to 
the bottom of the tube; lymphocytes and other mononuclear cells remain at the plasma- 
Histopaque interface. Most extraneous platelets are removed by low speed centrifugation 
during the washing steps.
2.2.1.1.2 Procedure
Freshly collected human blood from healthy volunteers was diluted in two volumes o f PBS 
supplemented with 2mM EDTA. 35mL of the diluted cell suspension was carefully layered 
onto 15mL of histopaque and centrifuged at 1500xg for 40min at room temperature in a 
swinging bucket rotor (without brakes). Following centrifugation, the upper layer was 
aspirated leaving the mononuclear cell layer undisturbed at the interface. The interface of 
cells was then carefully transferred into a fresh 50mL conical tube and diluted with PBS/ 
2mM EDTA followed by centrifugation at 2500xg for lOmin at 4°C. The supernatant was 
then discarded and the cell pellet was resuspended in RPMl 1640 culture medium 
supplemented with 10% fetal bovine serum (FBS) and 5% Pencillin/Streptomycin antibiotics. 
Cells were evenly resuspended in ImL complete RPMl, a 2pL sample was mixed with 18pL 
o f a 1:1 (v:v) solution of trypan blue (Sigma-Aldrich, UK) in PBS, resulting in a 1:10 dilution 
o f the cell suspension. A haemocytometer was used to count the cells under a light
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microscope. Cell viability was determined by calculating the percentage of unstained cells in 
the total population.
2.2.1.2 Removal of erythrocytes
Trace amounts of erythrocytes in the cell suspensions were eliminated using a human 
erythrocyte lysing kit (R&D systems, UK) following manufacturer’s instructions.
The cell suspension was centrifuged at 1500xg for lOmins and lysed using 5mL of 
erythrocyte lysis buffer and incubated for lOmins at room temperature. Following incubation, 
the cell suspension was washed with PBS and centrifuged for 10 mins at ISOOxg. Cells were 
counted following erythrocyte lysing as described in section 2 .2 .1 .1 . 2  and resuspended in 
complete RPMl 1640 cell culture medium ready to be seeded onto a plate and cultured.
2.2.1.3 Differentiation of monocytes into macrophages
Leukocytes were cultured for 2hrs at 37°C to ensure adhesion of moncocytes to the surface of 
the plate. Then, floating lymphocytes were carefully removed by aspiration. The monocytes 
were treated with 4ng/mL of recombinant IFN-y (50pg/mL stock) in RPMl 1640 cell culture 
medium and cultured for 1 week to induce their differentiation into macrophages.
2.2.1.4 Isolation of CD4+ T helper cells
CD4+ T cells were isolated by negative selection using MACS® human CD4 + T cell 
isolation kit (Miltenyi Biotec, UK) following manufacturer’s instructions.
B cells, NK cells and CD8  ^ T cells were indirectly labelled with a cocktail o f biotin- 
conjugated monoclonal antibodies (primary labelling reagent) and anti-biotin monoclonal 
antibodies conjugated to micro beads (secondary labelling reagent). Labelled cells were 
depleted by applying the column to a magnetic field of a separator, while unlabeled CD4^ T 
cells pass through the column.
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2.2.1.5 Isolation of oxidised LDL (oxLDL)
Freshly collected human blood from healthy volunteers was prepared by mixing with sodium 
citrate followed by centrifugation of the sample for 30mins at 13000rpm. The plasma was 
transferred into fresh g-Max quick seal® polyallomer tubes (Beckman Coulter Inc, UK). A 
12% Optiprep-plasma solution was prepared by diluting 8 mL of plasma with 2mL of 60% 
Optiprep® (Fresinius Kabe Norge, Norway) and further diluted in ultracentrifuge tubes 
(Beckman, USA) with a 6 % optiprep solution (60% optiprep diluted in PBS). The solution 
was carefully pipetted to the bottom of the ultracentrifuge tubes. The samples were 
centrifuged at 40,000xg for 4hrs at 16°C in an ultracentrifuge (Beckman Coulter Inc, UK).
After centrifugation, the LDL was distinguished as an orange colour ring in the interface of 
the tube. The ring was carefully extracted using a 2mL syringe and transferred into a dialysis 
membrane. The LDL was dialysed twice against IL of PBS each time for 48hrs and then 
stored in the dark at 4°C.
4mL out o f a 6 mL total volume o f LDL was oxidised by adding 2.5 pM of copper sulphate for 
every 5mL of LDL and incubated overnight at room temperature. OxLDL was then filtered 
through a 0.22pm filter (Millipore, UK) and dialysed again against PBS for 24hrs.
2.2.1.6 Preparation of protein extracts
2.2.1.6.1 Protein extraction from macrophages or lymphocytes
Macrophages (IxlO^ cells) or Lymphocytes (IxIO* cells) were collected by centrifugation at 
2500xg for 5mins discarding the supernatant. The pellet was resuspended in 0.5ml o f RIPA 
buffer (refer section 2.1.6 o f this Chapter), supplemented with IX protease inhibitor cocktail 
(refer section 2.1.6 of this Chapter). The homogenate was mixed by vortexing and incubated 
on ice for 30mins at 4°C to allow solubilisation of cell membrane lipids. After centrifugation
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at HOOOxg for 15mins, the supernatant was extracted and aliquots were prepared and stored 
at -20°C until further use.
2.2.1.7 Quantification of protein
2.2.1.7.1 Measurement of protein concentration
Protein concentration was measured using the Micro BCA protein assay kit (Thermo- 
Scientific, UK) following manufacturer’s instructions. The Micro BCA™ Protein Assay Kit 
is a detergent-compatible bicinchoninic acid formulation for the colorimetric detection and 
quantitation of total protein. The unique, patented method utilises bicinchoninicacid (BCA) 
as the detection reagent for Cu^\ which is formed when Cu^ '*’ is reduced by protein in an 
alkaline environment. A purple-colored reaction product is formed by the chelation o f two 
molecules of BCA with one cuprous ion (Cu^^). This water-soluble complex exhibits a strong 
absorbance at 562 nm that is linear with increasing protein concentrations.
The protein sample was diluted 1:50 in PBS, Bovine Serum Albumin (BSA) standards were 
diluted to obtain a range o f concentrations from 0.5pg/mL to 200pg/mL in PBS and 150pL 
of each standard and sample was added to a 96 well plate. This was followed by addition of 
150pL o f the freshly prepared assay working solution and mixture o f the reagents by shaking 
the plate for 30 seconds followed by an incubation at 37°C for 2 hours in a humidified 
chamber. The plate was allowed to cool at room temperature after which the absorbance was 
determined at 562nm using an automatic plate reader. The protein concentration was 
calculated using the equation of the straight line obtained from the linear part o f the standard 
curve (Fig 2.1). The purified protein samples were stored at -20°C in lOOpl aliquots.
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Figure 2.1 : Example of the standard curve obtained through the BCA protein assay. The
concentration of protein samples were determined by division of the absorbance value obtained for 
the sample through the gradient of the straight line. This concentration value in pg/mL was then 
multiplied by the dilution factor to obtain the true protein concentration of the sample.
2.2.1.8 Characterisation of protein extracts
2.2.1.8.1 Sodium Dodecyl Sulfate -  Polyacrylamide gel electrophoresis (SDS-PAGE)
2.2.1.8.1.1 Principle
SDS-PAGE is used to separate molecules based on size. The gel is a cross linked polymer 
matrix used to support and separate the molecules. Gels can be of constant density or gradient 
(Anderson, 1998).
Electrophoresis involves applying an electric current to the gel and allowing the proteins to 
migrate through the matrix. In order for the proteins to migrate through the gel, they are 
negatively charged by exposure to the detergent, SDS. The amount of bound SDS is relative 
to the size of the protein, and the proteins have a similar charge to mass ratio. Bands in 
different lanes separate based on the individual component sizes and a molecular weight
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(MW) marker that produces bands of known sizes is used to help identify proteins o f interest 
(Anderson, 1998).
2.2.1.8.1.2 Gel preparation
SDS polyacrylamide gels were prepared containing (12.5%, v/v (40% Bis/Acrylamide 
solution)), SDS-PAGE separating gel buffer (25.3%, v/v), ammonium persulphate (1.49%, 
v/v), Tetramethylethelinediamine (TEMED; 0.06%, v/v) and distilled water up to the 
appropriate volume. Reagents were mixed by gentle stirring to avoid formation of bubbles 
and directly loaded in a gel caster (BioRad, UK). The resolving gel was overlaid with butanol 
to ensure a flat edge which was washed away when polymerisation was complete. The 
butanol on the surface of the gel was removed and the top of the gel was washed with 
distilled water. The stacking gel containing acrylamideibisacrylamide (4.5%, v/v), SDS- 
PAGE stacking gel buffer (25%, v/v), ammonium persulphate (1.57%, v/v), TEMED (0.28%, 
v/v) and distilled water up to the appropriate volume. The stacking gel was overlaid on the 
resolving gel in the gel caster and a sample-well comb was inserted. The stacking gel was 
allowed to polymerise and after the removal o f the comb, the wells were washed several 
times with distilled water to remove excess acrylamide.
2.2.1.8.1.3 Gel loading
Protein samples were prepared by adding equal volumes o f the sample with loading buffer 
(refer section 2.1.6 o f this Chapter), 200mM p-Mercaptoethanol (Sigma, UK), 10% v/v 
Glycerol (Fischer scientific, UK) in a 0.5mL microcentrifuge tube. The samples were not 
boiled since Cxs are prone to aggregate at high temperatures preventing proper resolution in 
the gel.
Equal amounts of protein were loaded to each well in the gel. Kaleidoscope prestained 
protein markers (6.4-198.4Da; BioRad, UK) were loaded in parallel to help determine the
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approximate molecular weight (MW) of the protein samples. Electrophoresis was carried out 
at 40mA at room temperature until the dye front end entered into the running buffer.
2.2.1.8.2 Detection of proteins by Western Blotting
2.2.1.8.2.1 Principle
The western blotting technique provides information about the presence, relative molecular 
weight and quantity o f an antigen by combining protein separation via gel electrophoresis 
with specific recognition of antigens by antibodies (Anderson, 1998).
2.2.1.8.2.2 Sample blotting
Proteins resolved by SDS-PAGE were transferred to a polyvinylidine difluoride (PVDF) 
membrane (Amersham, UK) by placing the membrane (pre-equilibrated with transfer buffer) 
in direct contact with the gel. The membrane and gel were sandwiched with filter paper pads 
previously soaked in transfer buffer (refer section 2.1.6 of this Chapter) on both sides and 
then placed in a wet blotting transfer unit (BioRad, UK) and transferred at lOOV for Ihr or at 
30V overnight at 4°C.
After transfer, the efficiency of transfer was assessed by staining the PVDF membrane with 
Ponceau S solution (refer section 2.1.6 of this Chapter) for 2mins at room temperature and 
later washing the membrane with distilled water to visualise protein blots.
2.2.1.8.2.3 Immunolabeling of transferred proteins
After transfer, the protein binding sites on the PVDF membrane were blocked with skimmed 
milk in PBS (5%, w/v) for Ihr at room temperature by gentle agitation. Following blocking, 
the solution was discarded and the membranes were incubated in the same buffer containing 
appropriate primary antibodies (refer Table 2.3 for types and final concentrations). The 
membranes were incubated for 2hrs at room temperature by rolling and were later washed
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with PBS/0.1% Tween for ISmins three times. Following washing, the membranes were 
incubated for Ihr at room temperature with the secondary antibody conjugated to horse­
radish peroxidase (refer Table 2.4 for types and final concentrations) in a 5%, w/v solution of 
skimmed milk in PBS. The membranes were repeatedly washed as mentioned above 
following incubation.
2.2.1.8.2.4 Detection of immunolabeled proteins
The detection o f immunolabeled proteins was carried out by using enhancing 
chemiluminescence (ECL) (Amersham, UK). A reaction mix of stable peroxide solution 
mixed with an equal amount of luminol buffer was prepared and the membranes were 
incubated with this solution at room temperature for Imin. The solution was discarded and 
the membranes were placed in a photographic cassette and exposed to X-ray film (Hyperfilm; 
Amersham, UK). The protein markers on the membranes helped to estimate the approximate 
MW of the protein signals on the film.
2.2.1.8.2.5 Densitometric analysis of protein blots
Semi-quantification of protein blots was carried out by scanning and the analysis of 
developed films using a SynGene Bioimaging Densitometer controlled by a GeneSnap 
(Syngene, UK).
2.2.1.9 Statistical analysis
Statistical analysis was performed by one way ANOVA with a Bonferroni post test using 
GraphPad Prism software (version 5.02, GraphPad Software Inc., USA). Unless otherwise 
stated, experiments were done in triplicates. Values are expressed as mean ± SEM. In all 
cases, statistical significance was concluded if the 2-tailed probability was '^P<0.05, 
or
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CHAPTER 3
CHARACTERISATION OF THE EXPRESSION OF 
CONNEXINS IN MACROPHAGES INDUCED BY OXIDISED
LDL
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3.1 Introduction
Monocytes are members of the mononuclear phagocyte system that originates in the bone 
marrow (Whitelaw and Bell, 1966). Monocytes travel through peripheral blood vessels after 
leaving the bone marrow. As compared with healthy conditions, in many disease states, there 
is increased bone marrow production of monocytes that have a shorter circulation time 
(Leder, 1967). At the site of inflammation, monocytes differentiate into macrophages or 
dendritic cells by growing and increasing their lysosomal content, the amount of hydrolytic 
enzymes, the number and size of mithochondria and the extent of their energy metabolism 
(Hume et al., 2002, Grage-Griebenow et al., 2001).
Macrophages are typically involved in the defence against microorganisms through the 
interaction with lymphoid and stromal cells during an immune response (Geissmann et al., 
2010, Yang et al., 2000). Macrophage clusters are frequent in tissues affected by diverse 
inflammatory disease states such as tuberculosis, human immunodefiency virus infection, 
cancer and most predominantly; in creating the progressive plaque lesions o f atherosclerosis, 
in which cell-cell proximity allow the formation of intercellular contacts between cells that 
may be necessary to accomplish relevant functions (Lucas and Greaves, 2001, Herbein and 
Varin, 2005, Sica et al., 2008).
3.1.1 Connexin expression and gap junction formation in human macrophages
As discussed in Chapter 1 (section 1.6.1), Cxs are expressed in multiple cell types o f the 
immune system. Levy et. al. first reported the establishment of intercellular communication 
between macrophages based on electrical coupling of adherent murine macrophages (Levy et 
al., 1976). Subsequently, GJs were morphologically described in the progeny o f canine 
macrophages by freeze fracture electron microscopy (Porvaznik and MacVittie, 1979). 
Electron microscopy laid the foundation for describing GJ structures established between 
murine macrophages and an intestinal epithelial cell line (Martin et al., 1998a), between
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hamster monocytes as well as monocytes and neutrophils (Jara et al., 1995), and between 
rainbow trout macrophages and neutrophils (Kôllner and Kotterba, 2002). Furthermore, this 
evidence related to GJIC between monocytes/macrophages and other cells has been 
supported by dye transfer assays (Martin et al., 1998a). In primary culture of murine 
microglias, a low dye coupling was observed. This coupling was dramatically increased with 
the treatment o f Interferon (lFN)-y and/or Lipopolysaccharide (LPS) and Tumour Necrosis 
Factor (TNF)-a as well as inhibited by a GJ blocker (Eugenan et al., 2001). Furthermore, 
these studies are in conflict with other reports that demonstrate the lack o f GJIC between 
monocytes/macrophages and other cells (Eugenan et al., 2003). These conflicting reports 
have stated that the transfer of dye was not observed in untreated human or mouse 
monocytes/macrophages, between human monocytes/macrophages and ECs or between 
human monocytes/macrophages and SMCs (Eugenan et al., 2003, Polacek et al., 1993, Alves 
et al., 1996).
To date, Cx43 has been found to be the most predominantly expressed Cx in human 
monocytes/macrophages. Moreover, Cx43 mRNA has been detected in macrophage foam 
cells of human atherosclerotic carotid arteries (Polacek et al., 1993). Interestingly, Cx37 was 
also found to be expressed in macrophages in early atheromas but not Cx43 (Kwak et al., 
2002). The induced expression o f other Cxs in monocytes/macrophages was not detected 
after treatment with LPS or TNF-a or IFN-y (Polacek et al., 1993, Eugenan et al., 2003).
Although, studies have indicated Cx expression in human macrophages, the profile of Cx 
expression in monocytes/macrophages induced by atherogenic antigens still remains unclear. 
In this chapter, the profile of Cx expression in human macrophages induced by oxidised low 
density lipoprotein (oxLDL) is described. Our study involved isolating macrophages from 
human peripheral blood and stimulating them with oxLDL. These macrophages were further 
utilised in the molecular characterisation of GJs. Furthermore, the effects o f statins on Cx
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expression in oxLDL stimulated macrophages were assessed. Two commercially available 
statins; namely Simvastatin and Pravastatin were used to assess its effects on Cx37, Cx40 and 
Cx43 mRNA and protein expression in macrophages pre-treated with oxLDL. This involved 
the initial optimisation of the dose and time dependent effect o f statins on Cx37, Cx40 and 
Cx43 expression. This optimised dose and time dependent treatment of statins was used in 
the rest of the study.
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3.2 Methods
Cell culture procedures involving PBMC isolation and the differentiation o f monocytes into 
macrophages were routinely followed as described in Chapter 2; section 2.2.1.1, 2.2.1.2 and
2.2.1.3 respectively. The effect o f oxLDL, Simvastatin and Pravastatin on macrophage Cx 
expression was assessed by RT-PCR (sections 3.2.2-3.2.7), western blotting (sections 2.2.1.6- 
2.2.1.8) and confocal fluorescence microscopy (sections 3.2.8 and 3.2.9).
3.2.1 Treatment of macrophages with oxLDL and statins
Macrophages isolated from peripheral blood were pre-treated with 50pg/mL of oxLDL 
(Img/mL stock; refer Chapter 2; section 2.2.1.5) for 48hrs. These oxLDL pre-stimulated 
macrophages were further with lOOpM of Simvastatin (5mM stock; CalbioChem, UK) and 
Pravastatin (5mM stock; CalbioChem, UK) respectively.
3.2.2 Analysis of connexin expression in macrophages
3.2.2.1 Total RNA extraction and purification 
3.2.2.x.1 RNase decontamination treatment
All RNase/DNase plasticware and pipette tips (Gilson, UK) were used. All RNA 
manipulations were performed in a PCR workstation. Decontamination of surfaces including 
pipettes was carried out by exposure to UV light for lOmins after wiping with an RNase 
removing solution (RNase Away; Gibco, UK).
3.2.2.1.2 Isolation of total RNA
Isolation of total RNA was carried out using BIOTECX ULTRASPEC™ 11 RNA isolation kit 
(Biotecx, USA). This method is based on the use o f a formulation o f 14M solution of 
guanidine salts and urea (Chaosolv) which acts as denaturing agents. The chaosolv in
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conjunction with phenol and other detergents is used to precipitate total RNA from tissues 
and cells.
3.2.2.1.3 RNA extraction and purification
Cells (1x10^) were collected by centrifugation at 12000xg for 3mins and then homogenised in 
1 ml of ULTRASPEC™ RNA (Biotecx, USA) by trituration through a pipette. The cell lysate 
was transferred to an RNase free microfuge eppendorf tube and incubated for 5mins at 4°C to 
allow the complete disassociation of nucleoprotein complexes. Samples were vigorously 
mixed for 15 secs and incubated on ice for 5mins after the addition of 0.2ml of chloroform 
per 1ml o f ULTRASPEC™ RNA. The homogenate was then centrifuged at 12000xg for 
5mins at 4°C. The resulting homogenate was found to form two phases in the tubes which 
comprise of a lower organic phase and an upper aqueous phase. The organic phase comprises 
of DNA and protein whereas the aqueous phase comprises of RNA.
The aqueous phase was collected without disturbing the interphase and transferred to a fresh 
tube. An equal volume of isopropanol was added and samples were incubated for lOmins at 
4°C and then centrifuged at 12000xg for lOmins at 4°C.
The supernatant from the precipitated solution was carefully removed, centrifuged and the 
pellet was washed twice with 75% ethanol by vortexing and centrifuged at 7500xg for 5mins 
at 4°C. The pellet was dried under vacuum for 5-lOmins taking care not to dry it completely 
as it would decrease its solubility. The dried pellet was resuspended in 200pL o f RNase free 
water and stored at -70°C until further use.
3.2.2.3 Synthesis of cDNA by reverse transcription
First strand cDNA synthesis was carried out by using Ipg o f total RNA extracted from 1x10^ 
human macrophages. Reverse transcription was performed in 20pL final volume containing 
Oligo dT primer mix and lOmM dNTP mix (both from Bioline, USA). Each reaction mix was
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incubated for lOmins at 65°C followed by incubation with RNase inhibitor, and 200U of 
MMLV-RT (Bioline, USA) for 60mins at 45°C. Samples were preserved at -20°C until 
further use.
3.2.2.4 Spectrophotometric quantification of nucleic acid concentration
The quantification o f the nucleic acid concentration was achieved by measuring the 
absorbance at A26onm because pure DNA absorbs ultraviolet light with an absorption peak at 
this wavelength. A Nanodrop (Thermo Scientific, USA) was loaded with IpL o f the nucleic 
samples one at a time and the A260/280 of each sample was determined.
3.2.2.5 Amplification of DNA using polymerase chain reaction
3.2.2.5.1 Principle
The polymerase chain reaction (PCR) is an in vitro nucleic acid amplification method that 
involves the amplification of a single or few copies of a piece of DNA across several orders 
of magnitude, generating thousands to millions of copies of a particular DNA sequence. 
Specifically, substrate DNA is denatured at a high temperature to give single stranded 
(template) molecules. This is followed by annealing of the short oligonucleotide sequence- 
defined primers to regions o f the template at a lower temperature. The thermal cycle is 
concluded by the amplimers being enzymatically extended by the coupling o f appropriate 
base-paired dNTPs on the template at an intermediate temperature, thus producing another 
double stranded DNA copy of the original target. Each PCR comprises a set o f time and 
temperature-controlled incubation with specific functions.
3.2.2.5.2 Procedure
A final volume of 20pL of the reaction mix in each PCR tube (Star Labs, UK) was prepared 
containing lOpL o f PCR Master Mix™ (the master mix contains 0.05U/pL o f Taq DNA 
polymerase, PCR reaction buffer, 4mM MgCl2 and 0.04mM of each dNTP; Promega, UK),
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2|xL of cDNA, IpL o f each respective Cx-specific forward/reverse primers (refer Chapter 2; 
Table 2.1 for details on the primers used), and 6pL of Nuclease-free water (Promega, UK)
The PCR was carried out using a Unocycler (VWR, UK). The following steps were used in 
the amplification program: Initiation at 95°C for 5mins followed by 40 cycles of dénaturation 
at 95°C for Imin, annealing at 55°C for 30secs, and elongation at 72°C for Imin. The reaction 
was terminated by a final extension step at 72°C for 5min and 4°C to store the PCR products 
until further use.
3.2.2.6 Agarose gel electrophoresis
Analysis of DNA fragments was carried out by agarose gel electrophoresis. The agarose gel 
was prepared using molecular grade agarose (Fisher Scientific, UK) at a 1.5% concentration 
based on the expected size o f the DNA fragment to be visualised. The agarose was mixed 
with IX TAE buffer and heated until it completely dissolved in the buffer. The gel was 
prepared in a gel caster (EmbiTec, USA) after adding 4pL o f Gel Red (Biotium, USA) to the 
solution.
A lOpL sample of DNA was mixed by pipetting with 2pL of DNA loading buffer. The 
samples and a lOObp DNA molecular size marker (New England Biolabs, UK) were loaded 
in parallel on a separate well in the gel. Electrophoresis was carried out at lOOV until the 
loading dye front migrated upto about two-thirds o f the distance from the top o f the gel. The 
electrophoretic separation was visualised by exposing the agarose gel to a UV 
transilluminator and photographed using a gel documentation system (BioRad, UK). The 
molecular marker was used as a reference to calculate the approximate MW of the visualised 
bands.
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3.2.2.7 Densitometric analysis of mRNA expression
Semi-quantification o f mRNA expression after PCR was carried out by analysing the 
acquired images using a SynGene Bioimaging Densitometer controlled by a GeneSnap 
(Syngene, UK).
3.2.3 Analysis of the expression of connexin proteins in macrophages
3.2.3.1 Western blotting
Detection o f Cx protein expression was carried out by Western blotting. Protein extracts were 
prepared from resting or activated macrophages as described in Chapter 2 (section 2.2.1.6). 
Whole cell protein extracted from macrophages was resolved by SDS-PAGE and transferred 
to PVDF membranes. Detection of Cx proteins was first carried out by incubating the 
membrane with Cx37, Cx40 and Cx43 specific primary antibodies followed by incubation 
with HRP-conjugated secondary antibodies and developed using ECL (refer Chapter 2, 
sections 2.1.5 and 2.2.1.8).
3.2.9 Immunolabelling of macrophage cells on coverslips
Macrophages were prepared as described previously (refer Chapter 2, sections 2.2.1.1-2.2.1.3 
and 3.2.1) on coverslips and fixed by adding 2mL of ice cold methanol and incubated at - 
20°C for 5mins. Cells were then washed twice with PBS and the excess carefully removed by 
wiping around the coverslips gently avoiding contact with the cells directly. A hydrophobic 
protective border was drawn around the coverslips using a PAP pen (Vector Laboratories, 
USA) to facilitate the incubation of cells with subsequent solutions.
Blocking was carried out using lOOpL o f goat serum (Serotec, UK) in PBS (5%, v/v) for 
30mins at room temperature followed by washing o f cells with PBS repeatedly for 5mins at 
room temperature. The blocking solution was then discarded and the cells were incubated 
with lOOpL of their respective primary antibodies (Rabbit anti-Cx37, Cx40, Cx43 and Mouse
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anti-CD 14; refer Chapter 2; Table 2.3 for types and working dilutions) for Ihr at 37°C. The 
solution was discarded and the cells were washed 4 times with PBS for lOmins. All further 
steps were carried out in the dark. The cells were incubated with lOOpL of their respective 
secondary antibodies (goat anti-rabbit Alexa 488 and goat anti-mouse Alexa 568; refer 
Chapter 2; Table 2.3 for types and working dilutions) for 45mins at 37°C. The cells were 
washed 4 times with PBS for lOmins and incubated with lOOpL of a 20pM solution of 
nuclear dye; DRAQ5™ (5mM stock; eBioscience, UK) in PBS per coverslip for 30mins at 
room temperature.
The coverslips were gently taken out o f the plates and dried with tissue ensuring that the cells 
were not disturbed. Coverslips were mounted on SuperFrost™ microscope slides (Fisher 
Scientific, UK) using FluorSave™ (CalbioChem, UK) and sealed with nail varnish around 
the edges. All slides were stored in the dark at 4°C until its visualisation.
3.2.10 Visualisation of macrophage cells by confocal microscopy
The cells on the slides were visualised using a Zeiss LSM 510 confocal microscope 
controlled by LSM 510 Meta software (Carl Zeiss, USA). The microscope is equipped with a 
helium/neon/argon laser and fitted with the appropriate filter blocks for the detection o f FITC 
fiuorochromes. Images for localisation studies are presented as projection views of a number 
o f optical sections of ~0.5pM thickness using a 40x lens, encompassing signal from the 
whole depth of the sample.
3.3 Statistical analysis of connexin expression in macrophages
Statistical analysis on Cx mRNA and protein expression in macrophages was carried out by 
one way ANOVA with a Bonferroni post test using GraphPad Prism software (version 5.02, 
GraphPad Software Inc., USA; refer Chapter 2; section 2.2.1.9).
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3.3 Results
3.3.1 Simvastatin and Pravastatin reduces Cx37, Cx40 and Cx43 protein expression in 
macrophages in a dose- and time-dependent manner
Analysis o f dose response is a fundamental and essential concept that correlates exposures 
and the spectrum of induced effects. The dose response of Simvastatin and Pravastatin on 
Cx37, Cx40 and Cx43 expression in macrophages was carried out to the statins influence on 
Cx expression and determine the lowest dose for an effect to occur (the threshold effect). 
Figure 3.1 shows the dose response effect of the statins on Cx expression that was determined 
by Western blotting.
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Figure 3.1: Dose dependent effect of Simvastatin and Pravastatin on Cx37, Cx40 and Cx43 
protein expression in human macrophages in vitro. Cx protein expression was detected by 
Western blot using polyclonal antibodies against 0x37, 0x40 and 0x43 (Panel A, B and C). The 
graphs represent the densitometric analysis of the expression levels of 0x37, 0x40 and 0x43 
normalised to (3-actin protein levels. Significance of the results was assessed by comparing non­
treated samples against treated samples. The data is presented as mean (n=3) ± SEM, *p<0.05,
**p<0.01.
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As shown in Figure 3.1, macrophage treatment with Simvastatin and Pravastatin significantly 
reduced Cx37, Cx40 and Cx43 protein expression. Treatment of macrophages with 
Simvastatin at concentrations of 60pM, 80pM and lOOpM significantly reduced Cx37 
expression by 1.68 fold (OpM: 1.68±0.50 vs 60pM: 1.00±0.10; p<0.05), 2.84 fold (OpM: 
1.68±0.50 vs 80pM: 0.59±0.14; p<0.05) and 4 fold (OpM: 1.68±0.50 vs lOOpM: 0.42±0.14; 
p<0.05) respectively. Macrophages treated with lOOpM and 200pM Simvastatin significantly 
reduced Cx40 expression by 2.73 fold (OpM: 1.34±0.01 vs lOOpM: 0.49±0.18; p<0.5) and 
2.68 fold (OpM: 1.34±0.10 vs 200pM: 0.50±0.28; p<0.05) respectively. Simvastatin 
treatment at a concentration of lOOpM also significantly reduce macrophage Cx43 expression 
by 1.8 fold (OpM: 1.35±0.01 vs lOOpM: 0.75±0.18; p<0.05). Macrophage treatment with 
Pravastatin significantly reduced Cx37 expression at concentrations o f lOOpM, 200pM and 
300pM by 1.52 fold (OpM: 1.51±0.18 vs lOOpM: 0.99±0.10; p<0.01), 1.24 fold (OpM: 
1.51±0.18 vs 200pM: 1.21±0.13; p<0.05) and 2.04 fold (OpM: 1.51±0.18 vs 300pM: 
0.74±0.18; p<0.05) respectively. Macrophages treated with lOOpM and 200pM Pravastatin 
significantly reduced Cx40 expression by 1.25 fold (OpM: 0.54±0.16 vs lOOpM: 0.43±0.06; 
p<0.01) and 1.68 fold (OpM: 0.54±0.16 vs 200pM: 0.32±0.11; p>0.05) respectively. 
Pravastatin treatment at concentrations of 80pM, lOOpM, 200pM and 300pM were found to 
significantly reduce macrophage Cx43 expression by 4 fold (OpM; 2.72±0.18 vs 80pM: 
0.68±0.55; p>0.05), 3.77 fold (OpM: 2.72±0.18 vs lOOpM: 0.72±0.30; p>0.01), 3.88 fold 
(OpM: 2.72±0.18 vs 200pM: 0.70±0.34; p>0.05) and 3.23 fold (OpM: 2.72±0.18 vs 300pM: 
0.84±0.65; p>0.05) respectively. Based on these results, a dose o f lOOpM for both 
Simvastatin and Pravastatin were selected as the optimal concentration; indicating a threshold 
effect on reducing Cx37, Cx40 and Cx43 expression.
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The next step was to identify the optimal time needed to observe an effect of Simvastatin and 
Pravastatin on macrophage Cx37, Cx40 and Cx43 protein expression. Figure 3.2 shows the 
time dependent effect o f statins on Cx expression as determined by Western blotting.
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Figure 3.2: Time course effect of Simvastatin and Pravastatin on Cx37, Cx40 and Cx43 
protein expression in human macrophages in vitro. Macrophages were treated with 100pM 
of Simvastatin and Pravastatin throughout a time course ranging from Ohrs to 48hrs. Cx protein 
expression was detected by Western blot using a polyclonal antibody against Cx37, Cx40 and 
Cx43 (Panel A, B and C). The graphs represent the densitometric analysis of the expression 
levels of Cx37, Cx40 and Cx43 normalised to (3-actin protein levels. The significant effect 
based on the different time points of statin treatment on Cx expression were assessed by 
comparing untreated macrophages against macrophages treated from 2hrs to 48hrs. The data 
is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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Macrophages were treated with lOOpM of Simvastatin and Pravastatin over a time course of 
Ohrs to 48hrs. Simvastatin was found to significantly reduce macrophage Cx37 expression at 
time points of 24hrs and 48hrs by 4.7 fold (Ohrs; 1.46±0.12 vs 24hrs: 0.31±0.13; p<0.05) and
10.4 fold (Ohrs: 1.46±0.12 vs 48hrs: 0.14±0.007; p<0.01) respectively; significantly reduce 
Cx40 expression at time points of 24hrs and 48hrs by 1.86 fold (Ohrs: 1.36±0.28 vs 24hrs: 
0.73±0.28; p>0.05) and 2.77 fold (Ohrs: 1.36±0.28 vs 48hrs: 0.49±0.10; p>0.05) respectively; 
and significantly reduce Cx43 expression at time points of 24hrs and 48hrs by 1.77 fold 
(Ohrs: 0.62±0.12 vs 24hrs: 0.35±0.10; p>0.05) and 2.69 fold (Ohrs: 0.62±0.12 vs 48hrs: 
0.23±0.07; p>0.05) respectively. Pravastatin was found to significantly reduce macrophage 
Cx37 expression at time points of 24hrs and 48hrs by 2.63 fold (Ohrs: 1.45±0.37 vs 24hrs: 
0.55±0.09; p>0.05) and 3.45 fold (Ohrs: 1.45±0.37 vs 48hrs: 0.42±0.13; p>0.05) respectively; 
significantly reduce Cx40 expression at time points of 24hrs and 48hrs by 1.86 fold (Ohrs: 
0.80±0.16 vs 24hrs: 0.43±0.08; p>0.05) and 2.28 fold (Ohrs: 0.80±0.16 vs 48hrs: 0.35±0.07; 
p>0.05) respectively; and significantly reduce Cx43 expression at time points of 24hrs and 
48hrs by 2.19 fold (Ohrs: 0.92±0.11 vs 24hrs: 0.42±0.19; p>0.05) and 2.42 fold (Ohrs: 
0.92±0.11 vs 48hrs: 0.38±0.17; p>0.05) respectively.
A dose of lOOpM of either Simvastatin or Pravastatin over a time course o f 24hrs was 
selected as the optimised concentration and time required for treatment of macrophages. This 
optimised concentration and time of treatment with statins was utilised throughout this study.
3.3.2 OxLDL induces differential expression of Cx37, Cx40 and Cx43 mRNA in 
macrophages
In order to fully understand the underlying mechanisms behind the effects observed, it was 
essential to first determine Cx mRNA and protein levels induced by the treatments. Utilising 
the data obtained from the dose response effect o f Simvastatin and Pravastatin on Cx37, 
Cx40 and Cx43 protein expression (refer section 3.3.1), the effect of oxLDL, Simvastatin and
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Pravastatin on Cx37, Cx40 and Cx43 mRNA and protein expression in macrophages were 
analysed by RT-PCR, western blot and fluorescence confocal microscopy approaches.
The expression of Cx37, Cx40 and Cx43 mRNA was studied by RT-PCR with and without in 
vitro stimulation o f macrophages with oxLDL. The effect o f Simvastatin and Pravastatin on 
Cx37, Cx40 and Cx43 mRNA expression was also studied in macrophages stimulated with or 
without oxLDL in vitro (Fig 3.3).
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Figure 3.3: Effect o f macrophage stimulation on the expression o f Cx37, Cx40 and Cx43 
mRNA by human macrophages pre-stimulated or not w ith oxLDL. The graphs show the 
densitometric analysis of the expression levels of mRNA levels encoding Cx37 (Panel A), 
Cx40 (Panel B), and Cx43 (Panel C) assessed by RT-PCR and normalised to GAPDH mRNA 
levels. The effects of the statins on Cx expression were assessed by comparing statin treated 
macrophages pre-treated with oxLDL against non-treated macrophages and macrophages 
treated with the statins alone. The data is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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Pravastatin was found to significantly reduce Cx37 mRNA expression in macrophages 
stimulated with oxLDL by 1.36 fold (oxLDL: 0.67±0.03 vs oxLDL+Pravastatin: 0.49±0.03; 
p<0.05). Simvastatin and Pravastatin significantly reduced Cx40 mRNA expression by 1.31 
fold (oxLDL: 0.92±0.20 vs oxLDL+ Simvastatin: 0.70±0.12; p<0.05) and 1.31 fold (oxLDL: 
0.92±0.20 vs oxLDL+Pravastatin: 0.70±0.09; p<0.05) respectively in oxLDL stimulated 
macrophages. OxLDL significantly enhanced Cx43 mRNA expression by 1.75 fold (Non- 
Treated: 0.53±0.23 vs oxLDL: 0.93±0.23; p<0.05) and this effect was attenuated by 
Simvastatin and Pravastatin by observing a 2.32 fold (oxLDL: 0.93±0.23 vs 
oxLDL+Simvastatin: 0.40±0.22; p<0.05) and 1.55 fold (oxLDL: 0.93±0.23 vs 
oxLDL+Pravastatin: 0.60±0.14; p<0.05) significant decrease in Cx43 mRNA expression in 
macrophages pre-treated with oxLDL.
3.3.3 OxLDL enhances Cx37, Cx40 and Cx43 protein expression in macrophages
The effect of oxLDL, Simvastatin and Pravastatin on Cx37, Cx40 and Cx43 protein 
expression was detected and analysed by western blot and fluorescence confocal microscopy 
in macrophages stimulated in vitro with or without oxLDL (Fig 3.4).
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Figure 3.4: Effect o f Simvastatin and Pravastatin on the expression o f Cx37, Cx40 and 
Cx43 protein by human macrophages pre-stimulated or not w ith oxLDL. Cx protein 
expression was detected by Western blot using polyclonal antibodies against Cx37, Cx40 and 
Cx43. The graphs represent the densitrometic analysis carried out to detect Cx37 (Panel A), 
Cx40 (Panel B) and Cx43 (Panel 0) and normalised to (3-actin protein levels. The effects of the 
statins on Cx protein expression were assessed by comparing statin treated macrophages 
stimulated with oxLDL against non-treated macrophages and macrophages treated with the 
statins alone. The data is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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Simvastatin was found to significantly halt Cx40 protein expression by 1.62 fold (Non- 
Treated: 0.26±0.05 vs Simvastatin: 0.16±0.04; p<0.05) and Pravastatin significantly reduced 
Cx37 and Cx40 protein expression by 1.33 fold (Non-Treated: 0.99±0.26 vs Pravastatin: 
0.74±0.16; p<0.05) and 1.23 fold (Non-Treated: 0.26±0.05 vs Pravastatin: 0.21±0.04; 
p<0.05) respectively in non-stimulated macrophages. Macrophages pre-stimulated with 
oxLDL resulted in a significant increase in the expression o f Cx37, Cx40 and Cx43 protein 
by 1.5 fold (Non-Treated: 0.99±0.26 vs oxLDL: 1.49±0.118; p<0.05), 1.53 fold (Non- 
Treated: 0.26±0.05 vs oxLDL: 0.40±0.06; p<0.05) and 2.35 fold (Non-Treated: 0.68±0.28 vs 
oxLDL: 1.60±0.13; p<0.05) respectively when compared to Cx37, Cx40 and Cx43 
expression levels in non-stimulated macrophages. Treatment of oxLDL stimulated 
macrophages with Simvastatin resulted in a significant decrease of Cx37, Cx40 and Cx43 
protein expression by 2.09 fold (oxLDL: 1.49±0.118 vs oxLDL+Simvastatin: 0.71±0.22; 
p<0.05), 2.66 fold (oxLDL: 0.40±0.06 vs oxLDL+Simvastatin: 0.15±0.04; p<0.01) and 3.26 
fold (oxLDL: 1.60±0.13 vs oxLDL+Simvastatin: 0.49±0.19; p<0.01) respectively. 
Pravastatin was also found to significantly reduce Cx37, Cx40 and Cx43 protein expression 
in oxLDL stimulated macrophages by 1.77 fold (oxLDL: 1.49±0.118 vs oxLDL+Pravastatin: 
0.84±0.23; p<0.05), 5.71 fold (oxLDL: 0.40±0.06 vs oxLDL+Pravastatin: 0.07±0.04; p<0.01) 
and 2.38 fold (oxLDL: 1.60±0.13 vs oxLDL+Pravastatin: 0.67±0.23; p<0.01) respectively.
Image analysis of Cxs on cells by confocal laser scanning microscopy is a gold standard 
showing the typical distribution of Cx expression localised in the plasma membrane and GJs 
established between cells. Figure 3.5, 3.6 and 3.7 shows the detection of Cx37, Cx40 and 
Cx43 expressed in macrophages and the effects of oxLDL, Simvastatin and Pravastatin on 
these Cxs expressed by macrophages.
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Figure 3.5: Image analysis of the effect of oxLDL, Simavastatin and Pravastatin on Cx37 
protein expression in human macrophages by LSCM. Cx expression was detected by 
LSCM on fixed cells labelled with polyclonal antibody against human 0x37 and a secondary 
antibody labelled with Alexa Fluor 488. Cells were counter stained with DRAQ, a nuclear dye; 
and CD 14, a cell plasma membrane marker characteristic of differentiation from human 
monocyte in to macrophage.
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Figure 3.6: Image analysis of the effect of oxLDL, Simavastatin and Pravastatin on Cx40 
protein expression in human macrophages by LSCM. Cx expression was detected by 
LSCM on fixed cells labelled with polyclonal antibody against human Cx40 and a secondary 
antibody labelled with Alexa Fluor 488. Cells were counter stained with DRAQ, a nuclear dye; 
and CD14, a cell plasma membrane marker characteristic of differentiation from human 
monocyte in to macrophage.
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Figure 3.7: Image analysis of the effect of oxLDL, Simavastatin and Pravastatin on Cx43 
protein expression in human macrophages by LSCM. Cx expression was detected by 
LSCM on fixed cells labelled with polyclonal antibody against human Cx43 and a secondary 
antibody labelled with Alexa Fluor 488. Cells were counter stained with DRAQ, a nuclear dye; 
and CD 14, a cell plasma membrane marker characteristic of differentiation from human 
monocyte in to macrophage.
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The results show that Cxs appear as largely green bright, punctuate regions located especially 
at cellular contact regions and that oxLDL enhanced Cx37, Cx40 and Cx43 protein 
expression in macrophages. Simvastatin and Pravastatin both reduced Cx37, Cx40 and Cx43 
expression in non-stimulated macrophages and abolished Cx37, Cx40 and Cx43 protein 
expression in macrophages previously stimulated with oxLDL.
110
3.4 Discussion
GJs not only play a role in leukocyte transmigration, but also contribute to the development 
of atherosclerosis (Wong et al., 2004). Although studies have indicated that Cx37 and Cx43 
are expressed by macrophages of the immune system (Alves et al., 1996, Kwak et al., 2002, 
Beyer and Steinberg, 1991), no detailed characterisation of Cx distribution and the influence 
of an atherogenic stimulant on Cx expression by macrophages derived from peripheral blood 
currently exist.
In this chapter, the results obtained from the mRNA and protein expression o f Cxs in human 
macrophages derived from peripheral blood and the effect of oxLDL and anti-inflammatory 
drugs such as statins on Cx expression are discussed.
An important part o f these studies involved the identification of Cx37, Cx40 and Cx43 in 
macrophages derived from peripheral blood at the gene and protein level under resting and 
stimulatory conditions. These Cxs were chosen as they are constitutively expressed in a range 
of immune cells. It had been reported that human monocytes do not contain the mRNA of 
Cx43 (Polacek et al., 1993). However, these findings were contradicted in demonstrating that 
human monocytes/macrophages derived from peripheral blood treated with LPS or TNF-a 
plus IFN-y induced the expression of at least Cx43 (Eugenin et al., 2003). Our studies show 
that not only Cx43 but also Cx37 and Cx40 mRNA and protein are expressed by 
macrophages derived from peripheral blood under resting conditions.
Macrophages enhanced the in vitro expression of Cx43 mRNA when stimulated with oxLDL. 
However, the results obtained at the protein level contrasted with those derived from the 
study of the mRNA expression. The results obtained by Western blot and fluorescence 
confocal laser scanning microscopy indicated that oxLDL not only enhanced Cx43 but also 
Cx37 and Cx40 protein expression. These differences at the mRNA and protein level indicate
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a differential regulation of Cxs in the process of transcription and translation (Oyamada et al., 
2005, Beyer et al., 2009). Thus, the number of mRNA copies does not necessarily reflect the 
number of functional protein molecules (Guo et al., 2008).
Typically, macrophages phagocytose oxLDL through scavenger receptors and differentiate 
into characteristic foam cells in pathological conditions (Boyle, 2005). OxLDL have 
chemotactic and immunogenic properties that enhance the inflammatory response (Libby, 
2002). Hence, the upregulation of Cx expression through stimulation in macrophage whole 
cell extracts may not be proportional to the amount o f protein assembled into functioning 
connexon hemichannels at the plasma membrane level i.e. the basic hemichannel subunits 
that form GJs, especially under stimulation since cells maintain a balance between 
intracellular stores of Cxs and those assembled into GJs (Martin et al., 1998c, Nadarajah et 
al., 1998).
Furthermore, macrophages under resting conditions were found to express more Cx37 when 
compared to the expression levels o f Cx40 and Cx43. However, the level o f Cx43 expression 
in macrophages stimulated with oxLDL was found to be significantly higher when compared 
to Cx37 and Cx40. This is an indication that Cx43 mRNA and protein expression are directly 
up-regulated by antigenic challenge and further support the hypothesis based on recent 
studies that Cx43 is likely to participate in antigen processing and presentation (Krenacs et 
al., 1997).
Inhibitors o f HMG-CoA reductase (statins) lower plasma cholesterol in humans and reduce 
atherosclerosis-related morbidity and mortality (Vaughan et al., 2000). Because several in 
vitro studies have identified numerous pleiotropic effects of statins on vascular cells that 
could modulate atherogenesis and plaque rupture via mechanisms other than lowering 
cholesterol (Takemoto and Liao, 2001), we wanted to evaluate the effects o f statins on Cx
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expression by macrophages. When monocyte derived macrophages from peripheral blood 
pre-stimulated with oxLDL were treated with Simvastatin and Pravastatin, a significant 
decrease in Cx37, Cx40 and Cx43 mRNA and protein expression was observed by RT-PCR, 
Western blot and fluorescence confocal laser scanning microscopy studies. Furthermore, 
Simvastatin and Pravastatin treatment of macrophages were found to exhibit a significantly 
higher inhibitory effect o f the oxLDL enhanced expression level of Cx43 when compared to 
Cx37 and Cx40. A hypothetical mechanism of action of the statins based on the evidence 
could be that in the presence of oxLDL, statins inhibit transcription and/or induce instability 
o f Cx37, Cx40 and Cx43 in turn effecting Cx synthesis and/or promoting turnover o f Cx 
protein.
Overall, these results indicate for the first time that Simvastatin and Pravastatin are able to 
abrogate any such effects produced by oxLDL and could further be an indication of a statin 
anti-inflammatory effect on macrophages.
In conclusion, the results obtained provide novel evidences related to the profile of Cx 
expression in macrophages exposed to an atherogenic insult. The study also highlights a 
novel pathway of regulation by which anti-atherogenic drugs such as statins may be acting to 
regulate inflammation. These findings encouraged us to explore the involvement o f GJs 
during lymphocyte activation and proliferation since the activation of specific immune 
responses requires a direct physical interaction between antigen-presenting cells and 
lymphocytes. The following Chapters address an analysis involving the influence of oxLDL 
on lymphocyte gap junction functionality, its effect on lymphocyte proliferation and 
intracellular signalling cascades stimulated -in vitro.
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CHAPTER 4
CHARACTERISATION OF THE EFFECT OF OXIDISED 
LDL ON THE EXPRESSION AND FUNCTION OF 
CONNEXINS AND GAP JUNCTIONS DURING T CELL 
ANTIGEN-INDUCED PROLIFERATION
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4.1 Introduction
Atherosclerosis is an inflammatory disease in which immune cells infiltrate the 
atherosclerotic plaque. These inflammatory cells are mainly blood-borne T cells and 
macrophages. They accumulate during the early phases o f plaque formation (Libby et al., 
2011). Intercellular communication involving cytokines, chemokines, and growth factors is 
known to play an important role in the development of atherosclerotic lesions (Morel et al., 
2009). One of the key channels underpinning intercellular communication are GJs, which are 
the focus of research by various groups who have shown their participation in leukocyte 
biology and the generation of immune responses (Oviedo-Orta and Howard Evans, 2004, Li 
and Herlyn, 2005, Neijssen et al., 2005, Wong et al., 2006, Morel et al., 2009).
The first evidences describing the presence of GJs in lymphocytes were published in the early 
1970s. Two separate groups detected electrical coupling between lymphocytes isolated from 
bovine lymph nodes or human peripheral blood after stimulation with phytohaemagglutinin 
(PHA) (Hiilser and Peters, 1971, Hiilser and Peters, 1972, Oliveira-Castro et al., 1973, 
Oliveira-Castro and Barcinski, 1974). Subsequently, the ultrastructural detection o f GJs 
between PHA stimulated lymphocytes was observed (Gaziri et al., 1975, Kapsenberg and 
Leene, 1979). This was followed by ultrastructural reports o f heterocellular GJs between 
lymphocytes and ECs or Langerhans cells (Campbell, 1983, Concha et al., 1988, Concha et 
al., 1993). Moreover, bidirectional transfer of cytoplasmic fluorescent dyes between 
lymphocytes and the endothelium has been reported (Guinan et al., 1988). Cx distribution and 
GJIC has been studied in human and mouse lymphocyte subpopulations (Oviedo-Orta et al., 
2000). Both human and mouse lymphocytes display functional GJ channels, as assayed by 
dye transfer, which can be reduced by pharmacological agents or synthetic peptides known to 
block GJ communication. Furthermore, it was recently found by cell cycle staining, 
thymidine incorporation assays and carbocyfiuorescein succinimidyl ester (CFSE) analysis of
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cells exposed to mimetic peptide inhibitors of the plasma membrane Cx channels and 
antibodies generated to an extracellular region o f Cx, that upon antigen recognition, 
lymphocytes require Cxs to sustain their proliferation (Oviedo-Orta et al., 2010).
Although these studies provided strong evidence for the formation of functional GJ channels 
by lymphocytes and the involvement of Cxs in lymphocyte proliferation, no data exists on the 
involvement of GJs during lymphocyte proliferation induced by atherogenic antigens. Based 
on these findings, we hypothesised that GJIC underpins macrophage-T cell interactions and 
that the structural and functional composition of Cxs and GJs is affected by atherogenic 
factors during T cell proliferation. Therefore, the aim o f this chapter was to characterise the 
effect of atherogenic stimuli on the expression and function of Cxs and GJs during T cell 
antigen-induced proliferation. The objectives of our study involved assessing the effect o f 
oxLDL, Simvastatin, Pravastatin, 18-a-glycyrrhetinic acid, ^^ ’"^^GAP27 and "^®GAP27 on; 
CD4^ T cell-macrophage GJ coupling by dye transfer and Cx expression during CD4^ T cell 
proliferation by using a DNA-based cell proliferation kit (CyQUANT®).
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4.2 Methods
Cell culture procedures involving PBMC isolation, differentiation of monocytes into 
macrophages and CD4^ T cell isolation were routinely followed as described in section 
2.2.1.1, 2.2.1.2, 2.2.1.3 and 2.2.1.4 respectively. The effects of oxLDL, simvastatin and 
pravastatin on T cell proliferation were measured by CyQUANT assay (refer section 4.2.2 
below). Macrophage-T cell GJ coupling was assessed by flow cytometry by measuring 
calcein AM dye transfer in co-cultures using cells pre-treated with oxLDL and/or Simvastatin 
and Pravastatin.
4.2.1 Evaluation of dye transfer between macrophages and CD4^ T helper cells
4.2.1.1 Calcein AM
Calcein AM (Molecular weight: 994.8) is a polyanionic acetoxymethyl (AM) fluorescein 
ester derivative. These fluorescent indicators and chelators make up one o f the most useful 
groups of compounds for the study o f live cells. Modification of carboxylic acids with the 
AM ester group results in an unchanged molecule that can permeate cell membranes. Once 
inside the cell, the lipophilic blocking groups are cleaved by nonspecific esterases, resulting 
in a fluorescent and negatively charged molecule (Molecular weight: 623.1, charge -4) that is 
unable to diffuse out of the cells. In case of calcein AM, the AM ester is colourless and non- 
fluorescent until hydrolysed (Invitrogen, UK) (Grieshaber et al., 2010, Abbaci et al., 2008, 
Oviedo-Orta et al., 2000, Lulevich et al., 2009).
4.2.1.2 DiICi8(3)
DiICig(3) is part of the group of long-chain carbocyanine fluorescent lipophilic tracers. Cell 
membranes provide a convenient conduit for loading live and fixed cells with lipophilic dyes 
for cells can tolerate a high concentration of lipophilic dye and the lateral diffusion o f the dye 
within the membranes can serve to stain the entire cell, even if the dye is applied locally.
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Lipophilic tracers have been used to label cells, liposomes, viruses and lipoproteins a wide 
variety o f long-term tracing applications, including cell transplantation, migration, adhesion 
and fusion studies (Daubeuf et al., 2009, Oviedo-Orta et al., 2000).
The lipophilic carbocyanines are weakly fluorescent in water but highly fluorescent and quite 
photostable when incorporated into membranes. They have high excitation coefficients 
(>125,000 cm'^M"^ at their longest-wavelength absorption maximum) though modest 
quantum yields, and short excited-state lifetimes (~1 nsec) in lipid environments. Once 
applied to cells, dyes diffuse laterally within the plasma membrane, resulting in the staining 
of the entire cell. Transfer of these probes between intact membranes is negligible. DilCig 
and its analogues exhibit very low cell toxicity; however, moderate inhibition o f electron 
transport chain activity has been reported with some analogues (Invitrogen, UK) (Lassailly et 
al., 2010, Jaderstad et al., 2010).
4.2.1.3 Pre-loading method
A pre-loading dye transfer method was used to assess GJIC. Macrophages were pre-treated 
with 50pg/mL of oxLDL (Img/mL stock; refer section 2.2.1.5) for 48hrs followed by 
treatment with lOOpM of simvastatin (5mM stock; CalbioChem, UK), lOOpM of pravastatin 
(5mM stock; CalbioChem, UK) for 24hrs, lOOpM of 18-a-glycyrrhetinic acid (ImM  stock; 
Sigma, UK) for 24hrs and 300pM of Cx mimetic peptides (^ ’^"^^GAP27 and '^®GAP27; refer 
Table 2.2 for details; Activotec, UK) for 24hrs respectively seeded in multi-well plates (refer 
Chapter 2; section 2.2.1). The pre-treated macrophages were dye-loaded with 5pM calcein 
AM and freshly isolated CD4+ T cells (refer Chapter 2; section 2.2.1.4) were dye-loaded with 
5pM DilCis (dyes were first diluted in PBS containing Ig glucose/litre from ImM stock 
solutions made in DMSO) for 30min at 37°C in RPMI-1640 culture medium. The calcein 
AM loaded macrophages and DilCig loaded CD4+ T cells were washed three times with 
PBS.
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The DilCis loaded CD4^ T cells were co-cultured with the calcein AM loaded macrophages 
for 30 min at 37°C. Following the 30 min incubation, the CD4^ T cells in suspension were 
collected from the plates and washed three times after vortexing (to disrupt aggregates) with a 
solution containing PBS and lOmM EDTA.
4.2.1.4 Flow Cytometry analysis
Samples were analysed by flow cytometry for calcein (excitation at 488nm and emission at 
535nm) and for DilCig (excitation at 488nm and recorded at 585nm) using a FACS Canto 
with a FACS Diva software version 5.2 (BD Biosciences, UK) with the assistance of Dr. 
Alexandra Bermudez-Fajardo.
Before each experiment, compensation was calculated by using the auto-compensation 
function of the FACSDiva software and applied to subsequent analysis. Negative controls 
were also included in each experiment: an unstained cell sample was analysed to assess 
autofluorescence and separate cell samples were also labelled with isotype matched negative 
controls, at the same concentration o f calcein and DilCig used throughout the study. Data 
from 100,000 cells were acquired from each sample and results were expressed as the mean 
green fluorescent intensity caused by dye transfer above an arbitrary value set on negative 
cells.
4.2.2 Treatment of macrophages and CD4^ T cells for the CyQUANT assay 
1x10^ macrophages isolated from peripheral blood (refer Chapter 2, section 2.2.1) were 
treated with 25pg/mL of Mitomycin C (Img/mL stock; Sigma, UK) for Ihr. Mitomycin C is 
a potent crosslinker of all protein synthesis thereby inhibiting the secretion of soluble cell 
proliferating factors (Blake et al., 2006, Temess et al., 2008). Mitomycin C was used to study 
a gap junction mediated uni-directional response leading to T cell proliferation in the absence 
of soluble signals.
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After the Ihr incubation, the macrophages were treated with 4pg/mL of Tetanus Toxin 
(50pg/mL stock; Sigma, UK) for 24hrs. Pre-treatment with tetanus toxin would facilitate the 
use of memory cells (pre-existing in the individual) for a quick expansion o f the T cell pool 
(Perreau and Kremer, 2005, Muul et ak, 2001).
Mixed leukocyte reactions were setup by co-culturing macrophages with naive CD4^ T cells. 
These mixed leukocyte reactions were stimulated with 50pg/mL of oxLDL (Img/mL stock; 
refer section 2.2.1.5) for 48hrs, with/without lOOpM of simvastatin (5mM stock; 
CalbioChem, UK), lOOpM of pravastatin (5mM stock; CalbioChem, UK) for 24hrs, lOOpM 
of 18-a-glycyrrhetinic acid (ImM stock; Sigma, UK) for 24hrs and 300pM of Cx mimetic 
peptides (^ ’^"^^GAP27 and "^^GAP27; refer Table 2.2 for details; Activotec, UK) for 24hrs 
respectively.
4.2.3 Assessment of CD4^ T cell proliferation using CyQUANT® cell proliferation assay
4.2.3.1 Assay principle
The CyQUANT® cell proliferation assay is a homogenous method for cell viability and 
cytotoxicity studies. It is based on a DNA-binding dye with a masking reagent and the 
resulting staining o f cells with intact cell membranes only, affords a high accurate measure of 
healthy cells. Designed for high throughput application with mutli-well plates, the protocol is 
work-flow friendly with just one addition and no requirements of wash steps or cell lysis. The 
reagent is added directly to cell in complete medium, incubated for 30 to 60mins and read on 
standard plate readers (Invitrogen, UK) (Jones et ak, 2001).
4.2.3.2 Procedure
Mixed leukocyte reactions were setup in 96 well plates, treated as mentioned above in section
4.2.1 and incubated at 37°C for 5 days. After the 5 day incubation, the floating CD4^ T cells 
were collected and stored at -80°C prior to analysis o f cell proliferation. CD4^ T cell
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proliferation was determined using a CyQUANT® kit according to manufacturer’s 
instructions (Invitrogen, UK).
A separate CD4^ T cell sample of IxlO^ cells was collected and stored on the day o f the cell 
isolation to be used for the construction o f a standard curve using the CyQUANT® assay. 
Briefly, the cells were thawed at room temperature. The CyQUANT® lysis buffer and 
CyQUANT® dye were diluted 1:20 in nuclease free water (Invitrogen, UK). The 
CyQUANT® dye was then diluted 1:400 in the diluted lysis buffer. The cells were 
resuspended in 400pL CyQUANT® dye prepared in lysis buffer and transferred to a 96-well 
plate in duplicate using 2 fold serial dilutions of cells starting from 2x10^ to 1.56x10^ cells 
per well in 200pL of CyQUANT® dye. After a 5min incubation o f the cells with the 
CyQUANT® dye at room temperature, the reaction was read using a CCD imaging system 
(BioRad, UK) with filters for 485nm excitation and 538nm emission. Numbers of 
proliferating cells were calculated using the equation of the straight line through the standard 
curve.
4.2.4 Statistical analysis on macrophage- T cell gap junction coupling and connexin 
expression during T cell proliferation
Statistical analysis on evaluating dye transfer between macrophage and CD4^ T cells and 
connexin expression during CD4^ T cell proliferation was carried out by one way ANOVA 
with a Bonferroni post test using GraphPad Prism software (version 5.02, GraphPad Software 
Inc., USA; refer Chapter 2; section 2.2.1.9).
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4.3 Results
4.3.1 Dye transfer shows functional gap junction coupling between macrophages and T 
cells
The dye transfer assay was carried out in order to assess whether GJ channels established 
between macrophages and CD4^ T cells were functional or not. Furthermore, this technique 
was carried out to provide insight in the understanding of the effect of oxLDL, Simvastatin, 
Pravastatin, 18-a-glycyrrhetinic acid, ^^ ’"^^GAP27 and "^^GAP27 on macrophage-T cell gap 
junctional coupling which have never been previously reported.
GJ coupling between macrophages and CD4’*' T cells was studied by dye transfer and 
analysed by flow cytometry with or without pre-stimulation of macrophages with oxLDL. 
The effect of Simvastatin, Pravastatin, 18-a-glycyrrhetinic acid, ^^ ’"^^GAP27 and "*^GAP27 on 
GJ coupling between macrophages and CD4^ T cells was also studied with or without in vitro 
stimulation of macrophages with oxLDL (Fig 4.1 and 4.2).
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Figure 4.1: Effect of Simvastatin, Pravastatin, 18-alpha glycyrrhetinic acid, 37,43GAP27 and 
40GAP27 on macrophage-CD4+ T cell intercellular dye transfer in vitro. CD4^ T cells were first 
labelled with DilCig and the co-cultured with calcein AM loaded macrophages. Direct intercellular 
communication through gap junction channels was assessed using flow cytometry analysis by 
measuring the amount of fluorescent calcein transferred from macrophages to T cells. Double­
positive (green/red) fluorescent cells (appearing in the upper-right quadrants) were quantified and 
expressed as a percentage of the total number of CD4^ T cells analysed (Panel A). The graph in 
Panel B represents the total percentage of double-positive fluorescent I  cells and the resulting 
effects of the statins and Cx blockers on dye transfer. The data is presented as mean (n=3) ± SEM, 
*p<0.05.
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Figure 4.2: Effect of Simvastatin, Pravastatin, 18-alpha glycyrrhetinic acid, 37,43GAP27 and 
40GAP27 on macrophage-CD4+ T cell intercellular dye transfer stimulated with or without 
oxLDL in vitro. CD4+ T cells were first labelled with DilCis and then co-cultured with calcein AM 
loaded macrophages. The amount of calcein transferred from macrophages to I  cells was assessed 
by flow cytometry. Double-positive (green/red) fluorescent cells (appearing in the upper-right 
quadrants) were quantified and expressed as a percentage of the total number of CD4^ T cells 
analysed (Panel A). The graph in Panel B represents the total percentage of double-positive 
fluorescent T cells and the resulting effects of the statins and Cx blockers on dye transfer in cells 
stimulated with or without oxLDL. The data is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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As shown in Figure 4.1, 18-a-gIycyrrhetinic acid blocked, in a significant manner the transfer 
o f calcein between non-stimulated macrophages and T cells by 18.41 fold (Non-Treated: 
31.3±1.69% vs 18-a-glycyrrhetinic acid: 1.7±1.66%; p<0.05). Figure 4.2 shows that by co- 
culturing T cells with macrophages previously stimulated with oxLDL resulted in a 
significant increase of calcein transfer from the macrophages to T cells by 2.75 fold (Non- 
Treated: 31.3±1.69% vs oxLDL: 86.1±6.58%; p<0.05) whereas Simvastatin and Pravastatin 
treatment reversed the oxLDL effects resulting a significant decrease in the percentage of 
total T cells that have taken up calcein by 3.03 fold (oxLDL: 86.1±6.58% vs 
oxLDL+Simvastatin: 28.4±10%; p<0.05) and 3.29 fold (oxLDL: 86.1±6.58% vs 
oxLDL+Pravastatin: 26.1±6.78%; p<0.05) respectively. Treatment of oxLDL stimulated 
macrophage-T cell reactions with 18-a-glycyrrhetinic acid and Cx specific blockers such as 
37,43g a p 27 and '^®GAP27 were also found to significantly block intercellular calcein transfer 
by 200 fold (oxLDL: 86.1±6.58% vs oxLDL+18-a-glycyrrhetinic acid: 0.43±0.49%; p<0.01), 
3.41 fold (oxLDL: 86.1±6.58% vs oxLDL+^^’^ ^GAP27: 25.2±8.14%; p<0.05) and 4.53 fold 
(oxLDL: 86.1±6.58% vs oxLDL+'^^GAP27: 19±6.72%; p<0.05) respectively.
4.3.2. Increase in the proliferation of CD4^ T cells by oxLDL was gap junction mediated
Based on the results that oxLDL, Simvastatin, Pravastatin, 18-a-glycyrrhetinic acid, 
^^ ’"‘^ GAP27 and "^^GAP27 affect macrophage-T cell gap junction coupling. The next part of 
the study was to assess the effect o f oxLDL, Simvastatin, Pravastatin, 18-a-glycyrrhetinic 
acid, ^^ ’"^^GAP27 and ^^^GAP27 on Cx expression during T cell proliferation. This study will 
provide for the first time evidence of the involvement o f GJs during T cell proliferation 
induced by atherogenic antigens.
Monocyte differentiated macrophages isolated from peripheral blood (refer Chapter 2; section 
2.2.1.1) were treated with tetanus toxin and co-cultured with freshly isolated CD4^ T cells
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(refer Chapter 2; section 2.2.1.4). Batches o f the tetanus toxin pre-treated macrophages were 
also treated with mitomycin C.
The effect of 18-a-glycyrrhetinic acid, ^^ ’"^^GAP27 and "^^GAP27 on Cx expression during 
CD4^ T cell proliferation in the presence or absence o f soluble signals was assessed with or 
without in vitro stimulation with oxLDL (Fig. 4.3 and 4.4).
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Figure 4.3: Effect o f 18-alpha glyoyrrhetinlc acid, 37,43GAP27 and 40GAP27 on CD4+ T cell 
proliferation stimulated with or w ithout oxLDL in vitro. CD4^ T cells were co-cultured with 
macrophages at a ratio of 1:1 and stimulated with or without oxLDL. These mixed leukocyte 
reactions were further treated with 18-alpha glycyrrhetinic acid, ^^  '‘^GAR27 and "‘°GAP27 and their 
effects on CD4'" I  cell proliferation was assessed using CyQUANT. Panel A shows the effects of 
18-alpha glycyrrhetinic acid, ^^'’^GAP27 and '*°GAP27 on proliferation of CD4^ I  cells whereas 
Panel B shows the effects of the above mentioned Cx blockers and oxLDL on CD4^ T cell 
proliferation. The data is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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Figure 4.4: Effect o f 18-alpha glycyrrhetinic acid, 37,43GAP27 and 40GAP27 on CD4+ T cell 
proliferation stimulated w ith or w ithout oxLDL in vitro in the absence o f soluble T cell 
proliferating signals. Macrophages pre-treated with tetanus toxin and fixed with mitomycin C were 
co-cultured with CD4'" T cells at a ratio of 1:1 and stimulated with or without oxLDL. These mixed 
leukocyte reactions were further treated with 18-alpha glycyrrhetinic acid, ^^ ’'*^GAP27 and '*°GAP27 
and their effects on CD4^ T cell proliferation in the absence of soluble T cell proliferating signals was 
assessed using CyQUANT. Panel A shows the effects of 18-alpha glycyrrhetinic acid, ^^'‘^GAP27 
and '*°GAP27 on proliferation of CD4^ T cells whereas Panel B shows the effects of the above 
mentioned Cx blockers and oxLDL on CD4"  ^T cell proliferation. The data is presented as mean (n=3) 
±SEM, *p<0.05, **p<0.01.
OxLDL was found to significantly enhance CD4^ T cell proliferation in the presence and 
absence o f soluble T cell proliferating signals (see Fig 4.1 and Fig 4.2) when compared to the 
control (non-treated) by 1.45 fold (Non-Treated: 4.98x10'^±0.88xl0'^ cells vs oxLDL: 
7.26x10'^±0.65xl0'^ cells; p<0.05) and 1.62 fold (Non-Treated: 2.22xl0'^±0.30xl0'^ cells vs 
oxLDL: 3.61xl0'^±0.21xl0'^ cells; p<0.05) respectively. Treatment of mixed leukocyte 
reactions with 18-a-glycyrrhetinic acid, ^ '^"^^GAP27 and "*^GAP27 were found to have a 
significant inhibitory effect on CD4^ T cell proliferation by 2.84 fold (Non-Treated: 
4.98x10'^±0.88xl0'^ cells vs 18-a-glycyrrhetinic acid: 1.75x10'^il.33x10"  ^ cells; p<0.05), 3.27 
fold (Non-Treated: 4.98x10'*±0.88xl0'^ cells vs ^^ ’"^^GAP27: 1.52xl0'^±0.29xl0'^ cells; p<0.01) 
and 2.94 fold (Non-Treated: 4.98x10^±0.88xl0^ cells vs ^^GAP27: 1.69xl0^±0.26xl0'^ cells; 
p<0.01) respectively. These inhibitory effects by 18-a-glycyrrhetinic acid (4.19 fold; Non- 
Treated: 2.22x10'^±0.30xl0'^ cells vs 18-a-glycyrrhetinic acid: 0.52x10'^±0.24xl0'^ cells;
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p<0.01), ^^ ’^ ^GAP27 (1.46 fold; Non-Treated: 2.22x10^±0.30xl0^ cells vs ^^ ’^ ^GAP27: 
1.52xl0^±0.29xl0^ cells; p<0.05) and ^®GAP27 (1.31 fold; Non-Treated: 2.22x10^±0.30xl0^ 
cells vs "^°GAP27: 1.69xl0'^±0.26xl0'^ cells; p<0.05) were also observed in the case o f CD4^ 
T cell proliferation in the absence of soluble T cell proliferation factors. Furthermore, 18-a- 
glycyrrhetinic acid and ^^ ’"^^GAP27 were also found to have a significant inhibitory effect on 
oxLDL induced CD4^ T cell proliferation by 1.32 fold (oxLDL: 3.61xl0'^±0.21xl0'^ cells vs 
oxLDL+18-a-glycyrrhetinic acid: 2.72x10"^±0.18 x 1 cells; p<0.05) and 1.57 fold (oxLDL: 
3.61xl0^±0.21xl0^ cells vs oxLDL+^^’^ ^GAP27: 2.28x10^.56x10"* cells; p<0.05) 
respectively in the absence of soluble T cell proliferation factors.
4.3.3 Simvastatin and Pravastatin inhibit connexin expression in proliferating CD4^ T 
cells in the presence or absence of soluble T cell stimulatory signals
The effect of Simvastatin and combinations of; Simvastatin with 18-a-glycyrrhetinic acid. 
Simvastatin with ^^ ’"*^GAP27 and Simvastatin with "*^GAP27 was assessed on Cx expression 
during CD4^ T cell proliferation with or without in vitro stimulation with oxLDL (Fig. 4.5).
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Figure 4.5: Effect o f Simvastatin, Simvastatin+18-alpha glycyrrhetinic acid,
Simvastatin+37,43GAP27 and simvastatin+40GAP27 on CD4+ T cell proliferation stimulated 
w ith or w ithout oxLDL in vitro. CD4^ T cells were co-cultured with macrophages at a ratio of 1:1 
and stimulated with or without oxLDL. These mixed leukocyte reactions were further treated with 
Simvastatin alone along with combinations of Simvastatin+18-alpha glycyrrhetinic acid, 
Simvastatin+^^’"^GAP27 and Simvastatin+'*°GAP27 and their effects on CD4'’ T cell proliferation 
was assessed using CyQUANT. Panel A shows the effects of Simvastatin, Simvastatin+18-alpha 
glycyrrhetinic acid, Simvastatin+^^’'*^GAP27 and Simvastatin+'*°GAP27 on proliferation of CD4^ T 
cells whereas Panel B shows the effects of Simvastatin along with combinations of the above 
mentioned Cx blockers and oxLDL on CD4+ T cell proliferation. The data is presented as mean 
(n=3) ± SEM, *p<0.05, **p<0.01.
As shown in Figure 4.5, treatment of mixed leukocyte reactions with combinations of 
Simvastatin+18-a-glycyrrhetinie acid, Simvastatin+^^’"*^GAP27 and Simvastatin+"*^GAP27 
resulted in a significant decrease in CD4^ T cell number by 2.55 fold (Non-Treated: 
4.98xl0"*±0.88xl0"* cells vs Simvastatin+18-a-glyeyrrhetinic acid: 1.94xl0"*±0.68xl0"* cells; 
p<0.01), 1.92 fold (Non-Treated: 4.98x10"*±0.88xl0"* cells vs Simvastatin+^^’"*^GAP27: 
2.58xl0"*±0.83xl0"* cells; p<0.05) and 3.86 fold (Non-Treated: 4.98x10"*±0.88xlO'* cells vs 
Simvastatin+'*^GAP27: 1.28xlO"*±G.37xlG'* cells; p<G.Gl) respectively. Treatment with 
Simvastatin alone significantly inhibited oxLDL induced CD4^ T cell proliferation by 1.39 
fold (oxLDL: 7.26x1 G'*±G.65xlO'* cells vs oxLDL+Simvastatin: 4.20x1 G'*±G.24xl O'* cells; 
p<G.G5) and these inhibitory effects were also observed with treatments of Simvastatin+18-a-
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glycyrrhyetinic acid (3.5 fold; oxLDL: 7.26x10'*±0.65xlO'* cells vs oxLDL+Simvastatin+18- 
a-glycyrrhetinic acid: 2.03xl0'*±l.14x10'* cells, p<0.05), Simvastatin+^^’^ ^GAP27 (2.42 fold; 
oxLDL: 7.26x10'*±0.65xl o '*  cells vs oxLDL+Simvastatin+^^’'*^GAP27: 2.99x10'*±0.46xl O'* 
cells, p<0.01) and Simvastatin+'*®GAP27 (1.92 fold; oxLDL: 7.26x10'*±0.65xlO'* cells vs 
oxLDL+Simvastatin+'*®GAP27: 3.78xl0'*+0.95xl0'*cells, p<0.05).
The effect of Simvastatin and combinations of; Simvastatin with 18-a-glycyrrhetinie acid. 
Simvastatin with ^^ ’'*^GAP27 and Simvastatin with '*^GAP27 was assessed on Cx expression 
during CD4^ T cell proliferation with or without in vitro stimulation with oxLDL in the 
absence o f soluble signals (Fig. 4.6).
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Figure 4.6: Effect o f Simvastatin, Simvastatin+18-alpha glycyrrhetinic acid,
Simvastatin+37,43GAP27 and Simvastatin+40GAP27 on CD4+ T cell proliferation stimulated 
with or w ithout oxLDL in vitro in the absence o f soluble T cell proliferating signais.
Macrophages pre-treated with tetanus toxin and fixed with mitomycin C were co-cultured with CD4^ T 
cells at a ratio of 1:1 and stimulated with or without oxLDL. These mixed leukocyte reactions were 
further treated with Simvastatin alone along with combinations of Simvastatin+18-alpha glycyrrhetinic 
acid, Simvastatin+^^'^^GAP27 and Simvastatin+'’°GAP27 and their effects on CD4^ T cell proliferation 
in the absence of soluble T cell proliferating signals was assessed using CyQUANT. Panel A shows 
the effects of Simvastatin, Simvastatin+18-alpha glycyrrhetinic acid, Simvastatin+^^'*^GAP27 and 
Simvastatin+'*°GAP27 on proliferation of CD4^ T cells whereas Panel B shows the effects of 
Simvastatin along with combinations of the above mentioned Cx blockers and oxLDL on CD4^ T cell 
proliferation. The data is presented as mean (n=3) ± SEM, *p<0.05, **p<0.01.
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It was observed that simvastatin+18-a-glycyrrhetinic acid and Simvastatin+^^’'*^GAP27 
treatment on co-cultures o f mitomycin C pre-treated macrophages with CD4^ T cells resulted 
in a significant decrease in CD4^ T cell number by 4.96 fold (Non-Treated; 
2.22x10'*±0.30xlo'* cells vs Simvastatin+18-a-glycyrrhetinic acid: 0.44x10'*±0.24xlO'* cells; 
p<0.01) and 2.27 fold (Non-Treated: 2.22x10'*±0.30xl O'* cells vs Simvastatin+^^’'*^GAP27: 
0.87xl0'*±0.31xl0'* cells; p<0.01) respectively (Fig 4.6). Simvastatin alone and 
Simvastatin+18-a-glycyrrhetinic acid were also found to exhibit significant inhibitory effects 
on oxLDL induced CD4^ T cell proliferation in the absence of soluble T cell proliferating 
signals by 2.28 fold (oxLDL: 3.61xl0'*±0.21xl0'* cells vs oxLDL+Simvastatin: 
1.58xl0'*±0.35xl0'* cells; p<0.05) and 6.6 fold (oxLDL: 3.61xl0'*±0.21xl0'* cells vs 
oxLDL+Simvastatin+18-a-glycyrrhetinic acid: 0.54x10'*±0.30xlO'* cells; p<0.05) respectively 
(Fig 4.6).
The effect of Pravastatin and combinations of; Pravastatin with 18-a-glycyrrhetinic acid, 
Pravastatin with ^^ ’'*^GAP27 and Pravastatin with '*®GAP27 was assessed on Cx expression 
during CD4^ T cell proliferation with or without in vitro stimulation with oxLDL (Fig. 4.7).
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Figure 4.7: Effect o f Pravastatin, Pravastatin+18-alpha glycyrrhetinic acid,
Pravastatin+37,43GAP27 and Pravastatin+40GAP27 on CD4+ T cell proliferation stimulated 
with or w ithout oxLDL in vitro. CD4^ T cells were co-cultured with macrophages at a ratio of 1:1 
and stimulated with or without oxLDL. These mixed leukocyte reactions were further treated with 
Pravastatin alone along with combinations of Pravastatin+18-alpha glycyrrhetinic acid, 
Pravastatin+^^'‘^GAP27 and Pravastatin+'*°GAP27 and their effects on CD4^ T cell proliferation 
was assessed using CyQUANT. Panel A shows the effects of Pravastatin, Pravastatin+18-alpha 
glycyrrhetinic acid, Pravastatin+^^'*^GAP27 and Pravastatin+^*°GAP27 on proliferation of CD4‘" T 
cells whereas Panel B shows the effects of Pravastatin along with combinations of the above 
mentioned Cx blockers and oxLDL on CD4+ T cell proliferation. The data is presented as mean 
(n=3) ± SEM, *p<0.05, **p<0.01.
As shown in Figure 4.7, treatment of mixed leukocyte reactions with combinations of 
Pravastatin+18-a-glycyrrhetinic acid, Pravastatin+^^'*^GAP27 and Pravastatin+'*^GAP27 
resulted in a significant decrease in CD4^ T cell number by 1.76 (Non-Treated: 
4.98x10^^+0.88x1 o'* cells vs Pravastatin+18-a-glycyrrhetinic acid: 2.48x10'*±0.43xlO'* cells; 
p<0.05), 1.7 fold (Non-Treated: 4.98x10'*±0.88xlO'* cells vs Pravastatin+^^'*^GAP27: 
2.48x10'*±0.43xlo'* cells; p<0.5) and 1.52 fold (Non-Treated: 4.98x10'*±0.88xlO'* cells vs 
Pravastatin+'*^GAP27: 2.86x10'*±0.74xlO'* cells; p<0.05) respectively. Treatment with 
Pravastatin alone was found to significantly inhibit oxLDL induced CD4^ T cell proliferation 
by 1.73 fold (oxLDL: 7.26x10'*±0.65xlO'* cells vs oxLDL+Pravastatin: 4.18xl0'*±0.78xl0'* 
cells; p<0.05) and these inhibitory effects were also observed with treatments of 
Pravastatin+^^'*^GAP27 (2.09 fold; oxLDL: 7.26x10'*±0.65xl O'* cells vs
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oxLDL+Pravastatin+^^’'*^GAP27: 3.46xl0'^+0.62xl0^ cells, p<0.01) and Pravastatin+'^^GAP2740 /
(1.92 fold; oxLDL: 7.26x10'^±0.65xl0'^ cells vs oxLDL+Pravastatin+'*®GAP27:
3.78xl0"*+0.99xl0"* cells, p<0.05).
The effect of Pravastatin and combinations of; Pravastatin with 18-a-glycyrrhetinic acid. 
Pravastatin with ^ '^"*^GAP27 and Pravastatin with '*®GAP27 was assessed on Cx expression 
during CD4^ T cell proliferation with or without in vitro stimulation with oxLDL in the
absence of soluble signals (Fig. 4.8).
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Figure 4.8: Effect o f Pravastatin, Pravastatin+18-alpha glycyrrhetinic acid,
Pravastatin+37,43GAP27 and Pravastatin+40GAP27 on CD4+ T ceil proliferation stimulated 
with or w ithout oxLDL in vitro in the absence o f soluble T cell proliferating signals.
Macrophages pre-treated with tetanus toxin and fixed with mitomycin C were co-cultured with 
CD4'' T cells at a ratio of 1:1 and stimulated with or without oxLDL. These mixed leukocyte 
reactions were further treated with Pravastatin alone along with combinations of Pravastatin+18- 
alpha glycyrrhetinic acid, Pravastatin+^^’'*^GAP27 and Pravastatin+'*°GAP27 and their effects on 
CD4^ T cell proliferation in the absence of soluble T cell proliferating signals was assessed using 
CyQUANT. Panel A shows the effects of Pravastatin, Pravastatin+18-alpha glycyrrhetinic acid, 
Pravastatin+^^'’^GAP27 and Pravastatin+'’°GAP27 on proliferation of 004"^ T cells whereas Panel 
B shows the effects of Pravastatin along with combinations of the above mentioned Cx blockers 
and oxLDL on CD4^ T cell proliferation. The data is presented as mean (n=3) ± SEM, *p<0.05,
**p<0.01.
It was observed that Pravastatin alone, pravastatin+18-a-glycyrrhetinic acid, 
Pravastatin+^^'*^GAP27 and Pravastatin+"*^GAP27 were found to exhibit significant 
inhibitory effects on oxLDL induced CD4^ T cell proliferation in the absence o f soluble T
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cell proliferating signals by 1.39 fold (oxLDL: 3.61xl0'*±0.21xl0'* cells vs
oxLDL+Pravastatin: 2.59x10'*±0.23xl0"* cells; p<0.05), 3.37 (oxLDL: 3.61xl0'*±0.21xl0'* 
cells vs oxLDL+Pravastatin+18-a-glycyrrhetinic acid: 1.67xl0'*±0.30xl0'* cells; p<0.05), 
1.91 fold (oxLDL: 3.61xl0'*±0.21xl0'* cells vs oxLDL+Pravastatin+^^’'*^GAP27:
2.18xl0'*±0.24xl0'* cells; p<0.05) and 2.52 fold (oxLDL: 3.61xl0'*±0.21xl0'* cells vs 
oxLDL+Pravastatin+'*^GAP27: 2.02x10^^+0.19x1 O'* cells; p<0.05) respectively (Fig 4.8).
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4.4 Discussion
In chapter 3, the profile of Cx expression in macrophages derived from peripheral blood 
induced by oxLDL was described. To demonstrate the in vitro establishment o f functional GJ 
channels between human macrophages and T cells, a pre-loading transfer technique was used. 
This method is based on the use of the cell permeable compound calcein AM that becomes 
impermeable and emits green fluorescence after hydrolysis by intracellular esterases 
(Lulevich et al., 2009, Grieshaber et al., 2010). Thus, it can only diffuse between viable cells 
if the component cells have established intercellular contact through GJ channels (Abbaci et 
al., 2008). Furthermore, to demonstrate the outcome o f GJIC between macrophages and T 
cells leading to T cell proliferation, a CyQUANT assay was carried out to determine T cell 
number based on proliferation. The CyQUANT assay is based on the use o f a cell-permeant 
DNA-binding dye; as DNA content is highly regulated leading to cell number estimates being 
very accurate (Jones et al., 2001). The results pertaining to the effects of oxLDL, statins and 
GJ blockers such as 18-a-glycyrrhetinic acid, ^^  '*^GAP27 and ^*^GAP27 on macrophage-T-cell 
GJ coupling and Cx expression during T cell proliferation are discussed in this chapter.
Calcein dye transfer has been previously used to examine GJ communication between 
embryonic lens cells (Frenzel and Johnson, 1996), normal and tumour mammary epithelial 
cells (Tomasetto et al., 1993), tumour cells transfected with different Cxs (Koval et al., 1995), 
cells exposed to growth factors (Meyer et a l, 1992), between macrophage and intestinal 
epithelial cells (Martin et a l, 1998b), between contacting lymphocytes (Oviedo-Orta et a l,
2000) and also lymphocytes and endothelial cells (Oviedo-Orta, 2002).
A major advantage of using calcein over other current dye transfer methods is the possibility 
of labelling large groups of cells at the same time in which the intercellular dye spread 
through GJs can be monitored for several hours. Lipophilic carbocyanine tracers like Dil are 
also ideal labels for long-term cell tracing in vitro and in vivo, including studies o f cell
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migration, transplantation (Markus et a l, 1997), adhesion and fusion (Horan et al., 1990). 
The presence of Dil in the cell membrane does not appreciably affect cell viability, 
development or other basic physiological properties. Labelling of cell suspensions for long­
term tracing is typically performed from aqueous dispersions of the dyes (Ragnarson et al., 
1992). Stock solutions o f most o f the tracers may be prepared in alcohol or DMSO and then 
added to cell suspensions.
Using flow cytometry analysis, it was demonstrated that calcein dye transfer occurred 
between co-cultures of macrophages and CD4+ T cells. Blocking o f dye transfer between 
macrophages and CD4+ T cells was observed using a GJ inhibitor; 18-a-glycyrrhetinic acid 
that is a lipophilic aglycone with a steroidal structure isolated from liquorice root. Although, 
it’s specific mechanism o f action on GJ functionality is less clear, several studies have 
reported that it may influence Cx43 phosphorylation (Goldberg et al., 1996) and that 
extended exposure o f cells to 18-a-glycyrrhetinic acid at increasing concentrations lead to the 
inhibition of GJIC and time-/dose-dependent reductions in both Cx43 protein and mRNA 
expression (Guo et al., 1999).
Interestingly, when co-cultures of macrophages and CD4+ T cells were stimulated with 
oxLDL, dye transfer from macrophages to the CD4+ T cells was enhanced when compared to 
resting conditions. Inhibition of dye transfer between the two cell types stimulated with 
oxLDL was observed by using GJ blockers such as ^^ ’'*^GAP27, '*®GAP27 and 18-a- 
glycyrrhetinic acid. GAP27 peptides have been shown to act in a Cx-specific manner and 
have been widely applied to block GJs composed of Cx37, Cx40 and Cx43 (Martin et al., 
2005, Chaytor et al., 1997, Isakson and Duling, 2005). These peptides inhibit GJ transfer of 
fluorescent dyes (Chaytor et al., 1999), electrical coupling (Dora et al., 1999) and 
synchronised Ca^^ oscillations in smooth muscle cells (Isakson and Duling, 2005) and 
monolayer cells cultures (Boitano and Evans, 2000, Isakson et al., 2001). Furthermore, the
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Cx mimetic peptides have also been shown to inhibit GJ dependent artery oscillations 
(Chaytor et al., 1997), intercellular propagation of calcium waves across GJs (Boitano et al., 
1998) as well as dye coupling in HeLa cells expressing various recombinant Cxs (George et 
al., 1998b).
Braet et. al. (Braet et al., 2003a, Braet et al., 2003b) were the first to report that Cx mimetic 
peptides also inhibit Cx hemichannels. This observation was not unexpected, given the fact 
that the extracellular loop sequences, with which the peptides are likely to interact, are freely 
available in Cx hemichannel form. Furtherwork by other groups have demonstrated that 
GAP27 blocks uptake of the reporter dye propidium iodide and ATP release in Cx43- 
expressing cells indicating a selective inhibiton by GAP27 on Cx hemichannels composed of 
the Cx43 isoform (Braet et al., 2003a, Leybaert et al., 2003). Patch clamp studies have shown 
that the bound Cx mimetic peptides reduce within minutes the voltage-induced opening of 
Cx43 channels expressed in cardiomyocytes (Hawat et al., 2010) and inhibition of ATP 
release or dye uptake via Cx hemichannels was found to follow similar kinetics (Leybaert et 
al., 2003, De Vuyst et al., 2007).
Several possible mechanisms of GJ blocking by the Cx mimetic peptides have been put 
forward, including the reduced docking o f two performed Cx hemichannels with peptides on 
their extracellular loops, the breaking apart of existing GJ channels and interactions o f the 
peptides with an accessible Cx target followed by conformational changes that lead to GJ 
channel closure (Berthoud et al., 2000, Evans et al., 2006a). Further possibilities include the 
diffusion of the peptides in the extracellular space surrounding the GJ channels and into the 
intercellular clefts resulting in a separation of independent effects on GJ coupling from those 
on Cx hemichannels (Evans et al., 2006a).
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We also found that dye transfer was inhibited between oxLDL stimulated macrophages and 
CD4+ T cells by using the cholesterol lowering drugs; Simvastatin and Pravastatin. This 
could be an indication that the statins might be functionally involved in disrupting GJIC on 
atherogenic stimulation. These studies involving the effects of the statins and GJ blockers on 
dye transfer between oxLDL stimulated macrophages and CD4+ T cells support the 
hypothesis that T cell signalling through GJ channels might participate in homocellular or 
heterocellular regulatory interactions (Saez et al., 1999, Boitano et al., 1998, Oviedo-Orta and 
Howard Evans, 2004).
Complex homocellular and heterocellular type cross-talk occurring between lymphocytes 
involves multiple receptor-ligand complexes and ion channels and these cellular interactions, 
for example, have recently been conceptualised as comprising an immunological synapse 
(Krummel and Davis, 2002, Dustin et al., 2001, Bromley et al., 2001). Recent studies have 
shown Cx43, the main GJ protein of the immune system, accumulates at the immunological 
synapse and mediates bidirectional cross talk between APCs and T cells in murine and human 
systems (Mendoza-Naranjo et al., 2011). However, the nature of the intracellular signals 
exchanged through GJs at the synapse is presently unknown. Since T cell activation triggers 
important metabolic signalling pathways, the involvement o f oxLDL on direct cell 
communication through GJs is a further implication of the present work.
Cell growth requires the uptake of nutrients acquired from the extracellular environment. 
These, in turn, control the proliferation of T cells (Zea et al., 2004). In extracellular oxidising 
environments, free cysteine is converted rapidly into the disulfide-bonded form. T cells 
require a reducing environment to proliferate, as their cysteine uptake is limited to the thiolic 
forms (Droge et al., 1991). Macrophages control T cell-mediated responses according to the 
availability of cysteine and tryptophan for T cell proliferation. Thus, changes in cell 
membrane permeability implicating Cx channels might influence the proliferation o f T cells
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(Munn et al., 1999). We examined the effects of oxLDL, statins and GJ blockers during T cell 
proliferation. As expected, CD4+ T cells responded with a high rate of T cell proliferation 
when cultured with macrophages. This result corresponded to the observations by Oviedo- 
Orta et. al., where they had shown that CD4+ T cells respond with a high rate of T cell 
proliferation when cultured in the presence of feeder cells along with soluble CD3 and CD28 
antibodies (Oviedo-Orta et al., 2010). However, in the presence of GJ blockers such as 18-a- 
glycyrrhetinic acid, ^^ ’'*^GAP27 and '*®GAP27; proliferation of CD4+ T cells was significantly 
reduced. These observations were also found to correspond to the studies by Oviedo-Orta et. 
al., where they had identified a reduction in proliferation of CD4+ T cells in a dose- 
dependent manner on treatment with GAP27 and oleamide (Oviedo-Orta et al., 2010). 
Interestingly, oxLDL stimulation o f the mixed leukocyte reactions significantly enhanced 
CD4+ T cell proliferation when compared to resting conditions. This could be an indication 
that oxLDL induced GJ communication between proliferating T cells might coordinate their 
metabolic and cytokine-induced responses to allow the appropriate timing o f the specific 
immune responses.
Based on this evidence, we wanted to examine whether the reduction in CD4+ T cell 
proliferation was GJ mediated or dependent on other factors such as soluble T cell 
proliferating signals. We carried out our study by treating the macrophage-CD4+ T cell co­
cultures with mitomycin C that is a DNA cross linker and potent inhibitor o f soluble signals. 
We found that the proliferation of CD4+ T cells was significantly reduced to the same extent 
as without mitomycin C treatment. Furthermore, stimulation of macrophage-CD4+ T cell co­
cultures with oxLDL significantly enhanced proliferation of CD4+ T cells. However, 18-a- 
glycyrrhetinic acid and ^^ ’'*^GAP27 were found to exhibit a significant inhibitory effect on 
CD4+ T cell proliferation in the presence o f oxLDL. Cell viability was found to be 
approximately 98%, showing that inhibitory effects on CD4+ T cell proliferation were not a
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result of cell death. These findings support our hypothesis that GJ mediated communication 
and soluble factors play a role in T cell proliferation.
Recent studies have identified the cholestorel lowering drugs called statins exhibitng anti­
inflammatory and immunomodulatory functions (Palinski and Tsimikas, 2002, Blanco-Colio 
et al., 2003). These studies have further revealed their mechanistic basis involving decrease in 
IFN-y induced expression of MHC II antigens on endothelial and antigen presenting cells 
(APC) (Kwak et al., 2000). Certain statins were also found to bind to the adhesion molecule 
leukocyte function antigen-1 (LFA-I) on APCs in turn blocking the interaction with T cell 
expressing the counter-receptor intercellular adhesion molecule-1 (ICAM-I) (Weitz-Schmidt 
et al., 2001). In this respect, we wanted to examine the effects of simvastatin and pravastatin 
on Cx expression during oxLDL induced CD4+ T cell proliferation. Interestingly, simvastatin 
and pravastatin treatment showed a significant inhibition in oxLDL induced CD4+ T cell 
proliferation. We further examined whether this inhibition in CD4+ T cell proliferation was 
GJ mediated. We found that, oxLDL induced proliferation o f CD4+ T cells was significantly 
reduced on treatment with simvastatin and pravastatin in combination with GJ blockers such 
as 18-a-glycyrrhetinic acid, ^^ ’'*^GAP27 and ^*^GAP27. These inhibitory effects by the statins 
on CD4+ T cell proliferation were also found to be mirrored in oxLDL stimulated mixed 
leukocyte reactions treated with mitomycin C. These results are an indication that simvastatin 
and pravastatin can abrogate the proliferation of T cells by interfering with the activity o f Cxs 
on the cell surface and not by altering GJ communication between the T cells and APCs.
In the present work, it was not possible to distinguish the individual contribution to the 
channel functionality by Cx37, Cx40 and Cx43 due to the nature of the inhibitors used. In 
addition to exhibiting different compatibilities in heterotypic channel formation, intercellular 
channels constructed from different Cx proteins also display distinct functional properties. In 
conclusion, our results show that by modulating the expression of Cxs, T cells regulate the
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exchange of nutrients and other molecules. During T cell-mediated response, the Cxs are 
required to sustain the proliferation and therefore, the clonal expansion of activated T cells. 
Furthermore, the results obtained provide novel evidences related to the effects of an 
atherogenic stimulant such as oxLDL on macrophage-T cell GJIC leading to T cell 
proliferation and the anti-atherogenic effects of statins on this GJ mediated communication. 
These findings encouraged us to explore the involvement of GJ’s on T cell activation and 
signalling. The following Chapter addresses the analysis pertaining to the effects of 
atherogenic stimuli on Cx mediated T cell intracellular signalling.
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CHAPTER 5
ASSESSMENT OF THE EFFECT OF OXIDISED LDL ON 
CONNEXIN MEDIATED T CELL INTRACELLULAR
SIGNALLING
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5.1 Introduction
T cells are central players of the adaptive immune response, which help protect the host 
against different pathogens ranging from bacteria to fungi and viruses. In order to perform 
their function, T cells require activation, a process that leads to a variety of responses 
including proliferation, migration, cytokine production and even apoptosis (Smith-Garvin et 
al., 2009). T cells may become activated and this determines the nature of the immune 
response. To perform such a complex and sensitive task, T cells must respond to 
environmental cues that stimulate a complex signalling cascade (Smith-Garvin et al., 2009, 
Alarcon et al., 2011).
The current paradigm describes that T cell activation requires two signals for effective 
activation. The primary signal is provided by the binding o f antigens in the form o f peptides 
to the T cell antigen receptor (TCR) in the context of the class I or II major histocompatibility 
complex (MHC). The secondary signal or the co-stimulatory signal is provided by the 
interaction of coreceptors such as CD28 or CD4 with their counterparts in the antigen 
presenting cell (APC) (Zhang, 2001, Bell, 2005).
The TCR is a complex of six different polypeptides. The clonotypic a and p chains provide 
the specificity of the ligand binding by a process o f genetic rearrangement that provides 
millions of receptor variants. While the a  and p heterodimer binds directly to the 
peptide/MHC complex, the engagement of the intracellular signalling machinery is carried 
out through the invariant component of the TCR; the y, 8 and s chains (collectively known as 
the CD3 complex) and the ^ chains. Signal two or the co-stimulatory signal is provided by the 
interaction o f coreceptors such as CD28 or CD4 with their counterparts in the APC (Grakoui 
et al., 1999, Judd and Koretzky, 2000).
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The principal signalling pathway following TCR engagement is protein tyrosine 
phosphorylation. The tyrosine phosphorylation cascade will ultimately activate several 
transcription factors such as nuclear factor kappa-light-chain enhancer of activated B cells 
(NFkB), nuclear factor of activated T-cells (NFAT) and activator protein l(A P-l) (Hermiston 
et al., 2002). The common signalling element downstream of T cell costimulation is 
phosphatidylinositol 3-kinase (PI3K). Co-stimulatory signalling via PI3K results in the 
recruitment of protein kinase C (PKC) 0 that is a Ca^^ independent serine/threonine kinase, an 
essential member of the NFkB activation cascade and a central player in the mediation of T 
cell differentiation into Thl, Th2 and Thl7 effector lines (Marsland and Kopf, 2008).
Transcription factors belonging to the NFxB/Rel family are important for the maturation and 
survival o f T cells and the induced expression of gene products mediating innate and 
adaptive immunity (Kane et al., 2002, Ghosh and Karin, 2002). However, the components of 
the NFkB activation cascade triggered by T cell co-stimulation are just emerging. The NFkB 
transcription factor system consists of various DNA binding dimmers that are retained in the 
cytoplasm upon association with an inhibitory nuclear factor of kappa light polypeptide gene 
enhancer in B cells inhibitor alpha (IkB u) protein (Rothwarf and Karin, 1999, Dixit and Mak, 
2002). Activation of NFkB by a wide array o f stimuli such as cytokines or T cell co­
stimulation leads to the onset of signalling cascades that ultimately converge at the level of 
the IkB kinase (IKK) complex. This complex is composed of two catalytic subunits IKKa 
and IKKp protein. The IKK complex inducibly phosphorylates IkB u leading to the 
proteasomal degradation of IkB u and translocation o f the activated NFkB into the nucleus to 
upregulate genes involved in T cell development, maturation and proliferation (Karin and 
Ben-Neriah, 2000, Li and Verma, 2002). To study inflammation, the activity o f NFkB 
through the series of phosphorylation events by the various intracellular protein kinases 
involved in its activation was assessed in human T cells stimulated in vitro with oxLDL;
144
since NFkB enhances the expression of several proinflammatory molecules that lead to the 
activation of several inflammatory processes, including atherosclerosis which is the primary 
focus of this study.
Recent evidence has built up related to direct intercellular cross-talk via GJ channels in the 
haemotapoietic and immune systems, implying important physiological consequences as 
comprehensively described in Chapter 1; section 1.6. Intercellular coupling o f systemic or 
primary and secondary lymphoid lymphocyte conglomerates is increasingly appreciated as 
being enabled by GJs. These ubiquitous macromolecular assemblies that permit direct 
intercellular transfer of ions and metabolites of up to IkDa are widely regarded as signalling 
conduits underpinning metabolic cross-talk and intergration (SÂez et al., 2000, Oviedo-Orta 
and Howard Evans, 2004).
GJ intercellular channels are constructed of a family of multispanning proteins known as the 
connexins (Cxs) (White and Bruzzone, 1996). Among all the Cx isoforms, more is known 
about the biochemical properties and the posttranslational modifications of Cx43. This Cx is 
the most widely expressed and predominant isoform endogenously expressed in most cell 
types. In fact, even cell lines derived from tissues that do not normally express Cx43 often 
express it extensively and in some cases exclusively (Lampe and Lau, 2004b, Ek-Vitorin et 
al., 2006). To date, the only bona fide role of Cx43 is to form GJ channels between cells, and 
disruption o f these channels by any means decrease intercellular communication. For these 
reasons, Cx43 was used as the primary framework for this study.
In the GJ field, PKC has received considerable attention because PKC activators which 
promote tumorigenesis, both increase Cx43 phosphorylation and decrease GJ communication 
in a number o f different cell types (Brissette et al., 1991, Reynhout et al., 1992, Lampe, 
1994). Several PKC isofroms are implicated in Cx43 regulation (Lampe and Lau, 2004b,
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Bowling et al., 2001, Cruciani et al., 2001). The introduction of several inhibitors and 
activators o f PKC specific for different isotypes has helped identify PKC isoforms 
responsible for Cx43 regulation (Bowling et al., 2001, Lampe and Lau, 2004b, Cruciani et al.,
2001). For example, PKCy can phosphorylate Cx43 and reduce Cx43 GJ formation in lens 
epithelial cells. Experiments with specific inhibitors also indicate that PKCa, -p and -8  can 
disrupt coupling between fibroblasts (Lampe and Lau, 2004b). Furthermore, PKCa and - s  
can phosphorylate Cx43 in cardiomyocytes (Bowling et al., 2001). In the light o f this 
evidence, we hypothesised that GJs play a crucial role in T cell activation and that the 
macrophage-T cell signalling machinery that regulates T cell activation is affected by 
atherogenic factors. Therefore, the aim of this chapter was to assess the effect of oxLDL on 
Cx-mediated T cell intracellular signalling cascades. The objective of our study involved the 
effects of oxLDL, Simvastatin and Pravastatin on Cx43 linked to activation o f PKCO, IkB a, 
IKKa, IKKp and NFkBpSO intracellular proteins.
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5.2 Methods
Cell culture procedures involving PBMC isolation, differentiation of monocytes into 
macrophages and CD4^ T cell isolation were routinely followed as described in section 
2.2.1.1, 2.2.1.2, 2.2.1.3 and 2.2.1.4 respectively. The effects o f oxLDL and statins on T 
lymphocytes signal transduction pathways was assessed by western blotting (refer sections 
2.2.1.6-2.2.1.8) and immunoprécipitation to measure the expression of PKC0, IkB a, IKKa, 
IKKp, NFkBp50 intracellular proteins and phosphorylation of Cx43 by PKC0.
5.2.1 Treatment of macrophages and CD4^ T helper cells
Macrophages obtained as described in Chapter 2; section 2.2.1.1 were stimulated with 
50pg/mL of oxLDL (Img/mL stock; refer section 2.2.1.5) for 48hrs and treated with/without 
I00pM of Simvastatin (5mM stock; CalbioChem, UK) and 100pM of Pravastatin (5mM 
stock; CalbioChem, UK) for 24hrs respectively. These pre-treated macrophages were co- 
cultured with CD4^ T cells for 30mins. Additionally, these mixed leukocyte reactions were 
further treated with/without I0ng/mL of phorbol 12-myristate 13-acetate (PMA; 10pM stock; 
Sigma-Aldrich, UK) and 10pg/mL of PKC0 inhibitor (ImM  stock; CalbioChem, UK) 
respectively during the 30 mins incubation period.
5.2.2 Expression of Cx43, PKC0, IkBa, IKKa, IKKp, NFkBp50 proteins in CD4^ T 
helper cells
3.2.3.1 Western blotting
Detection of Cx43, PKC0, IkBa, IKKa, IKKp, NFkBp50, NFATcl, Erkl protein expression 
was carried out by Western blotting. Whole cell protein extracted from resting and activated 
CD4^ T cells was resolved by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) 
membranes. Detection of Cx43, PKC0, IkBa, IKKa, IKKp, NFkBp50 proteins was carried 
out by incubating the membrane with the respective specific primary antibodies followed by
147
5.2.3.1.2 Procedure
A 25pL slurry of protein L immobilised on agarose beads in PBS was used per 
immunoprécipitation reaction and incubated with primary antibodies (2.5pg o f Cx43 or 2pg 
of phosphoserine/threonine/tyrosine antibody per reaction; refer Table 2.3 for stock 
concentrations and working dilutions) for 4hrs at 4°C on a rotary mixer. After incubation 
with the primary antibody, the beads were washed twice with PBS and lOOpg o f protein 
samples were incubated with the beads-antibody mix overnight at 4°C on a rotary mixer. 
Protein extracts were prepared from resting or activated CD4^ T cells as described in Chapter 
2 (section 2.2.1.6). The next day, the samples were spun down at 12,000xg for Imin and the 
supernatant was collected as the unbound fraction. The pellet (bound fraction) was washed 2x 
with RIPA buffer and resuspended in an equal volume of RIPA buffer similar to the volume 
of the unbound fraction. Immunoprecipitated protein were detected by western blotting (refer 
Chapter 2, section 2.2.1.8).
5.2.4 Statistical analysis of PKC0, InBa, IKKa, IKKp, NFkB and phosphorylated 
connexin expression in CD4^ T cells
Statistical analysis on PKC0, IkB u, IKKa, IKKp, NFicBp50 and phosphorylated Cx43 protein 
expression in CD4^ T cells was carried out by one way ANOVA with a Bonferroni post test 
using GraphPad Prism software (version 5.02, GraphPad Software Inc., USA; refer Chapter 
2; section 2.2.1.9).
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5.3 Results
5.3.1 OxLDL enhances PKC0, IKKa and NFKBp50 protein expression in CD4 T cells
Prior to studying the effects o f oxLDL, simvastatin and pravastatin on Cx43 phosphorylation, 
we investigated the effects of the aforementioned atherogenic stimulant and anti­
inflammatory drugs on key intracellular protein kinases leading to the activation o f NFkB. 
The effect of oxLDL, simvastatin and pravastatin on PKC0, IKKa, IKKp, iKBa and 
NFKBp50 protein expression in CD4^ T cells was analysed by western blotting.
The effect of oxLDL, simvastatin and pravastatin on PKC0, IKKa, IKKp, IkB a  and 
NFkBp 50 protein expression was detected and analysed by western blotting in CD4^ T cells 
stim ulatedv/Y ro with or without oxLDL (Fig 5.1).
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Figure 5.2: Effect o f Simvastatin and Pravastatin on PKC0, IKKa, IKKp, IkBo and NPKBpSO 
protein expression in human CD4+ T cells stimulated w ith oxLDL. PKC0, IKKa, IKKp, kBa 
and NPKBpSO protein expression was detected by Western blot using polyclonal antibodies against 
IKKa, IKKp, NPKBpSO and monoclonal antibodies against PKC0 and kBa. The graphs represent 
the densitrometic analysis of the expression levels of PKC0 (Panel A), IKKa (Panel B), IKKp 
(Panel C), kBa (Panel D) and NPxBpSO (Panel E) normalised to p-actin protein levels. The effects 
of the statins on PKC0, IKKa, IKKp, kBa and NPxBpSO protein expression were assessed by 
comparing statin treated CD4+ T cells stimulated with oxLDL against non-treated CD4+ T cells and 
CD4+ T cells treated with the statins alone. The data is presented as mean (n=3) ± SEM, *p<0.05,
**p<0.01.
Simvastatin was found to significantly reduce IkB u  protein expression by 3.53 fold (Non- 
Treated: 0.46±0.16 vs Simvastatin: 0.13±0.1; p<0.05) in non-stimulated CD4+ T cells. CD4^ 
T cells stimulated with oxLDL resulted in a significant increase in PKC0, IKKa and
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NFkBp SO protein expression by 1.78 fold (Non-Treated: 0.61±0.19 vs oxLDL: 1.09±0.17; 
p<0.05), 1.17 fold (Non-Treated: 0.46±0.06 vs oxLDL: 0.54±0.13; p<0.05) and 1.27 fold 
(Non-Treated: 0.36±0.07 vs oxLDL: 0.46±0.07; p<0.05) respectively when compared to 
PKC0, IKKa and NPKBp50 expression levels in non-stimulated CD4^ T cells. Treatment of 
oxLDL stimulated CD4^ T cells with simvastatin resulted in a significant decrease in PKC0, 
IKKp and NFicBp50 protein expression by 2.05 fold (oxLDL: 1.09±0.17 vs
oxLDL+Simvastatin: 0.53±0.17; p<0.05), 1.33 fold (oxLDL: 0.60±0.11 vs
oxLDL+Simvastatin: 0.45±0.15; p<0.05) and 1.84 fold (oxLDL: 0.46±0.07 vs
oxLDL+Simvastatin: 0.25±0.10; p<0.05) respectively. Pravastatin was also found to 
significantly reduce PKC0, IKKa and NFicBp50 protein expression by 1.21 fold (oxLDL: 
1.09±0.17 vs oxLDL+Pravastatin: 0.90±0.11; p<0.05), 1.8 fold (oxLDL: 0.54±0.13 vs 
oxLDL+Pravastatin: 0.30±0.13; p<0.05) and 2.3 fold (oxLDL: 0.46±0.07 vs
oxLDL+Pravastatin: 0.20±0.10; p<0.05) respectively.
5.3.2 OxLDL induces PKC0 mediated phosphorylation of Cx43 and enhances 
phosphorylated Cx43 protein expression
Knowing that oxLDL, Simvastatin and Pravastatin affect expression of the intracellular 
proteins linked to the NFkB pathway, the next part o f the study involved understanding the 
mechanism o f Cx43 phosphorylation by PKC0 and the effect of oxLDL, simvastatin and 
pravastatin on PKC0 - mediated phosphorylation o f Cx43.
The effect of oxLDL, simvastatin and pravastatin on PKC0 mediated phosphorylation o f 
Cx43 was studied by immunoprécipitation and Western blot approaches in CD4^ T cells 
stimulated in vitro with or without oxLDL (Fig 5.2 and 5.3).
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Figure 5.3: Effect o f Simvastatin, Pravastatin, phorbol 12-myristate 13-acetate (PMA) and PKC0 
inhib itor on phosphorylated Cx43 protein expression in human CD4+ T cells stimulated w ith 
oxLDL. Whole cell protein lysate isolated from CD4+ T cells stimulated with or without oxLDL was 
immunoprecipitated for Cx43 and immunoblotted for phosphoserine/threonine/tyrosine (P-prot) and 
vice versa using a polyclonal antibody against Cx43 and a monoclonal antibody against P-prot. The 
graphs represent the densitrometic analysis of the expression levels of phosphorylated Cx43 (Panel A, 
B, C, and D) normalised to (3-actin protein levels. The data is presented as mean (n=3) ± SEM, 
*p<0.05, **p<0.01.
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Phorbol 12-myristate 13-acetate (PMA) was found to significantly enhance phosphorylated 
Cx43 protein expression by 2.06 fold (Non-Treated: 1.67±0.13 vs PMA: 3.45±0.3; p<0.05) in 
non-stimulated CD4^ T cells and by 1.81 fold (oxLDL: 4.65±0.50 vs oxLDL+PMA: 
8.43±0.98; p<0.05) in CD4^ T cells stimulated with oxLDL. By treating mixed leukocyte 
reactions with a PKC0 specific inhibitor, we found that the inhibitor exhibited significant 
inhibitory effects on phosphorylated Cx43 protein expression in non-stimulated CD4^ T cells 
by 2.87 fold (Non-Treated: 1.67±0.13 vs PKC0 inhibitor: 0.58±0.30; p<0.05) and in CD4^ T 
cells stimulated with oxLDL by 1.89 fold (oxLDL: 4.65±0.50 vs oxLDL+PKC0 inhibitor: 
2.45±0.37; p<0.05). Stimulation of CD4^ T cells with oxLDL was found to significantly 
enhance phosphorylated Cx43 protein expression by 2.78 fold (Non-Treated: 1.67±0.13 vs 
oxLDL: 4.65±0.50; p<0.05). Treatment of mixed leukocyte reactions with simvastatin and 
pravastatin exhibited a significant decrease on phosphorylated Cx43 protein expression in 
CD4^ T cells stimulated with oxLDL by 2.13 fold (oxLDL: 4.65±0.50 vs 
oxLDL+Simvastatin: 2.18±0.64; p<0.05) and 1.97 fold (oxLDL: 4.65±0.50 vs 
oxLDL+Pravastatin: 2.36±0.20; p<0.05) respectively. These inhibitory effects on 
phosphorylated Cx43 protein expression in CD4^ T cells stimulated with oxLDL were also 
found to be significant on treatment of mixed leukocyte reactions with simvastatin+PMA (2.1 
fold; oxLDL: 4.65±0.50 vs oxLDL+S imvastatin+PMA: 2.21±0.59, p<0.05),
pravastatin+PMA (1.8 fold; oxLDL: 4.65±0.50 vs oxLDL+Pravastatin+PMA: 2.57±0.40, 
p<0.05), simvastatin+PKC0 inhibitor (8.94 fold; oxLDL: 4.65±0.50 vs
oxLDL+Simvastatin+PKC0 inhibitor: 0.52±0.32, p<0.05) and pravastatin+PKC0 inhibitor 
(7.38 fold; oxLDL: 4.65±0.50 vs oxLDL+Pravastatin+PKC0 inhibitor: 0.63±0.50, p<0.05).
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5.4 Discussion
Initiation of an antigen-specific immune response requires productive engagement o f TCRs 
by MHC-peptide loaded complexes on the APC. This TCR engagement by cognate MHC- 
peptide is required for T cell activation and proliferation (Zhang, 2010). It is currently 
appreciated that chronic inflammatory cell mediated immune responses are involved in the 
pathogenesis of atherosclerosis (Ross, 1999, Hansson, 1997). Activated macrophages and T 
cells are present in human atherosclerotic lesions at all stages of their development (Ross, 
1999). T cells reside within atherosclerotic plaques in a microenvironment where they 
respond to oxLDL and other atherogenic antigens (Stemme et al., 1995, de Boer et al., 1997). 
Antigen-dependent T cell activation is a cell-cell contact-dependent process, suggesting that 
mediators o f intercellular communication involving GJs maybe directly involved (Bermudez- 
Fajardo et al., 2007). However, the study of the influence of atherogenic factors on Cx- 
mediated T cell activation and intracellular signalling remain far from clear.
In previous chapters, the effects of oxLDL on the profile of Cx expression in macrophages 
derived from peripheral blood, macrophage-T cell GJ coupling and Cx expression during T 
cell proliferation were described. Based on the findings described in previous chapters, we 
now examined for the first time the effect of oxLDL on Cx43-mediated T cell intracellular 
signalling.
It is well documented that oxLDL’s effects are mediated through signalling pathways, 
especially via the activation of transcription factors, which in turn stimulate the expression of 
genes involved in the inflammatory and oxidative stress response or in cell cycle regulation. 
NFkB has often been referred to as a central mediator of the immune response because of its 
regulation of the expression of inflammatory cytokines, chemokine, immune receptors and 
cell surface adhesion molecules (Li and Stark, 2002). NFkB is thought to be involved in 
multiple steps in the progression of atherosclerosis, including initiation o f monocyte
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adhesion, foam cell formation and inflammation (de Winther et al., 2005). In macrophages, it 
was reported that oxLDL activates NFkB via PKC and/or calcium-dependent pathways and 
that this phenomenon does not involve the endocytic processing of oxLDL (Han et al., 2000). 
Interestingly, our results showed that in vitro stimulation of CD4’’ T cells with oxLDL 
enhanced PKCO, IKKa, IKKp and NFKBp50 protein expression. This could indicate that 
oxLDL activates NFkB in CD4^ T cells through a PKC dependent phosphorylation 
mechanism and it should also be noted that oxLDL might activate different signalling 
pathways, which interact with each other. These interactions may reflect the complicated 
cross-talk between intracellular signalling pathways induced by oxLDL and other pro- 
atherogenic signals.
Emerging evidence has shown that statins lower LDL-cholesterol synthesis by the liver and 
therefore reduce serum level of this by modulating intracellular signalling pathways related to 
protein kinases in different cell types that include T lymphocytes (Montecucco and Mach, 
2009, Fehr et al., 2004), macrophages (Montecucco and Mach, 2009, Bu et al., 2011), 
dendritic cells (Dominguez et al., 2011), endothelial cells (Montecucco and Mach, 2009, Bu 
et al., 2011, Chiba et al., 2006) and smooth muscle cells (Bu et al., 2011). In particular, 
statins have been shown to inhibit PKC in human vascular endothelial cells in turn 
suppressing the activation of NFkB (Sun et al., 2006, Chiba et al., 2006, Prasad et al., 2005). 
Our results show that Simvastatin suppressed the expression o f IKKp and Pravastatin had a 
similar effect on the expression of IKKa in CD4^ T cell stimulated with oxLDL. In addition, 
both the statins suppressed the expression of PKCO and NFKBp50 in CD4^ T cell stimulated 
with oxLDL. This is an indication that the statins diminish proinflammtory effects and 
promote anti-inflammatory activities through the direct inhibiton of chemokine-, cytokine- 
and acute phase reactant-induced intracellular signalling pathways. In particular, the inhibiton 
of NFkB activity in T cells is crucial to reduce inflammation (Karin and Ben-Neriah, 2000,
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Kane et al., 2002). Overall, these results indicate that oxLDL activates PKCO through T cell 
co-stimulation and PKCO exerts its activating effects on NFkB upon triggering o f IKK 
activity.
In order to better understand Cx-mediated T cell intracellular signalling, we went on to 
investigate and establish a link between the activation of NFkB and Cx43 phosphorylation.
Phosphorylation of Cxs has been implicated in the regulation of GJ communication at several 
stages o f the Cx life cycle including hemichannel oligomerisation, export of the protein to the 
plasma membrane, hemichannel activity, GJ assembly, GJ channel gating and Cx degradation 
(Lampe and Lau, 2004b, Solan and Lampe, 2009, Solan and Lampe, 2005). Recent 
investigations have shown that activation of PKC can lead to phosphorylation of serine 
residues in the cytoplasmic carboxyl-terminal (CT) domain o f Cx43 (Bao et al., 2004a, 
Lampe et al., 2000). It has been shown that on treatment with a PKC activator; phorbol 12- 
myristate 13-acetate (PMA), Cx43 phosphorylation is increased and GJ communication is 
decreased in cardiomyocytes, madin-darby canine kidney cells, rat liver epithelial cells and 
bovine lens cells (Lampe, 1994, Brissette et al., I99I, Reynhout et al., 1992). Our study not 
only support these findings but also show that treatment with PMA increases Cx43 
phosphorylation in unstimulated CD4+ T cells but also increases Cx43 phosphorylation in 
CD4^ T cells stimulated with oxLDL. This suggests that oxLDL stimulation is involved in 
PKC -  mediated Cx43 phosphorylation. Recent reports have begun to dissect the molecular 
basis of the regulation o f Cx43 by PKC. Time course, pulse-chase and cell surface 
biotinylation experiments indicate that PMA acts by destabilising newly forming GJs while 
not affecting the ones already produced (Lampe, 1994). However, PMA effects on assembly 
have not as yet been linked to phosphorylation at a specific site in Cx43. The kinetics of 
PMA action can be complex since PMA can affect channel gating, GJ assembly and Cx half- 
life (Lampe, 1994, Ek-Vitorin et al., 2006).
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The introduction o f several inhibitors and activators o f PKC that are specific for certain 
isoforms has led to the investigation of its role that in the downregulation of GJIC. For 
example, recent studies have shown that overexpression o f PKCy or phorbol ester treatment 
o f lens epithelial cells caused a reduction in the cell surface expression of Cx43 and allowed 
co-immunoprecipitation o f PKCy and Cx43 (Wagner et ah, 2002), inhibition of GJ 
communication was found to be dependent on PKCa, p and 5 to different extents in various 
fibroblast systems (Cruciani et ah, 2001), PKCa and s were found to associate with Cx43 
expressed in cardiomyocytes (Bowling et ah, 2001) and fibroblast growth factor-2 which 
decreases cardiomyocyte GJ permeability and increases Cx43 phosphorylation, increased 
colocalisation of PKCe with Cx43 (Doble et ah, 2000). In addition, our studies show that 
phosphorylated Cx43 expression is reduced in CD4^ T cells treated with a PKCO specific 
inhibitor. Similar effects were also found in oxLDL stimulated CD4^ T cells treated with a 
PKCO inhibitor indicating that Cx43 phosphorylation in CD4^ T cells is PKCO dependent. 
Thus, it appears that several members of the conventional and novel PKC families influence 
GJ communication. One confounding factor is that different cells express distinct isotypes 
and therefore respond differently to these agents; therefore discretion should be exercised 
when referring to the spectrum of effects of these inhibitors on this group o f proteins. 
Understanding the actual sites of phosphorylation and the consequences of these events will 
probably be necessary before we fully understand the importance of different PKC isoforms 
in regulating GJ communication.
Furthermore, we also examined the effect of Simvastatin and Pravastatin on PKC0 mediated 
phosphorylation of Cx43 in CD4^ T cells. Our studies show that treatment o f CD4^ T cells 
with Simvastatin and Pravastatin suppressed phosphorylated Cx43 expression in the presence 
of oxLDL. In combination with PMA, Simvastatin and Pravastatin were shown to suppress 
phosphorylated Cx43 expression in the presence o f oxLDL indicating that the statins are able
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to abrogate the effects produced by oxLDL by inhibiting the activation of PKC. In an attempt 
to elucidate the mechanism of Simvastatin and Pravastatin on PKC0 mediated 
phosphorylation of Cx43, we treated CD4^ T cells with a PKC0 inhibitor and statins, our 
study showed that the PKC0 dependent phosphorylation o f Cx43 was strongly inhibited by 
both Simvastatin and Pravastatin in the presence of oxLDL indicating that the statins are able 
to prevent the PKC0 dependent mechanism of Cx43 phosphorylation.
In summary, our study is the first to assess the effects of oxLDL, Simvastatin and Pravastatin 
on Cx-mediated T cell activation and intracellular signalling. We have shown that oxLDL 
enhances PKC0, IKKa, IKKp and NFKBp50 expression. Our results also show that 
Simvastatin and Pravastatin are able to counteract the effect induced by oxLDL. We have 
also shown that phosphorylation o f Cx43 is PKC0 dependent and that oxLDL further 
enhances PKC0 mediated Cx43 phosphorylation. Furthermore, Simvastatin and Pravastatin 
were shown to block PKC0 activation thereby preventing the phosphorylation o f Cx43. 
Hypothetically, these results could be an indication that oxLDL promotes GJ mediated 
protein kinase phosphorylation of intracellular second messenger cascades. Although, our 
study demonstrates that PKC0 phosphorylates Cx43, the question relating to the mechanism 
o f PKC0 specifically phosphorylating Cx43 without the intervention o f other PKC isoforms 
needs to be further elucidated. Nonetheless, this study has made advances towards this 
understanding and has identified some important factors for future scrutiny.
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CHAPTER 6  
GENERAL DISCUSSION AND FUTURE WORK
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6.1 General Discussion and Future Work
6.1 General Discussion
Atherosclerosis is a progressive multifactorial disease that affects medium size and large 
arterial vessels. From the initial phases of leukocyte recruitment, to the eventual rupture of 
the vulnerable atherosclerotic plaque, inflammatory mediators appear to play a key role in the 
pathogenesis of atherosclerosis (Libby et al., 2011).
Recent data have shown evidence that gap junctions (GJ) not only play a role in leukocyte 
transmigration, but also contribute to the development of atherosclerosis (Wong et al., 2004). 
Three major Cxs (Cx37, Cx40 and Cx43) have been shown to be differentially expressed 
within atherosclerotic plaques at different stages of its development (Kwak et al., 2002, 
Bumier et al., 2009).
Based on these findings, we hypothesised that GJIC plays a crucial role on the steps leading 
to leukocyte activation and differentiation in response to atherosclerosis related antigens such 
as oxLDL, which in turn can induce a differential structural and functional effect on GJIC- 
mediated T cell activation.
To test our hypothesis, we first studied the expression profile of Cx mRNA and protein in 
human monocyte-derived macrophages in response to oxLDL in vitro. Under resting 
conditions, macrophages were found to express more Cx37 when compared to the expression 
levels of Cx40 and Cx43. However, the level of Cx43 expression in macrophages stimulated 
with oxLDL was found to be significantly higher when compared to Cx37 and Cx40. These 
results add support to recent findings by Eugenin et. al., where they demonstrated that human 
monocytes/macrophages treated with EPS or TNF-a plus IFN-y, conditions known to activate 
macrophages, induced the expression of Cx43 (Eugenin et al., 2003). This is an indication 
that Cx43 expression is a general feature of activated macrophages. In addition, the
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differential expression of Cxs by macrophages might be related to the physiological state of 
these cells, and different Cxs could form channels with different permeability properties to 
allow intercellular transfer o f molecules of different physiological importance (Eugenin et al., 
2003, Kwak et al., 2002, Alves et al., 1996).
Inhibitors o f HMG-CoA reductase (statins) lower plasma cholesterol in humans and reduce 
atherosclerosis-related morbidity and mortality (Vaughan et al., 2000). Because several in 
vitro studies have identified numerous pleiotropic effects of statins on vascular cells that 
could modulate atherogenesis and plaque rupture via mechanisms other than lowering 
cholesterol (Takemoto and Liao, 2001), we wanted to evaluate for the first time the effects of 
Simvastatin and Pravastatin on Cx37, Cx40 and Cx43 expression in macrophages stimulated 
with oxLDL. Treatment of macrophages with Simvastatin and Pravastatin significantly 
decreased the oxLDL driven enhancement of the expression of Cx37, Cx40 and Cx43 at both 
mRNA and protein level. Furthermore, Simvastatin and Pravastatin treatment o f macrophages 
showed a significantly higher inhibitory effect on the oxLDL-induced expression o f Cx43 
when compared to Cx37 and Cx40. This is the first demonstration that Simvastatin and 
Pravastatin can abrogate inflammatory effects induced by oxLDL via a Cx-mediated 
mechanism. We hypothesise that statins may excerpt this effect by inhibiting the transcription 
of Cx37, Cx40 and Cx43 mRNA which in turn affects their protein synthesis and turnover.
These results encouraged us to explore the role of GJs on lymphocyte activation and 
proliferation. The study was carried out to test the hypothesis o f whether the previously 
observed mRNA and protein expression levels o f Cx37, Cx40 and Cx43 in macrophages 
stimulated with oxLDL also correlated with the degree of intercellular communication.
Co-cultures o f macrophages and CD4^ T cells stimulated with oxLDL enhanced calcein AM 
dye transfer between cells when compared to resting conditions. The effect of oxLDL on
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macrophage-CD4^ T cell GJIC could be the direct consequence of the interaction between 
these cells and oxLDL, or o f the effect o f oxLDL-induced cytokines. Treatment of oxLDL 
stimulated macrophage-CD4^ T cell with ^^ ’"^^GAP27, "^^GAP27 and 18-a-glycyrrhetinic acid 
demonstrated the GJ-mediated nature of these effects. In this context, we can also propose the 
use of Cx mimetic peptides to reduce inflammation (Evans and Leybaert, 2007).
The expression of multiple Cxs by a single cell may provide a mechanism by which the cells 
regulate intercellular coupling through the formation of multiple channels. It has been shown 
that Cx37 and Cx40 can form functional GJ channels (Oviedo-Orta and Howard Evans, 2004, 
Oviedo-Orta et al., 2000). Additionally, it is established that Cx43 and Cx40 are 
incompatible, and do not form heterotypic channels, while Cx43 and Cx40 form functional 
channels with Cx37 (Oviedo-Orta et al., 2000, Bermudez-Fajardo et al., 2007). Thus, it is 
possible that macrophage-CD4+ T cell GJ channels studied here consist o f solely Cx43, 
solely Cx40 or mixtures o f Cx37 and either Cx43 or Cx40. Such differing Cx composition 
would allow for differential response to stimuli to be achieved by varying the pattern o f post- 
translational modification of the Cx proteins themselves (Hu and Cotgreave, 1997).
Simvastatin and Pravastatin also inhibited GJIC between oxLDL stimulated macrophages and 
CD4^ T cells. This is an indication that the anti-inflammatory effects of statins might be GJ- 
mediated which in turn may partially explain their atheroprotective effects. A potential 
mechanism based on the action of the statins could be linked to the modulation o f GJ 
assembly/disassembly. Alternatively, the statins may interact directly with GJs and alter 
channel gating (Kwak et al., 2002).
These findings encouraged us to investigate the effects of oxLDL and statins during T cell 
proliferation in vitro. The purpose of this investigation was to further understand the role o f 
GJs on the immune-modulatory mechanisms underlying oxLDL induced T cell proliferation.
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Atherogenic stimulation of macrophage-CD4^ T cell co-cultures with oxLDL enhanced CD4^ 
T cell proliferation when compared to resting conditions. This is an indication that oxLDL 
promotes the interaction between macrophages and T cells in turn generating a polarisation of 
actin filaments and microtubules, leading to the transport o f cell surface molecules including 
the TCR and co-stimulatory molecules (Wulfing and Davis, 1998). Similar events could lead 
to the transport o f Cx subunits to the cell surface and the formation o f functional GJs. 
Furthermore, oxLDL induced GJ communication between proliferating T cells might 
coordinate their metabolic and cytokine-induced responses to allow the appropriate timing of 
the specific immune responses.
Additionally, we examined GJ mediated CD4^ T cell proliferation in the absence of soluble T 
cell proliferating signals. By treating macrophage-CD4^ T cell co-cultures with mitomycin C; 
a DNA cross linker and potent inhibitor of soluble signals, CD4^ T cells were found to 
proliferate and the rate o f proliferation was enhanced in the presence of oxLDL. This 
suggests that oxLDL induces T cell activation and proliferation in the absence of soluble T 
cell proliferating signals resulting from intercellular communication mediated by multiple 
surface molecules such as TCR on the T cell face, MHC on the macrophage face, co­
stimulatory molecules, adhesion molecules and already accumulated Cx formed GJ channels 
on the cell surfaces between the two cell types (Mendoza-Naranjo et al., 2011).
Simvastatin and Pravastatin had an inhibitory effect on CD4^ T cell proliferation in the 
presence of oxLDL. These inhibitory effects by the statins on CD4^ T cell proliferation were 
mirrored in the absence of soluble T cell proliferating factors. A possible mechanism of 
action of the statins on T cell proliferation based on recent studies revolve around the fact that 
statins bind to the adhesion molecule leukocyte function antigen-1 (LFA-1) on APCs in turn 
blocking the interaction with T cells expressing the counter-receptor intercellular adhesion 
molecule-1 (ICAM-1) (Weitz-Schmidt et al., 2001). However, based on our studies, we show
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for the first time that statins can abrogate the proliferation of T cells exposed to an 
atherogenic insult by interfering with the activity of Cxs in turn altering GJ communication 
between the T cells and APCs. In addition to previous reports, a possible mechanism of 
action of Simvastatin and Pravastatin could be that they directly alter the structural 
conformation o f the GJ channels, which may lead to reduced channel assembly or increased 
degradation of hemichannels. Furthermore, there could also be the possibility o f the statins 
interacting with other membrane proteins which in turn interact with GJ channels. 
Irrespective of the mechanism o f action, our results point to a selective inhibition by the 
statins on oxLDL induced GJ channel activity between T cells and macrophages. Overall, 
these results support our hypothesis that oxLDL may have pro-inflammatory properties, 
mediated by inducing T cell activation and proliferation via modulation of Cx expression and 
GJIC between macrophages and CD4+ T cells.
Based on the cumulative findings involving the expression o f Cxs in macrophages induced by 
oxLDL and the effect o f oxLDL on the expression and function of Cxs and GJs during T cell 
antigen-induced proliferation; examination o f the effect o f oxLDL on Cx mediated T cell 
intracellular signalling was the next logical step. We carried out our study by setting up 
macrophage-CD4^ T cell co-cultures isolated from human peripheral blood and assessing the 
effects of oxLDL on PKC0 mediated phosphorylation o f Cx43 and the synthesis and 
phosphorylation o f PKC0, IKKa, IKKp, IxBa and NFkB intracellular proteins in CD4+ T 
cells under resting and stimulatory conditions in vitro.
NFkB has often been referred to as a central mediator o f immune response as its activation 
upregulates the expression of numerous proinflammatory genes involved in inflammation (Li 
and Stark, 2002). Furthermore, NFkB is thought to be involved in multiple steps in the 
progression o f atherosclerosis (de Winther et al., 2005). Cominacini et. al. had demonstrated 
that oxLDL dose-dependently increased the activation of NFkB in monocytes derived from
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human peripheral blood and that oxLDL had no effect in lymphocytes (Cominacini et al., 
2005). Interestingly, our studies showed that in vitro stimulation of CD4^ T cells with oxLDL 
not only enhanced NFxBp50 protein expression but also the expression o f the key 
intermediate intracellular proteins, PKCO, IKKa and IKKp that are functionally involved in 
the activation of NFKBp50 through a series of phosphorylation events. This could be an 
indication that oxLDL, through T cell stimulation, activates PKCO in turn exerting its 
activating effects on NFkB upon triggering o f IKK activity. Furthermore, recent studies have 
shown that statins could also modulate intracellular signalling pathways involving protein 
kinases in different cell types (Prasad et al., 2005, Chiba et al., 2006, Sun et al., 2006). 
Several studies have revealed that anti-inflammatory effects o f statins are related to the 
modulation o f NFkB signalling pathway in vascular endothelial, smooth muscle cells and 
monocytes (Hilgendorff et al., 2003, Hemandez-Presa et al., 2003, Viedt et al., 2003, 
Okamoto et al., 2002, Lin et al., 2005, Dechend et al., 2001). Our studies show for the first 
time that Simvastatin suppressed the expression of IKKp and Pravastatin suppressed the 
expression o f IKKa whereas both Simvastatin and Pravastatin suppressed the expression of 
PKCO and NFKBp50 in CD4^ T cells stimulated with oxLDL. This is an indication that the 
statins inhibit NFkB activation in T cells exposed to inflammatory stimuli, which suggests 
that this transcription factor is an important statin target. Furthermore, the mechanism by 
which the statins prevent NFkB activation is based on its effect in stabilising IkBu by 
inhibiting kinases in turn masking the nuclear localisation signals of NFkB, keeping it 
sequestered in an inactive state.
Recent studies have shown that activation of PKC can lead to phosphorylation o f serine 
residues in the cytoplasmic carboxyl-terminal (CT) domain of Cx43 (Lampe et al., 2000, Bao 
et al., 2004a) and that treatment with a PKC activator; phorbol 12-myristate 13-acetate 
increases Cx43 phosphorylation in turn decreasing GJ communication (Brissette et al., 1991,
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Reynhout et al., 1992, Lampe, 1994). Our studies not only support past findings involving an 
increase in Cx43 phosphorylation on PMA treatment but also show that treatment with PMA 
increases Cx43 phosphorylation in CD4^ T cells in both resting and oxLDL stimulated 
conditions. The expression levels o f phosphorylated Cx43 protein in CD4^ T cells stimulated 
with oxLDL treated with PMA was significantly higher when compared to resting conditions 
indicating that oxLDL exhibits a maximal effect on PKC phosphorylation of Cx43.
The introduction o f several inhibitors and activators o f PKC that are specific for certain 
isotypes has led to investigations o f the roles that these PKC isotypes may play a role in the 
downregulation of GJIC through Cx phosphorylation (Wagner et al., 2002, Cruciani et al., 
2001, Bowling et al., 2001, Doble et al., 2000). PKCO, a Ca^^ independent serine/threonine 
kinase is an essential member of the NFkB activation cascade and a central player in the 
mediation of T cell differentiation (Marsland and Kopf, 2008). Our study had shown that 
treatment o f CD4^ T cells with a PKCO specific inhibitor reduced phosphorylated Cx43 
expression indicating that phosphorylation of Cx43 in CD4^ T cells is PKCO dependent. 
Furthermore, similar effects in reduction of phosphorylated Cx43 were also found to be 
mirrored in oxLDL stimulated CD4^ T cells treated with the PKCO inhibitor. It is therefore 
possible that phosphorylation of Cx43 occurs primarily through NFkB activation and that 
oxLDL targets phosphorylation through a PKCO dependent mechanism.
We also examined the effect of Simvastatin and Pravastatin on PKCO mediated 
phosphorylation o f Cx43 in CD4^ T cells under resting and stimulatory conditions. Our 
studies show that treatment of CD4^ T cells with Simvastatin and Pravastatin suppressed 
phosphorylated Cx43 expression in the presence of oxLDL. This preliminary evidence 
encouraged us to investigate the effects of the statins on PKC mediated phosphorylation of 
Cx43. We found that Simvastatin and Pravastatin suppressed phosphorylated Cx43 
expression in oxLDL stimulated CD4^ T cells treated with a combination of each statin with
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PMA indicating that the statins are able to abrogate the effects produced by oxLDL in turn 
preventing the activation o f PKC. In an attempt to elucidate the mechanism o f Simvastatin 
and Pravastatin on PKC8 mediated phosphorylation o f Cx43, we treated CD4^ T cells under 
resting and stimulatory conditions with a combination o f each statin and the PKC0 specific 
inhibitor. We found that, in addition to the inhibitory effects o f the PKCO inhibitor. 
Simvastatin and Pravastatin suppressed the expression of phosphorylated Cx43. Taken 
together; these data demonstrate for the first time that Cx43 expression is down-regulated by 
the statins in response to oxLDL stimulation and that the inhibition of T cell activation by the 
statins also results in decreased phosphorylation of Cx43 through a PKC0 dependent 
mechanism.
6.2 Key Findings
We have shown for the first that human macrophages express Cx37, Cx40 and Cx43, they 
interact with CD4^ T cell via GJs and blocking o f functional GJ channels established between 
CD4^ T cells and macrophages affects T cell activation in turn reducing proliferation. This is 
an indication that GJIC is crucial in steps leading to T cell development. Furthermore, 
atherosclerosis related antigen; oxLDL enhances Cx37, Cx40 and Cx43 expression in 
macrophages and induces CD4^ T cell-macrophage GJIC whereas the cholesterol lowering 
drugs; Simvastatin and Pravastatin are able to attenuate any such effects produced by oxLDL. 
This is a clear indication that oxLDL induces GJ mediated T cell activation and proliferation 
and that abrogation of the oxLDL effect by Simvastatin and Pravastatin indicates an anti­
inflammatory and atheroprotective effect which may be GJ mediated. In summary, all these 
results underline Cxs as cardiovascular risk markers and potential therapeutic targets in the 
treatment of atherosclerosis. In addition, for the first time, our studies emphasise on the 
involvement of oxLDL and intercellular communication in the immune system. A summary
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of the proposed mechanisms by which oxLDL, Simvastatin and Pravastatin could modulate 
GJIC leading to T cell activation and proliferation are shown in Figures 6.1 and 6.2
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Figure 6.1: Proposed mechanism underlying the effects of oxLDL on connexin expression and 
gap junction mediated lymphocyte activation and proliferation. (1) oxLDL uptake by 
macrophages via receptor mediated endocytosis (2.1) enhances the expression of Cx37, Cx40 and 
Cx43 in turn activating T cells through the release of signalling molecules from Cx hemichannels or 
(2.2) by direct intercellular communication via gap junction channels established between the two cell 
types. (2.3) The T cell recognises the oxLDL derived peptide displayed by a MHC molecule on the 
macrophage via the T cell receptor complex (3) in turn triggering the activation of PKC0 and the 
subsequent (4.1, 4.2) phosphorylation of Cx43. The oxLDL induced PKC0 phosphorylation of Cx43 
results in its direct interaction with other tyrosine kinases that could directly trigger the (5, 6) activation 
of N F kB through a series of phosphorylation events that include the phosphorylation of the Ik B o  
protein by the IKK complex. (7 )  The activated N F kB translocates into the nucleus and upregulates 
genes involved in T cell development and proliferation.
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Figure 6.2: Proposed mechanism underlying the effects of Simvastatin and Pravastatin on 
oxLDL induced connexin expression and gap junction mediated lymphocyte activation and 
proliferation. (1, 2.1) Simvastatin and Pravastatin prevent the expression of Cx37, Cx40 and Cx43 in 
macrophages as a result of oxLDL uptake by receptor mediated endocytosis in turn (2.2) halting T 
cell-macrophage intercellular communication via gap junctions or Cx hemichannels. (2.3) The T cell 
recognises the oxLDL derived peptide displayed by a MHC molecule on the macrophage via the T 
cell receptor complex. (3, 4) Simvastatin and Pravastatin halt the oxLDL induced T cell activation by 
preventing the phosphorylation of Cx43 by PKC0 (5, 6, 7) in turn stabilising IkBo keeping N F kB 
sequestered in an in active state, unable to upregulate pro-inflammatory genes involved in T cell 
development and proliferation.
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6.3 Limitations of the study and recommendations for future work
Although, our studies have shown novel evidences highlighting the role and importance of 
GJIC in leukocyte biology, our research has given rise to many questions in need o f further 
investigation.
Although, the effect o f oxLDL on GJ mediated CD4+ T cell proliferation was assessed in the 
presence and absence of soluble T cell proliferating factors, we were unable to assess the 
effect o f oxLDL on the secretion of cytokines and growth factors in macrophage-T cell co­
cultures. We found that the levels o f IL-2, IL-4, IL-5, IL-6, IL-IO, Tumor Necrosis Factor 
(TNF), and Interferon-y (IFN-y) in the supernatant of the macrophage-T cell co-culture 
experiments were below the detection limits of the assay. These findings may be expected as 
cytokines are heat labile proteins that are also susceptible to degradation by proteases and 
have notoriously short half life. Furthermore, some secreted cytokines, especially IL-4, are 
rapidly taken up by other cells present in the culture. In further studies, a more accurate 
indication o f cytokine secretion could be obtained by the intracellular detection o f cytokine 
by flow cytometry. This method has the added advantage that the cells could be double 
labelled for the cytokine of interest and phenotypic surface markers. This, not only allows the 
identification o f the cell type secreting the cytokine but also give additional information 
about the dynamic interaction between macrophages and CD4^ T cells.
T cell activation and proliferation result from intercellular communication mediated by a 
highly organised protein network known as the immunological synapse formed through TCR 
engagement by an MHC-peptide (Grakoui et al., 1999). Although, our studies have 
highlighted and emphasised on the role o f GJIC in T cell activation; the effects of oxLDL on 
the accumulation of Cx at the immunological synapse, the mechanisms involved in their role 
in T cell Ca^^ signalling need to be further explored. This can be achieved by 
immunolabelling Cxs and the proteins that make up the immunological synapse between
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macrophages and T cells and assessing the effects of oxLDL by immunoconfocal 
microscopy. Furthermore, activation o f T cells via stimulation o f the TCR complex is marked 
by a rapid and sustained increase of intracellular Ca^^ which is required for gene 
transcription, cellular proliferation and differentiation. A sustained Ca^^ signal for many 
hours is also necessary to stimulate nuclear factor o f activated T-cells (NFAT), a transcription 
factor that regulates the expression of various cytokine genes, including IL-2. In further 
studies, the effect of oxLDL on the role o f Cxs and GJs on Ca^^ signalling can be measured 
by confocal microscopy on T cells co-cultured with macropohages stained with fluorescent 
calcium indicators.
In addition, we demonstrated through our studies that PKC0 phosphorylates Cx43 and 
activation of NFkB. However, the question relating to the mechanism of PKC0 specifically 
phosphorylating Cx43 without the intervention of other PKC isoforms needs to be further 
elucidated. Furthermore, channels permeability or stringency to different solutes may be 
decreased or increased by phosphorylation Cx43 and that the phosphorylation in controlling 
the gating system o f the hemichannels is residue-specific. It was not possible to discern a 
specific function associated with the phosphorylation of Cx43 during T cell activation, as 
there are multiple phosphorylation sites. This can be achieved through immunoprécipitation 
and immunoblotting analysis o f PKCa, p, y, 5, and s mediated phosphorylation o f Cx43 at 
serine residues under resting and oxLDL induced stimulatory conditions.
We also provided novel evidences related to the anti-inflammatory effects o f Simvastatin and 
Pravastatin on oxLDL induced Cx expression and GJIC leading to lymphocyte activation and 
differentiation. However, since our statin treatments relied on an in vitro model, we typically 
employed a concentration o f I00pM which is in excess of the submicromolar concentrations 
measured in the blood o f statin-treated patients. By necessity, most in vitro studies only 
examine the short term effects of statin treatment. The use of high concentrations in this
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setting may be a legitimate way o f detecting influences on inflammatory pathways that are 
only exerted at clinically relevant doses when used over the course o f years, rather than hours 
or days.
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